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ABSTRACT 
 
Since the initial association of the Panton Valentine leucocidin (PVL) toxin with 
highly virulent strains of Staphylococcus aureus found in the community, a firm 
epidemiological link has been established between the PVL encoding genes and 
community-acquired strains of both meticillin resistant (CA-MRSA) and susceptible 
(CA-MSSA) Staphylococcus aureus. While most research has predominantly 
concentrated on the genotyping of CA-MRSA strains, PVL-MSSA appear to pose an 
increasing public health risk. Currently though, there exists a dearth of 
epidemiological data on PVL-MSSA strains, particularly with regard to the lukS and 
lukF genes which encode the PVL toxin. 
 
This first aim of the present study therefore was to explore the genetic diversity of a 
group of PVL-MSSA clinical local isolates in order to contribute to the limited current 
data and provide insight into the evolution and emergence of PVL-MRSA isolates. In 
addition, as current typing systems are cumbersome, time consuming and expensive, 
this present study was also aimed at the development of a rapid high resolution melt 
(HRM) typing system for the characterisation of PVL-positive isolates. The PVL toxin 
is encoded for by two highly conserved adjacent genes (lukF and lukS) which are co-
transcribed. Variations in these genes correlate with a strain‘s genotype. Therefore, the 
present study set out to genotype isolates based on the four major SNPs at positions 
527 and 663 of the lukS gene and 1396 and 1729 of the lukF gene. The final aim of the 
present study was the development of an enzyme linked immunosorbent assay 
(ELISA) system (for the detection and quantification of both PVL and alpha 
haemolysin) that has potential application in clinical diagnosis and as a research tool. 
 
Characterisation of a collection of UK PVL-MSSA isolates by MLST and spa typing 
which is presented in the present study, showed a genetic similarity to circulating 
PVL-MRSA strains, with 94.7% of the isolates belonging to CA-MRSA related 
genetic backgrounds (ST1, ST22, ST30, ST772 and ST88). Three novel spa types 
(t6642, t6643 and t6769) and a novel ST (ST1518) were however detected in this 
population. Furthermore, the presence of identical PVL phages and haplotypes in the 
PVL-MSSA isolates to those previously described in PVL-MRSA isolates point 
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strongly at the role these strains may play as precursors of emerging lineages of 
clinical significance. 
 
The HRM assay developed in this study was able to accurately genotype PVL-positive 
isolates based on the double allelic variations in both the lukS and lukF genes. The 
high degree of sensitivity of this technique was clearly demonstrated by its ability to 
differentiate between the lukS A527/G663 and G527/T663 genotypes which theoretically 
should have the same melt temperature. Despite the issues in data interpretation, 
which arose following attempts to improve the discrimination of this technique by the 
addition of a third locus (spa), the technique still showed potential as a useful tool for 
the rapid genotyping of PVL-positive isolates. 
 
While HRM was useful in rapidly detecting and genotyping PVL-positive isolates, the 
actual level of protein production of both PVL and HLA toxins could only be 
determined following the development and validation in the present study of a simple 
competitive ELISA platform which exploited the high affinity biotin/streptavidin 
interaction to improve sensitivity. This technique would be especially useful in 
settings which lack the specialised equipment required for genetic studies like HRM. 
 
In summary, in addition to contributing to the limited epidemiological information 
about PVL-MSSA strains and demonstrating a clear role for these strains in the 
evolution of PVL-MRSA strains, the present study has developed two distinct 
methods to aid the study of S. aureus PVL producing strains which are becoming a 
significant healthcare problem worldwide. The present study will contribute to our 
understanding of these strains and to the development of intervention strategies to 
curb their spread and threat. 
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RT-PCR Real time PCR 
sae S. aureus exoprotein expression 
SaPI Staphylococcal pathogenicity island 
sar Staphylococcal accessory gene regulator 
SCC Staphylococcal cassette chromosome 
SCIN Staphylococcal complement inhibitor 
SDS Sodium dodecyl sulphate 
SGB Stacking gel buffer 
SLV Single locus variant 
SNP Single nucleotide polymorphism 
SPA Staphylococcal protein A 
SRU Staphylococcus Reference Unit 
SSL-7 Staphylococcal superantigen-like protein-7 
ST Sequence type 
Taq Thermus aquaticus 
TEMED Tetramethylethylenediamine 
Tm Melting Temperature 
TS Tim Sloan 
TSB Trypticase Soy Broth 
TSST Toxic shock syndrome toxin 
U Units 
UV Ultra violet 
v/v Volume per volume 
WGS Whole genome sequencing 
w/v Weight per volume 
xpr Extracellular protein regulator 
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Chapter One 
 
1 Introduction and Literature Review 
 Introduction 1.1
In 2002, initial reports were made linking the cytotoxic Panton-Valentine leucocidin 
(PVL) toxin specifically with community-acquired S. aureus (CA-MRSA) as opposed 
to the hospital-acquired S. aureus (HA-MRSA) strains (Gillet et al., 2002). 
Subsequently, over the years, an epidemiological link has been firmly established 
between PVL encoding genes and community-acquired strains of both meticillin 
resistant (CA-MRSA) and susceptible (CA-MSSA) S. aureus strains (Chheng et al., 
2009, Diep et al., 2004, Enany et al., 2007, Liassine et al., 2004, Linde et al., 2005, 
Miklasevics et al., 2004, Tsai et al., 2008, Vandenesch et al., 2003, Witte et al., 2005). 
These CA-MRSA isolates often cause severe infection in young healthy 
immunocompetent individuals and differ from HA-MRSA in antimicrobial 
susceptibility pattern, clonal origins and type of mec element. Furthermore, PVL 
encoding genes were found to be highly represented within this population. Up to 
100% prevalence was observed among CA-MRSA strains as opposed to the 2% 
frequency noted in the general S. aureus population (Kilic et al., 2006, Kilic et al., 
2008, Makgotlho et al., 2009, Prevost et al., 1995a). PVL toxin is encoded by two 
adjacent, co-transcribed genes, lukF and lukS. These genes which make up the highly 
conserved ≈1.9 kb lukSF-PV locus are carried by several temperate phages. (Kaneko 
et al., 1998, Kaneko et al., 1997, Narita et al., 2001, Baba et al., 2002, Diep et al., 
2006b, Ma et al., 2006, Ma et al., 2008, Takano et al., 2008b, Berglund et al., 2008b, 
Otter et al., 2010). Despite the undeniable epidemiological link between PVL 
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encoding genes and CA-MRSA, the contribution of the PVL toxin in both the 
virulence and pathogenesis of this group of isolates has not yet been conclusively 
demonstrated. 
 
Current research in this field has hence been geared towards answering this question. 
Most virulence studies involved the use of various animal and infection models but 
failed to provide actual evidence of toxin production (Labandeira-Rey et al., 2007, 
Voyich et al., 2006, Bubeck Wardenburg et al., 2008). A few studies which focused 
on analysing actual toxin production in infected tissues and in vitro, noted wide strain 
to strain variations in the amount of PVL toxin produced by clinical isolates (Badiou 
et al., 2008, Croze et al., 2009, Hamilton et al., 2007, Loughman et al., 2009, Said-
Salim et al., 2005). In addition to the wide array of factors already noted to affect PVL 
expression levels (Bronner et al., 2000, Dumitrescu et al., 2008a), more recent 
findings (Wirtz et al., 2009) on differential transcription of PVL encoding genes from 
the øSa2mw phage, following mitomycin treatment in several S. aureus strains, appear 
to indicate an effect of staphylococcal genetic background on PVL expression. Over 
the years, genetic background has played a pivotal role in the evolution, spread and 
epidemiology of S. aureus particularly with respect to the acquisition of the mecA 
element (Enright et al., 2002) and virulence genes (Diep et al., 2006a), the global 
spread of MRSA clones (Vandenesch et al., 2003), and agr type (Jarraud et al., 2002). 
The relationship between the genetic background of these strains and the levels of 
both PVL and alpha haemolysin toxins produced has however not yet been 
investigated. Strain typing to generate the necessary information on genetic 
background would be necessary to answer these questions. Despite the acceptable 
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discriminatory abilities of current typing methods, these methods can however be 
cumbersome, expensive and time consuming. 
 
 Staphylococcus aureus 1.2
 
Staphylococci 
In 1881, Alexander Ogston a Scottish physician was the first person to describe a 
distinct form of ‗grouped cocci‘ (Ogston, 1881). These occurred in clumps as opposed 
to the ‗chain cocci‘ previously described within the micrococci family. He went on in 
1882 to name this group of isolates ‗Staphylococcus‘. This was derived from the 
Greek word ‗staphyle‘ for bunch of grapes (Ogston, 1882). The staphylococci are a 
family of Gram positive, catalase positive, non-motile, non-spore forming, 
facultatively anaerobic cocci which range in size from 0.7 – 1.2 µm in diameter. As 
previously mentioned, these organisms are characterised by their ability to form 
clusters. They however also occur singly, in pairs or tetrads. Over 30 species of 
Staphylococcus have been described to date. Of these, the most pathogenic and 
prominent is S. aureus. This group of isolates derives its species name from the 
characteristic golden coloured colony. One distinguishing characteristic of this group 
in relation to other pathogenic Staphylococcus spp of clinical significance is in its 
ability to produce the coagulase enzyme. This characteristic has led to the general 
delineation of staphylococci into S. aureus and coagulase negative Staphylococci 
(CoNS). In addition, S. aureus strains are characterised by their ability to tolerate high 
salt concentrations (7.5 – 10% w/v NaCl) and ferment mannitol (Lowy, 1998). 
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Staphylococcus aureus 
While the initial focus on S. aureus was due to its status as the most common 
bacterium in pus (Power, 1886), it additionally plays a significant role in abscesses. 
This organism was also associated with both recurrent and chronic infections (West, 
1911, Wright, 1904, Hiss and Zinsser, 1909). S. aureus is however a member of the 
normal human flora. This commensal organism commonly found in the anterior nares 
and other moist areas of the skin, was earlier reported to be carried persistently by  
20 – 30% of the population with 60 – 70% of people intermittently carrying this 
organism (Kluytmans et al., 1997, Lowy, 1998). A more recent survey however puts 
the carriage figures as 20% for persistent carriers, 30% intermittent and about 50% of 
the population as non-carriers (Wertheim et al., 2005). Despite this commensal status, 
S. aureus is almost notorious in its remarkable ability to cause a wide array of diseases 
(Archer, 1998, Casey et al., 2007) capable of affecting almost all organs. These 
infections range from the often mild skin and soft tissue infection to potentially life 
threatening conditions such as bacteraemia (Table 1.1). These infections are often 
endogenous, arising due to a breach either in the skin or mucosal barriers. This breach 
then permits spread of the organism into areas where it is capable of causing disease 
(Lowy, 1998). This ability of S. aureus is linked with an impressive repertoire of 
virulence factors, with a direct causal relationship sometimes noted between specific 
factors and certain disease conditions. 
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Table 1.1: Spectrum of diseases associated with S. aureus. 
 
Infection Type 
Skin and Soft tissue infection Others (Invasive infection) 
Skin abscess, 
Folliculitis, 
Furunculosis, 
Pyomyositis, 
Myositis, 
Peritonitis 
Cellulitis, 
Impetigo, 
Necrotizing fasciitis, 
Scalded skin syndrome, 
Surgical site infections, 
 
Bacteraemia, 
Osteomyelitis, 
Pneumonia, 
Septic shock, 
Conjunctivitis, 
Meningitis, 
Pyelonephritis, 
UTI, 
Septic arthritis, 
Infective endocarditis, 
Necrotizing pneumonia, 
Toxic shock syndrome, 
Infective endocarditis, 
Pleural emphyema, 
Pulmonary abscesses, 
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 Virulence Determinants 1.3
S. aureus produces numerous cell surface-located, as well as secreted virulence 
factors, which aid it in virtually all stages of infection. Some of these virulence factors 
are directly responsible for specific disease-associated features. An example of this is 
toxic shock syndrome caused by toxic shock syndrome toxin 1 (TSST-1) (Lowy, 
1998). Other virulence factors protect the organism from the host immune response, 
thus enabling colonisation and/or more successful infection. Examples of these 
include the S. aureus microcapsule which prevents phagocytosis (Wertheim et al., 
2005), coagulase which activates the formation of fibrin clots (O'Riordan and Lee, 
2004) and protein A which inhibits the opsonic capabilities of IgG by binding to the 
Fc region of this molecule (Archer, 1998). Protein A – IgG binding also prevents 
complement activation and helps prevent early detection of invading organisms 
(Lambris et al., 2008). In addition to protein A, several other factors aid in 
complement evasion. Staphylokinase reacts with plasminogen to generate plasmin, an 
active serine protease capable of degrading C3 and C5 complement proteins and 
thereby inhibiting activation of the complement cascade (Rooijakkers et al., 2005b). 
Extracellular fibrinogen-binding protein (Efb) binds C3b and inhibits opsonisation 
(Jongerius et al., 2007). The staphylococcal complement inhibitors (SCINs) block 
complement activation by stabilising the C3 convertase in a state that is non-
functional (Rooijakkers et al., 2005a). Other complement evasion molecules include 
the staphylococcal superantigen-like protein-7 (SSL-7) and the chemotaxis inhibitory 
protein of S. aureus (CHIPS) (Lambris et al., 2008). 
 
Another set of factors, notable for their associated enzymatic capabilities, enhance 
invasion and spread by breaking down host tissues. Examples of these include the 
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proteases, hyaluronidase, elastases and lipase (Lowy, 1998, Gordon and Lowy, 2008). 
S. aureus also produces a wide array of toxins. Some of these are named for the 
system they affect (e.g. staphylococcal enterotoxins, exfoliative toxin) and others the 
disease condition they create (TSST-1). Other toxins are named based on the specific 
cell types on which they act on (e.g. leucocidins and alpha haemolysin). In addition, 
both TSST-1 and a number of staphylococcal enterotoxins are notable for their ability 
to stimulate a broad repertoire of T cells, earning these entities the label of 
superantigens (Lowy, 1998, DeLeo et al., 2009). 
 
The sum total of these virulence factors makes S. aureus a successful pathogen 
capable of affecting nearly all human systems. It is pertinent to note however, that no 
one strain produces all these factors and often, increased virulence of a strain is 
directly proportional to the number of virulence determinants carried (Blair, 1962, 
Peacock et al., 2002b). 
 
This strain to strain variation in virulence factors primarily results from genetic 
exchange between these organisms. Several virulence genes are part of the S. aureus 
core chromosomal genome. These genes are conserved within > 95% of the species 
and encode virulence factors expressed by most S. aureus isolates. Examples of these 
include protein A, clumping factor, fibrinogen-binding protein A, coagulase, alpha 
toxin, lipase and superoxide dismutase (Moore and Lindsay, 2001). A number of other 
virulence genes in S. aureus while currently integrated into the chromosome, are 
extra-chromosomal in origin. These genes have been acquired as a result of horizontal 
transfer between strains on mobile genetic elements (MGE). For example, the genes 
encoding staphylokinase, exfoliative toxin A, Panton Valentine leucocidin, 
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staphylococcal enterotoxin A, P, and K, are all carried on phages (Betley and 
Mekalanos, 1985, Coleman et al., 1989, Kaneko et al., 1998, Yamaguchi et al., 2000, 
Kuroda et al., 2001, Goerke et al., 2009). The genes for enterotoxin D and exfoliative 
toxin B, on the other hand, are carried on plasmids (Bayles and Iandolo, 1989, 
Yamaguchi et al., 2000). 
 
In addition to phages and plasmids, a third notable group of MGEs are the 
pathogenicity islands (PAIs). PAIs make a major contribution to a strain‘s 
pathogenicity and are distinct in that other MGEs such as transposons, phages and 
plasmids may be found within a PAI. PAIs are a subset of genomic islands (GEIs), 
named due to the presence of gene clusters which encode virulence factors (Hacker 
and Kaper, 2000). Like other types of GEIs, PAIs are large discrete genomic regions 
with a different GC content to the rest of the host chromosome. In addition, other 
criteria used to define a genomic region as a PAI include: 1. Presence of the PAI in the 
genome of pathogenic strains of a species but general absence in non-pathogenic 
strains. 2. Carriage of more than one virulence gene. 3. Characteristic insertion at 
specific regions of the host chromosome associated with the tRNA loci. 4. Size range 
of 10 to 180 kb. 5. Presence of flanking repeated sequences. 6. Instability, with the 
occurrence of spontaneous deletions. 7. Carriage of mobility genes (such as integrases 
or transposases) which aid in the insertion and deletion of the PAI (Knapp et al., 1986, 
Hacker et al., 1990, Hacker et al., 1997, Blum et al., 1994). 
 
The discrete genomic regions now referred to as PAIs, were first described in E. coli 
536, a haemolytic uropathogenic strain of E. coli (Knapp et al., 1986). This study 
mapped the hly genes which code for haemolysin, to chromosomal inserts. These 
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inserts were flanked by 16 bp direct repeats, often spontaneously deleted and absent in 
non-haemolytic strains. The term PAI was subsequently applied to these characteristic 
‗chromosomal inserts‘ (Hacker et al., 1990) following the observation that deletion of 
a similar ‗chromosomal insert‘ in E. coli 536 and other E. coli strains resulted in the 
loss of two linked virulence gene clusters. 
 
Several PAIs have been described in S. aureus (Novick, 2003) and are referred to as 
staphylococcal pathogenicity islands (SaPIs). These are associated with the genes 
encoding staphylococcal enterotoxins B, C, K and L and the toxic shock syndrome 
toxin (TSST-1) gene (Johns and Khan, 1988, Lindsay et al., 1998). SaPIs have been 
described as discrete chromosomal elements ranging in size from 15 – 20 kb, which 
are found at specific locations and mobilised specifically by certain staphylococcal 
phages. The prototype SaPI is SaPI1, the first PAI to be described in S. aureus and 
gram positive organisms as a whole (Lindsay et al., 1998). SaPI1 is a 15.2 kb discrete 
genomic region containing the genes which encode for TSST-1 (tst) as well as 
staphylococcal enterotoxins K and L. This MGE is flanked by 17 nucleotide direct 
repeats. Additionally, mobility in SaPI1 has definitively been shown to be mediated 
by a generalised transducing phage, 80α. 
 
Of the different MGEs, some were acquired early in the evolutionary history of certain 
lineages and passed down vertically. Horizontal transfer of MGE and hence virulence 
factors into susceptible lineages has been the predominant factor in the evolution of 
virulent clinical strains (Lindsay et al., 2006). Not surprisingly, MGEs also play a 
second major role in S. aureus – the development of drug resistance. 
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 Antibiotic Resistance 1.4
In addition to the wide array of virulence factors produced, and its ability to cause 
disease, S. aureus is also renowned for its remarkable ability to rapidly develop 
resistance to every single antimicrobial agent developed against it. With the large 
scale production of penicillin in 1943 (Anon, 1943) and its subsequent widespread 
clinical use, a golden age seemed to have arrived with respect to the treatment of  
S. aureus infections. Up to this point S. aureus infections had been associated with 
high mortality rates (Murray, 1934, Skinner and Keefer, 1941). This euphoria was 
however short lived as penicillin-resistant isolates were detected as early as 1947. One 
study published during this period, noted an increase in incidence of resistance from 
12.5% to 38% in a single year (Barber, 1947, Friedmann, 1948). Resistance was 
subsequently linked with the production of penicillinase, a β-lactamase enzyme first 
described in 1944 (Kirby, 1944). β-lactamase hydrolyses the penicillin β-lactam ring 
leading to inactivation of antibiotic activity. The genes encoding β-lactamases were 
thought to be extra-chromosomal and found to be carried generally on plasmids 
(Richmond, 1965b). Occasionally though, these genes were found on the chromosome 
and thought to be linked with the staphylococcal β-lactamase transposon Tn552 
(Novick, 1963, Richmond, 1965a, Novick and Richmond, 1965, Asheshov, 1969, 
Lyon and Skurray, 1987). 
 
Over the years, new antibiotics were developed to combat S. aureus, but this pathogen 
was found to evolve mechanisms to thwart the actions of each drug at a very alarming 
rate (Schito, 2006, Lyon and Skurray, 1987). This resulted in widespread prevalence 
of multi-drug resistant strains, creating a bleak outlook for the prognosis of S. aureus 
infections rather similar to that of the pre-antibiotic era. 
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 Meticillin And Development Of Meticillin Resistance 1.4.1
By the end of the 1950s, penicillin-resistant strains of S. aureus which were often also 
multi-drug resistant (Jantet, 1959, Bradley and Meynell, 1961), had become endemic 
in hospitals, apparently selected for by the widespread use of antibiotics (Kempe, 
1956). Several surveys noted a rising incidence of such strains with incidences of up 
to 95.9% (Munch-Petersen and Boundy, 1962) and 92% (Koch and Donnell, 1957) 
reported in association with concomitant increases in mortality rates. Munch-Petersen 
and Boundy (1962) provided a summary of reports of penicillin resistance over a 
period of 17 years. This study involved an analysis of 248 articles published between 
1942 and 1959. Despite the overall increase in incidence, a wide variation in the 
reported incidence of penicillin resistance was noted and ranged from 0% - 95.9%. 
This wide variation was however a function of differences in the study populations. 
For the studies which reported on isolates obtained from individuals outside of 
hospital, the maximum reported incidence of penicillin resistance was 60.4%. In 
contrast, studies involving hospital isolates, reported incidences of up to 95.9%. 
 
This rising incidence appeared to be driven specifically by penicillin resistance despite 
the multi-antibiotic resistant nature of these isolates. The discovery of meticillin, a 
beta-lactamase resistant penicillin, in the early 1960s, was therefore considered to 
herald in a new age in antimicrobial chemotherapy. Right from the start, this semi-
synthetic derivative of penicillin (Figure 1.1) showed great promise. Several studies 
demonstrated the ability of meticillin to successfully clear a range of infections caused 
by penicillin-resistant S. aureus, often with dramatic results (Harding and Thompson, 
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1961, Dickinson and Pride, 1962, Ross, 1962). In addition to being penicillinase 
resistant, this bactericidal drug exhibited low toxicity and more promisingly, appeared 
to be associated with a low frequency of resistance development (Douthwaite and 
Trafford, 1960, Stewart, 1960, Dickinson and Pride, 1962). 
 
 
 
Figure 1.1: Illustration of the chemical formula of penicillin (A) and 
meticillin (B) 
www.oculist.net/downaton502/prof/ebook/duanes/pages/v9/ch039/004
f.html  
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Resistance of S. aureus isolates to meticillin was first detected in 1961, even prior to 
widespread use of the drug in clinical settings (Jevons, 1961). However at this time, 
reports of meticillin resistance were few and far between. Furthermore, a lack of 
emergence of resistance development was reported, even following prolonged therapy 
(Barber, 1961, Stewart, 1961). Hence, meticillin resistance was not expected to 
constitute a major problem in clinical practice. In the following decade and a half, the 
success of meticillin as frontline therapy for infections caused by these penicillin-
resistant and often multi-drug resistant S. aureus strains, appeared to support this 
theory. Despite isolated reports of meticillin resistance from all across the globe 
(Çetin et al., 1962, Borowski et al., 1964, Gravenkemper et al., 1965, Dornbusch et 
al., 1969, Maniar, 1969, Kayser, 1975), by the mid-1970s, MRSA had not yet been 
recognised as a major public health issue. Ominously however, an increase in 
incidence of MRSA had been noted in a number of publications during this period. 
Turner and Cox reported an increase from 5.4% to 16.6% in Liverpool General 
Hospital (UK) between 1963 and 1965 (Turner and Cox, 1967). In 1970, Ridley 
reported a 10% increase in 5 years, which was in contrast to that of strains received 
for phage typing by the Public Health Laboratory Service, Colindale (UK) where the 
incidence in 1964 was 0.6%, an increase of 0.4% from that of 1960 (Ridley et al., 
1970). A higher incidence of 55.6% was reported in a burns ward in Birmingham UK 
in 1975, compared to that of 39.8% in 1967 (Ayliffe et al., 1977). Overall, despite the 
increase in incidence, at this time, MRSA was still not yet deemed a major public 
health issue (Parker and Jevons, 1964, Skirrow and Rogers, 1971, Bran et al., 1972). 
 
When meticillin resistant strains were detected, they were predominantly found in 
hospitals, where they were sometimes responsible for severe outbreaks with high 
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mortality. Several of these strains were termed ‗Epidemic MRSA‘ (EMRSA), so 
named for their ease of spread within hospitals (Benner and Kayser, 1968, Michel and 
Priem, 1971, Noone and Griffiths, 1971). From the late 1970s, the situation with 
regards to meticillin resistance changed. A dramatic rise in reports of colonisation and 
infection by MRSA strains was noted. Reports from Australia mentioned epidemic 
proportions by 1979, up from 18% noted in 1970 (Gillespie et al., 1984). In New 
York, researchers noted an increase in MRSA strains submitted for phage typing from 
125 between 1977 – 1978 to 2309 in the year 1982 – 1983 (Schaefler et al., 1984). At 
the University of Mississippi Medical Centre, a rise in incidence of MRSA strains 
from 11% in 1979 to 50% in 1981 was observed (Markowitz et al., 1983). In Ireland 
302 MRSA isolates were detected from superficial site infections in 1980 compared to 
20 in 1976. Over the same time period, the number of MRSA strains isolated from 
deep seated infections increased from 3 to 118 (Cafferkey et al., 1983). Reports 
similar to these were quite widespread (Giamarellou et al., 1981, Vickery et al., 1986, 
Boyce et al., 1981, Townsend et al., 1984, Boyce et al., 1983). One common feature of 
these reports was the recognition of a change in the nature of circulating MRSA 
strains. These were noted as being distinct from previously characterised strains of 
that time, by belonging to a different phage group or showing a novel resistance 
pattern and also by their ability to spread between hospitals. First reports of these 
EMRSA strains in England were made in 1981 (Law and Gill, 1988) with spread both 
within and between hospitals noted. These epidemic strains were often responsible for 
serious infection, were recalcitrant to control measures and accounted for up to half of 
all nosocomial staphylococcal infections (Duckworth et al., 1988, Law and Gill, 1988, 
Kerr et al., 1990, Cooke and Marples, 1987). 
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Over the following decades, MRSA strains became pandemic, constituting a major 
public health problem worldwide but generally remained hospital-associated. In one 
study, 74% of spinal cord injury patients were reported to have acquired the organism 
following hospital admission (Thom et al., 1999). Furthermore, MRSA isolates were 
notorious for causing outbreaks in critical care units, affecting patients with reduced 
immunity and often resulting in prolonged length of hospitalization, with high levels 
of mortality (Reshad et al., 1994, Doebbeling, 1995, Blot and Hoste, 2001, Murphy et 
al., 2001, Hunt et al., 1988, Martin et al., 1989, Reboli et al., 1989). Rather 
interestingly, pandemic strains of epidemic MRSA occurring in more than one 
country, were found to belong to only a handful of lineages and are thought to have 
evolved independently (Enright et al., 2002). 
 
 Mechanism of Meticillin Resistance 1.4.2
 mecA Mediated Meticillin Resistance 1.4.2.1
From the first reports, meticillin resistance was found to be both intrinsic and 
heterogenous. Intrinsic in the sense that resistance was not associated with 
penicillinase production which would result in drug inactivation, and heterogenous, 
with respect to the fact that expression of resistance varied between cells in a culture 
grown at 37°C. Only a small proportion of these cells exhibited the resistant 
phenotype (Barber, 1961). Research has since linked meticillin resistance with the 
presence of a unique/novel class of penicillin-binding-protein (PBP-2A) which is 
predominant in MRSA but absent in MSSA. PBP-2A exhibits a much reduced affinity 
for beta lactam antibiotics (Brown and Reynolds, 1980, Hartman and Tomasz, 1984, 
Hartman and Tomasz, 1981). The 2130 bp mecA gene which encodes for this 
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transpeptidase, together with its regulatory genes mecI and mecRI make up the mec 
gene complex. 
 
Though located on the chromosome (Sjostrom et al., 1975, Kuhl et al., 1978), the mec 
gene complex is carried by a mobile genetic element, the staphylococcal cassette 
chromosome mec (SCCmec). At present, the exact origin of this mobile genetic 
element has not been determined. The detection of non-mecA-containing SCC 
elements in several species of CoNS however led researchers to conclude that this 
mobile genetic element most likely originated from the CoNS (Mongkolrattanothai et 
al., 2004, Katayama et al., 2003, Kuroda et al., 2005, Takeuchi et al., 2005, Hanssen 
and Ericson Sollid, 2006). Isolates carrying these SCC elements, presumably then 
acquired the mec gene complex to form SCCmec. The mecA gene itself is however 
thought to have evolutionary links with the coagulase-negative Staphylococcus sciuri. 
A study of thirteen different Staphylococcus spp of animal origin, found that a mecA 
gene homologue with 80% nucleotide identity was present in all 134 strains S. sciuri 
examined (Couto et al., 1996). 
 
The SCCmec element was first described in 1998 (Ito and Hiramatsu, 1998) and was 
found to consist of three main components, the mec and ccr gene complexes and the 
regions separating these which are termed the junkyard or joining regions. Variations 
occur in all these regions leading to different SCCmec types as defined by the 
combination of mec and ccr (Table 1.2). By 2009, eight different SCCmec types had 
been described (Figure 1.2) (Ito et al., 1999, Katayama et al., 2000, Ito et al., 2001, 
Ma et al., 2002, Ito et al., 2004, Oliveira et al., 2006, Berglund et al., 2008a, Zhang et 
al., 2009, Okuma et al., 2002).  
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Table 1.2: Composition of the eight SCCmec types described by 2009. 
SCCmec Type Composition 
Type I type 1 ccr/class B mec 
Type II type 2 ccr/class A mec 
Type III type 3 ccr/class A mec 
Type IV type 2 ccr/class B mec 
Type V type 5 ccr/class C mec 
Type VI type 4 ccr/class B mec 
Type VII type 5 ccr/class C1 mec 
Type VIII type 4 ccr/class A mec 
Adapted from www.sccmec.org/Pages/SCC_TypesEN.html 
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Figure 1.2: Schematic representation of variation in the eight 
SCCmec types described by 2009 showing the different composition 
and arrangement of mec (in pink) and ccr gene complexes (in blue). 
The isolate identities are indicated in brackets. 
The figure was reproduced from: A report by the International working group on the 
classification of staphylococcal cassette chromosome elements (Anon, 2009). 
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 Non-mecA Mediated Resistance 1.4.2.2
In addition to the mecA mediated meticillin resistance exhibited by the majority of 
MRSA isolates, several studies have reported cases of non-mecA mediated meticillin 
resistance. These studies described a distinct group of isolates which exhibited low 
level resistance (oxacillin MIC of 2 – 8 µg/ml), lacked the mec gene complex and 
furthermore, were characterised by uniform resistance with no detectable numbers of 
highly resistant cells. These strains were termed, borderline resistant S. aureus 
(BORSA). This resistance was found to be mediated by two different mechanisms 
depending on the S. aureus strain. One group of researchers (McDougal and 
Thornsberry, 1986) reported an association between staphylococcal β-lactamase 
production and BORSA. In this study, the presence of β-lactamase was found to have 
an effect on the MIC of oxacillin for β-lactamase positive BORSA strains but not for 
β-lactamase positive MRSA strains. For the β-lactamase positive BORSA strains, a 
significant reduction in MIC was noted when a β-lactamase inhibitor (clavulanic acid 
or sulbactam) was added during susceptibility testing (2 – 0.27 µg/ml). Thus 
indicating a β-lactamase mediated meticillin borderline resistance. In contrast, the 
addition of β-lactamase inhibitor during susceptibility testing of β-lactamase positive 
MRSA isolates, had no effect on oxacillin MIC. This β-lactamase mediated meticillin 
borderline resistance was confirmed by several other researchers (McMurray et al., 
1990, Montanari et al., 1990, Petersson et al., 1999). 
 
This phenomenon was found to occur predominantly in phage group 94/96 (also 
known as phage group V) isolates, due to the presence of a 17.2 kb β-lactamase-
expressing plasmid (pBW15) (McMurray et al., 1990, Zierdt et al., 1992). The 
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findings of one study further suggested that the borderline meticillin resistance is a 
phenomenon specific only to isolates carrying the pBW15 plasmid. This suggestion 
was based on the observation that hyper-production of β-lactamases by several other 
strains which lacked the pBW15 plasmid failed to result in borderline resistance (Barg 
et al., 1991). 
 
An earlier study characterising BORSA (Tomasz et al., 1989) had identified a second 
possible mechanism of non-mecA mediated meticillin resistance. In this study, β-
lactamase negative BORSA were found to produce ‗normal‘ PBP which however 
differed in their penicillin binding capabilities and the levels produced. PBP-1 and 
PBP-2 were found to exhibit lower binding capabilities while PBP-4 was produced in 
elevated levels. No mention was however made of the phage grouping for the isolates 
in this study. 
 
At present though, no comprehensive data exists for the prevalence of these BORSA 
and researchers are divided on the clinical significance of these strains especially with 
respect to treatment failures (Swenson et al., 2001, Petersson et al., 1999, Massanari et 
al., 1988, Kernodle et al., 1990). 
 
 Community-acquired MRSA 1.5
Prior to the mid-1990s, the majority of MRSA strains worldwide were reported 
circulating in hospitals, driven by the combination of high antibiotic use and patient‘s 
impaired immunity. These strains were notorious for persistence and spread and often 
linked with a high degree of morbidity and mortality (Cooke and Marples, 1987, Law 
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and Gill, 1988, Thompson et al., 1982, Martin et al., 1989, Peacock et al., 1980). By 
the late 1990s, a change in this epidemiological trend of MRSA was observed. 
Increasing reports were made of MRSA infections in community settings in patients 
with no known hospital links. Sporadic reports of community-acquired MRSA (CA-
MRSA) had been made over the years, but these strains had generally been described 
among intravenous drug users or in long term care facilities, such as nursing homes 
(Saravolatz et al., 1982, Markowitz et al., 1983, Storch et al., 1987). Newly emerging 
strains of CA-MRSA were however not linked to these populations but rather affected 
healthy individuals with no known risk for MRSA infections (Herold et al., 1998, 
Price et al., 1998, CDC, 1999, L'Heriteau et al., 1999, Gwynne-Jones and Stott, 1999, 
Berman et al., 1993). Several studies reported outbreaks among members of sports 
teams and in healthy teenagers (Lindenmayer et al., 1998, Stacey et al., 1998). A study 
carried out at the University of Chicago Children‘s Hospital to ascertain CA-MRSA 
prevalence noted an increase from 10 per 100, 000 admissions between 1988 and 1990 
to 259 per 100 000 admissions between 1993 and 1995. In this study, isolates were 
defined as CA if obtained within 72 h of hospitalization (Herold et al., 1998). 
Similarly, Purcell and Fergie (2002) reported an increase in prevalence of CA-MRSA 
from 2.9% of all S. aureus isolates in 1990 to 40.3% in 2001 at Driscoll Children‘s 
Hospital Texas. While the majority of infections described involved skin and soft 
tissue (Prevost et al., 1995a, Frank et al., 1999, Gorak et al., 1999, Bukharie et al., 
2001), reports were made of more severe infections such as endocarditis and 
necrotising pneumonia (Mallory et al., 1997, Gillet et al., 2002, Villar et al., 1999), 
often in previously healthy and young individuals. 
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Concurrently, some studies reported a surge in colonisation of the general public. 
These studies noted CA-MRSA colonisation highs ranging from 3.3% to 13.2% 
(Hidron et al., 2005, Vlack et al., 2006, Huang et al., 2007, Lo et al., 2007, Lo et al., 
2008, Lu et al., 2005, Creech et al., 2005, Wang et al., 2009, Sdougkos et al., 2008). 
This was in contrast to studies prior to 2003 which reported CA-MRSA colonisation 
highs ranging from 1.5% to 3% (Abudu et al., 2001, Suggs et al., 1999, Kenner et al., 
2003, Jernigan et al., 2003). 
 
By 2005, CA-MRSA had been linked with more severe outcomes and significant 
fatalities (Peleg and Munckhof, 2004, Tseng et al., 2005, Francis et al., 2005, Miller et 
al., 2005, Miyashita et al., 2002). At this time, these strains were also reported to be 
gradually spreading into healthcare facilities (Klevens et al., 2006, Kourbatova et al., 
2005, Saiman et al., 2003). 
 
 Characteristics of CA-MRSA strains 1.5.1
No standardized criteria for defining CA-MRSA strains existed and therefore, some 
variations consequently occurred between researchers (Ispahani et al., 1987, Moreno 
et al., 1995, Naimi et al., 2001, Herold et al., 1998). The key points in CA-MRSA 
definition however focused on the timing of isolation and healthcare links. There were 
significant differences in the details. In one study, an isolate was termed CA if 
detected within 24 h of hospitalization of the patient (Naimi et al., 2001). Other 
studies reported strains as CA if MRSA was isolated within either 48 h (Ispahani et 
al., 1987, Moreno et al., 1995) or 72 h (Herold et al., 1998) of hospitalization. Other 
additional factors sometimes used in defining S. aureus isolates as CA included: 
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history of prior hospital contact or hospitalisation, antibiotic history, history of 
injection drug use or presence of an indwelling medical device (Hughes et al., 1976). 
 
One significant feature not addressed in these definitions was the source of the 
infecting strains. While these so called ‗CA-MRSA‘ could potentially have been HA-
MRSA spread to communities via discharged patients, healthcare visitors or 
healthcare workers, initial reports revealed an unusual antimicrobial susceptibility 
profile of CA-MRSA. Unlike the generally multi-resistant HA-MRSA, the CA-MRSA 
isolates demonstrated susceptibility to most antimicrobial agents apart from the beta-
lactam antibiotics. Additionally, these strains were found to belong to different, often 
more diverse lineages from those previously associated with HA-MRSA, as described 
by both PFGE patterns and multilocus sequence typing (MLST) (Purcell and Fergie, 
2002, Herold et al., 1998, Abi-Hanna et al., 2000, Block and Carmichael, 1978, 
Okuma et al., 2002). 
 
The final factor supporting the hypothesis of independent evolution of these CA-
MRSA strains by SCCmec acquisition by MSSA strains in the community, rather than 
a spread of HA-MRSA, was the variation in SCCmec elements found among CA 
isolates. Unlike their hospital counterparts, CA-MRSA carried a then novel SCCmec 
element, the type IV SCCmec element. These type IV elements were notably smaller 
than the previously described SCCmec types, with a size range of 21 – 25 kb and 
lacking in non β-lactam resistance genes (Figure 1.2). This resulted in the unique 
resistance phenotype that was initially noted and a higher fitness level than the 
hospital-acquired strains. CA-MRSA appeared to have evolved independently in 
specific locations, varying in clonal distribution with a representation among more 
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diverse genetic backgrounds (Daum et al., 2002, Okuma et al., 2002, Cookson, 2000). 
In addition, CA-MRSA strains were found to multiply faster in vitro. Okuma et al. 
(2002) reported a significantly lower mean doubling time of 28.79 ± 7.09 min for CA-
MRSA in contrast to the mean doubling time of 38.81 ± 7.01 min observed for the 
HA-MRSA strains. 
 
 Panton-Valentine leucocidin 1.6
 Link to CA-MRSA 1.6.1
Following the establishment of MRSA in the community, several studies explored the 
unique characteristics of these strains, especially with respect to virulence, and 
identified a common factor among CA-MRSA strains. This factor was the PVL toxin 
(Vandenesch et al., 2003, Said-Salim et al., 2003, Dufour et al., 2002). The genes 
encoding this toxin were found to be highly represented within this population. Up to 
100% prevalence was observed among CA-MRSA strains as opposed to a prevalence 
of only 2% observed in the general S. aureus population (Kilic et al., 2006, Kilic et al., 
2008, Makgotlho et al., 2009, Prevost et al., 1995a). A higher prevalence of PVL 
within distinct populations of S. aureus was initially noted in a 1995 French 
publication (Prevost et al., 1995a). This study looked at two different S. aureus 
populations. The first group of isolates comprised 309 consecutive clinical strains, 106 
of which were from tracheal aspirations and sputa. Within this population, only 1.6% 
(5) of isolates carried the genes encoding for PVL. These isolates were subsequently 
designated PVL-positive. In sharp contrast to this low prevalence, 16.8% of a second 
group of S. aureus isolates were PVL-positive. This second group comprised 346 
isolates originating specifically from either blood cultures, cutaneous infections or 
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nasal carriage. The majority (246, 71.1%) of these isolates however were from 
cutaneous infections. 
 
A similar higher prevalence of PVL-positive isolates was noted in a 1999 study (Lina 
et al., 1999). In this study which analysed 172 selected community acquired isolates 
from the French National Reference Center for Staphylococci (Lyon, France) strain 
collection, 37.2% were PVL-positive. The epidemiological link of PVL with CA-
MRSA was subsequently further strengthened over the following years. Several 
publications dealing with a wide range of sample sizes from various countries reported 
prevalence‘s of PVL-positive CA-MRSA ranging from 8% – 100%, most of which 
were between the range of 69.4% and 100% (Diep et al., 2004, Liassine et al., 2004, 
Vandenesch et al., 2003, Frazee et al., 2005, Yamasaki et al., 2005, Wannet et al., 
2004, Faria et al., 2005, David et al., 2008, Larsen et al., 2009b, Cheung et al., 2008, 
Huang et al., 2008, Vourli et al., 2009). Notable among these studies was the 2003 
report by Vandenesch and colleagues (Vandenesch et al., 2003). This study analysed 
117 CA-MRSA isolates from six countries (United States, France, Switzerland, 
Australia, New Zealand and Western Samoa). 100% of these CA-MRSA isolates were 
PVL-positive. In contrast, PVL encoding genes were not detected in the 57 HA-
MRSA strains analysed simultaneously. This low prevalence of PVL-positive isolates 
in either the general S. aureus population or HA-MRSA specifically, was also 
reported in other studies (Vandenesch et al., 2003, Holmes et al., 2005, Huang et al., 
2008, Liu et al., 2009, Vindel et al., 2009, Kilic et al., 2006, Kilic et al., 2008) and 
ranged from 0% – 20%, with the majority below 2%. 
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Initially, strains carrying the genes encoding PVL were more commonly associated 
with certain infections such as primary skin infections and community-acquired 
pneumonia rather than deep seated infections or urinary tract infections (Lina et al., 
1999, Prevost et al., 1995a, Cribier et al., 1992, Finck-Barbancon et al., 1991). 
Reports of PVL-associated necrotising pneumonia were not as widespread as those for 
skin and soft tissue infection, but a rise in incidence of necrotising pneumonia 
occurred concurrently with an increase in prevalence of strains carrying the genes 
encoding PVL. The predilection of this often fatal infection for young apparently 
healthy, immune-competent individuals, and the high level of mortality associated 
with necrotizing pneumonia however made it a serious public health concern (Le 
Thomas et al., 2001, Gillet et al., 2002, Osterlund et al., 2002, van der Flier et al., 
2003, Hyvernat et al., 2007, Gillet et al., 2008). 
 
Subsequently, strains of CA-MRSA emerged worldwide causing diverse types of 
infections and are epidemic in the USA due to the spread of the single USA300 clone. 
These have spread into healthcare facilities amid reports of increased antibiotic 
resistance (Bocchini et al., 2006, Enany et al., 2007, Ramos et al., 2009, Sdougkos et 
al., 2007, Tsai et al., 2008, Diep and Otto, 2008, Moran et al., 2006, Linde et al., 2005, 
Bratu et al., 2005, Gonzalez et al., 2006, Tristan et al., 2007). 
 
In the UK, though the incidence of CA-MRSA is relatively low and reports infrequent 
(Elston and Barlow, 2009), the Health Protection Agency (HPA) has noted a steady 
rise in the number of PVL-positive MRSA. These PVL-positive MRSA however, 
account for less than 50% of the total number of reported cases of infection by PVL-
positive S. aureus (Table 1.3).
47 
 
Table 1.3: Rising incidence of PVL-positive S. aureus isolates in the UK. 
 
Year  MSSA PVL  MRSA PVL  Total PVL  
2005    107  117    224  
2006    337  159    496  
2007    729  477  1206  
2008  1013  724  1738  
 
Data from HPA Colindale 2009. 
 
Data reflects PVL-positive isolates referred to the HPA based on clinical suspicion (recurrent boils, abscesses, 
necrotising skin and soft tissue infection, community-acquired necrotising pneumonia) and a unique 
gentamicin/trimethoprim antibiotic resistant profile (HPA, 2008, Boakes et al., 2011b). 
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These HPA figures were however not generated following systemic surveillance. 
Rather, the figures represent PVL-positive isolates identified from strains referred to 
the Staphylococcal Reference Unit (SRU) for PVL toxin profiling based on clinical 
suspicion as described in the HPA guidance on diagnosis of PVL-positive cases of  
S. aureus infection (HPA, 2008). This data could therefore reflect an increase in case 
detection and not necessarily provide a true representation of PVL prevalence in 
England and Wales. In contrast to reports from the United States where most PVL-
positive strains are MRSA USA300, an analysis of UK data indicates that infection by 
PVL-positive MSSA is more common than that by PVL-positive MRSA (Ellington et 
al., 2007, Hussain et al., 2007, Mushtaq et al., 2008, Thomas et al., 2009, Cunnington 
et al., 2009, Shallcross et al., 2009). 
 
Over the years several reports have been made of the association of PVL-positive 
MSSA with infection worldwide (Nolte et al., 2005, Adler et al., 2006, Schleucher et 
al., 2008, Kalka-Moll et al., 2008). A study by Gillet and colleagues in 2007 noted a 
higher incidence of PVL-MSSA as opposed to PVL-MRSA as a cause of necrotising 
pneumonia (Gillet et al., 2007). These CA-MSSA strains differ from their CA-MRSA 
counterparts in having a more diverse genetic background (Miller et al., 2007). They 
however exhibit similar clinical and epidemiological characteristics (Golding et al., 
2010, Bocher et al., 2008, Miller et al., 2007), resulting in indistinguishable infections 
(Murray et al., 2004). PVL-positive strains of MSSA have similarly been associated 
with more severe infection (Schefold et al., 2007, Mongkolrattanothai et al., 2003, 
Perbet et al., 2010, Swaminathan et al., 2006, Lorenz et al., 2007, Ramos et al., 2009). 
Though the majority of research worldwide generally focuses on CA-MRSA carrying 
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the PVL encoding genes, several reports of a higher prevalence of PVL-positive 
MSSA strains rather than PVL-positive MRSA strains (Severin et al., 2008, 
Baranovich et al., 2009, Sila et al., 2009), points at a looming threat that has most 
probably been overlooked. 
 
 PVL Origins 1.6.2
The PVL toxin was first described in 1932 (Panton and Valentine, 1932). This bi-
component toxin was initially separated into what he termed the slow and fast 
fractions based on the speed of elution during ion exchange chromatography (Woodin, 
1959). These two components, LukF and LukS, were initially reported to have 
molecular weights of 32 kDa and 38 kDa (Woodin, 1959) and 38 kDa and 32 kDa 
(Finck-Barbancon et al., 1991) respectively. LukF and LukS have however now been 
shown to be proteins of 34 kDa and 32 kDa respectively (Prevost et al., 1995b), which 
act synergistically to produce the active PVL toxin. 
 
Based on its mode of action, the PVL toxin is associated primarily with two families 
of toxins. The first of which is the synergohymenotrophic toxins. This family first 
described in 1993, is so named because members contain two components acting 
synergistically as membrane damaging toxins (Supersac et al., 1993). Members of this 
family include the gamma haemolysin and LukE-LukD leucocidins. Together with the 
staphylococcal alpha toxin, they also form part of a larger family, the β-barrel pore 
forming toxins (PFT). These are secreted as water soluble entities that bind and 
assemble on target cell membranes to form pores (Menestrina et al., 2003). 
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Several differences occur between the PVL toxin and other members of these two 
families of toxins. While production of gamma haemolysin has been noted in 
approximately 99% of all S. aureus strains, only 2% produce PVL. PVL also differs in 
being toxic only for leukocytes rather than for erythrocytes (Kaneko and Kamio, 2004, 
Prevost et al., 1995a). This toxicity is further host specific. A thousand times more 
toxin is required to result in toxicity in mouse and monkey polymorphonuclear cells 
(PMNs) than compared to human and rabbit cells (Loffler et al., 2010). Initial studies 
showed that PVL interacted with the cell membrane of human and rabbit leukocytes 
resulting in various cellular abnormalities. These abnormalities include a loss of 
motility, withdrawal of pseudopodia, disappearance of granules, alterations of cell 
membrane permeability and cell swelling. Mouse, sheep and guinea-pig leukocytes 
however, appeared resistant to these effects (Gladstone and Van Heyningen, 1957, 
Woodin and Wieneke, 1966, Grojec and Jeljaszewicz, 1981). Furthermore, the effect 
of PVL on leukocytes was found to be limited to PMNs, monocytes and macrophages. 
Lack of toxicity for lymphocytes is presumably due to the observed lack of a LukS 
binding site on these cells (Gauduchon et al., 2001). Unlike the alpha toxin, which 
forms heptameric pores, PVL forms octameric pores composed of 4 units of both the 
LukF and LukS subunits (Miles et al., 2002).  
 
Studies by Genestier and colleagues in 2005 pointed at a variation in pore size created 
by the PVL toxin. This variation was dependent on the concentration of toxin present. 
Higher concentrations of toxin were shown to result in the formation of larger pores 
generally causing necrosis. At low toxin concentrations, cells tended to undergo 
apoptosis. The ability of the PVL toxin to induce apoptosis was thought to result from 
the action of the toxin on the mitochondrion following entry of PVL molecules into 
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the cells when present at low concentration (Genestier et al., 2005). This toxin has 
also been noted to induce the liberation of inflammatory mediators such as histamine, 
cytokines and chemokines (Hensler et al., 1994, Tseng et al., 2009), as well as exhibit 
potent dermonecrotic characteristics (Ward and Turner, 1980). 
 
 Genetics of PVL 1.6.3
The two PVL subunits are coded for by a pair of adjacent co-transcribed genes, lukF 
and lukS (Prevost et al., 1995b), which together make up the ≈1.9 kb lukSF-PV locus 
(Figure 1.3). 
 
 
 
 
Figure 1.3: Schematic representation of the lukSF-PV locus 
The lukSF-PV locus is composed of the lukS and lukF genes in the order shown in the 
figure. Numbering corresponds to nucleotide positioning of the lukS and lukF genes 
with relation to the lukSF-PV locus 
 
 
  
  
1 939 941 1918 
lukS lukF 
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The lukF and lukS gene sequences are highly conserved within PVL-positive  
S. aureus strains, with only 12 major single nucleotide polymorphisms (SNPs) 
described to date (Takano et al., 2008b). Most of the mutations in the lukSF-PV locus 
are synonymous, not resulting in an amino acid change. Of the non-synonymous 
mutations, the SNPs at nucleotides 181 and 470 which result in a change from 
phenylalanine to valine and tyrosine to phenylalanine, respectively (Takano et al., 
2008b), occur only in minor variants. More focus has been on the major non-
synonymous mutation found at nucleotide 527. This causes a histidine to arginine 
amino acid change at amino acid position 176, reported to change the predicted 
molecular size of the LukS protein subunit from 35,294 Da to 35,313 Da (Kaneko et 
al., 1998, Kaneko et al., 1997, Narita et al., 2001, Baba et al., 2002, Diep et al., 2006b, 
Ma et al., 2006, Ma et al., 2008, Takano et al., 2008b, Berglund et al., 2008b, Otter et 
al., 2010, Wolter et al., 2007). The possibility of this widespread H176R mutation 
resulting in functional implications for the toxin was hypothesized based on molecular 
modelling (O'Hara et al., 2008). However, direct studies on toxicity in two 
independent studies established that the H176R mutation does not result in significant 
variations in leucotoxicity and pore forming capabilities of the resulting toxin 
(Berglund et al., 2008b, Besseyre des Horts et al., 2010). 
 
Interestingly, the sequence variations present in the genes encoding the LukF and 
LukS proteins appear to correlate with evolutionary origins of a specific strain of  
S. aureus. Members of a specific multilocus ST have generally been reported to have 
the same lukSF-PV sequence variations (Table 1.4). 
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Table 1.4: Relationship between lukSF-PV sequence variants and evolutionary origins  
  Nucleotide positions of allelic variations in PVL encoding genes 
  lukS  lukF 
 ST 33 105 181 216 345 470 527 663  1396 1729 
 1 G T T C C T G T  A A 
 8/1518 G T T C C T G T  A G 
 22/59 G T T C C T A G  G A 
 30/50 G T T C C T A G  A A 
 80 A T T C T T A G  A A 
 88 G C NA NA C NA A G  G A 
 Phage            
 øPVL108/ øSLT G T T C C T A G  A A 
 ø2958PVL G T T C C T A G  G A 
 øPVL G T T G C T A G  G A 
 
Compiled from (Takano et al., 2008b, Berglund et al., 2008b, Otter et al., 2010, Wolter et al., 2007) 
NA: Data Not Available 
ST denotes multilocus sequence types associated with the various lukSF-PV sequence variants 
The three last rows of the table show the lukSF-PV sequence variations associated with some PVL phages 
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 PVL phages 1.6.4
The genes encoding PVL were subsequently shown to be extra chromosomal in 
origin, carried by specific phages, of which at least six have been described in the 
literature (øSLT, øPVL, ø108PVL, ø2958PVL, øSa2USA and øSa2mw) (Kaneko et 
al., 1998, Kaneko et al., 1997, Narita et al., 2001, Baba et al., 2002, Diep et al., 2006b, 
Ma et al., 2006, Ma et al., 2008). The six temperate bacteriophages described were 
similar in size ranging from 41,401 bp to 45,924 bp, but composed of two different 
distinct phage head morphologies, icosahedral and elongated. While only 15% identity 
was noted between the DNA sequence of øSLT and øPVL, the PVL genes were 
highly conserved within all phages with a 99.8% identity observed. 
 
 PVL Controversy 1.6.5
With an apparently firmly established epidemiological link between PVL and  
CA-MRSA, the focus of PVL research subsequently shifted to demonstrating a role 
for PVL as a major virulence factor in CA-MRSA infections. Several studies were 
carried out between 2006 and 2009 to answer this question (Labandeira-Rey et al., 
2007, Brown et al., 2009, Cremieux et al., 2009, Voyich et al., 2006, Bubeck 
Wardenburg et al., 2007a, Bubeck Wardenburg et al., 2008, Diep et al., 2008, 
Montgomery and Daum, 2009). These studies looked for possible effects of the PVL 
toxin in CA-MRSA infections, using different animal and infection models, and both 
isogenic PVL-positive and PVL-negative strains, but resulted in varied and sometimes 
contradictory conclusions. 
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On one hand, results from several studies pointed at a role for PVL as a virulence 
factor in osteomyelitis, pneumonia and skin and soft tissue infections (Labandeira-Rey 
et al., 2007, Brown et al., 2009, Cremieux et al., 2009). These studies reported that 
infection with PVL-positive isolates resulted in a higher degree of morbidity, stronger 
inflammatory response and increased levels of mortality at 24 h when compared with 
infection with PVL-negative strains in different animal infection models examples of 
which include models of pneumonia model and skin infection model in mice and a 
rabbit osteomyelitis model. 
 
On the other hand, a 2008 study by Diep and colleagues using a mouse bacteraemia 
model (Diep et al., 2008), reported findings which could perhaps indicate a role for 
the PVL toxin early in infection. Animals infected with PVL-positive strains had a 
higher bacterial density in the kidneys at 24 h and 48 h post infection than when 
compared to infection with isogenic PVL-negative strains. However, by 72 h a similar 
bacterial density was observed in the kidneys of animals infected with either the PVL-
positive or the PVL-negative isogenic strains. 
 
A third group of researchers however failed to clearly demonstrate a role for PVL in 
virulence (Voyich et al., 2006, Bubeck Wardenburg et al., 2007a, Bubeck Wardenburg 
et al., 2008, Diep et al., 2008, Montgomery and Daum, 2009). In these studies, no 
difference was observed between PVL-positive and their PVL-negative isogenic  
S. aureus strains with respect to morbidity, mortality, PMN lysis or plasma membrane 
damage. One study, involving a mouse pneumonia model, even noted a higher degree 
of mortality following infection with PVL-negative strains (Bubeck Wardenburg et 
al., 2008). 
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At first glance, though the notion that similar research could produce widely differing 
results provided a source of puzzlement, closer scrutiny of study design provided 
clues for the discrepancies between results of these experiments. These study designs 
were not identical but rather, differed on several fronts. Various animal and infection 
models were represented within the different studies. Examples of these include a 
mouse pneumonia model, a mouse skin and soft tissue model, a rabbit osteomyelitis 
model, a rat pneumonia model and a rabbit disseminated infection model. More 
studies though, made use of the mouse model of infection. Mice PMNs have however 
been previously reported to be relatively insensitive to PVL in comparison to human 
or rabbit PMNs (Gladstone and Van Heyningen, 1957, Woodin and Wieneke, 1966, 
Grojec and Jeljaszewicz, 1981). Hence, questions have been raised on the suitability 
of the mouse model in analysing the contribution of PVL to disease virulence and the 
possible effect this could have on experiment outcome (Schwartzman et al., 2007, 
Loughman et al., 2009). Furthermore, reports that in contrast to BALB/cAnNHsd 
mice, no significant mortality occurred in BALB/c mice following intranasal 
inoculation with 5 × 10
7
 cfu of either PVL-positive or PVL-negative isogenic LAC 
strains Bubeck Wardenburg et al. (2008) pointed at subtle variations in susceptibility 
to PVL even between mice strains. 
 
In addition to the variation in animal infection models, the different studies also 
further varied in the type of S. aureus strain used. Examples of the different S. aureus 
strains utilized in these studies include two laboratory S. aureus strains (RN6390 and 
BK9918) and three standard S. aureus strains (Newman, LAC and MW2). Further 
variations were noted in the mode of inoculation, method of sample preparation for 
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analysis of morbidity, criteria for defining morbidity, growth media employed and 
inoculum size. 
 
Based on these variations in study design several issues were raised. These included 
(1) the effect of using a S. aureus strain containing a plasmid expressing high levels of 
PVL (Labandeira-Rey et al., 2007) on result validity, (2) the accuracy of the 
parameters used to define infection in the animal models (with analysis of myositis 
beneath wound infections shown to provide better discrimination than a cursory look 
at just the superficial wound size), (3) the importance of timing in assessing weight 
loss and (4) the procedure for determining lung inflammation (Brown et al., 2009, 
Bubeck Wardenburg et al., 2008, Bubeck Wardenburg et al., 2007a). 
 
The importance of some of these key factors in disease outcome was eventually 
addressed systematically in a 2009 study using a mouse model (Tseng et al., 2009). 
This study involved the use of a larger inoculum (10
9
 cfu) than previously described 
(10
7
 cfu) in the Voyich and Bubeck studies (Voyich et al., 2006, Bubeck Wardenburg 
et al., 2008). Use of a 10
9
 cfu inoculum clearly showed differences between muscle 
lesions caused by PVL-positive strains compared with PVL-negative strains in CD1 
and BALB/c mice genotypes. No differences were however noted between skin 
lesions produced following infection with either PVL-positive or PVL-negative 
strains. Furthermore, this link between PVL-positive strains and severity of muscle 
lesions was also shown to depend on mouse strain. Unlike the results observed with 
the CD1 and BALB/c mice genotypes, for C57/B6 and SKH1 mice, no differences 
were observed between muscle lesions caused by PVL-positive strains compared with 
PVL-negative strains. This correlated with the level of cytokine induction. In the CD1 
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and BALB/c mice, the level of macrophage inflammatory protein-2 (MIP-2) and 
keratinocyte-derived chemokine (KC) were significantly higher following infection 
with PVL-positive strains compared with PVL-negative strains (≈42,000 pg/ml versus 
≈10,000 pg/ml and ≈25,000 pg/ml versus ≈12,000 pg/ml for MIP-2 and KC 
respectively in CD1 mice; ≈39,000 pg/ml versus ≈27,000 pg/ml and ≈42,000 pg/ml 
versus ≈20,000 pg/ml for MIP-2 and KC respectively in BALB/c mice). In contrast, 
infection of C57/B6 and SKH1 mice with PVL-positive strains, did not elicit 
significantly higher level of chemokine (≈41,000 pg/ml versus ≈39,000 pg/ml and 
≈38,000 pg/ml versus ≈31,000 pg/ml for MIP-2 and KC respectively in C57/B6 mice; 
≈26,000 pg/ml versus ≈27,000 pg/ml and ≈21,000 pg/ml versus ≈24,000 pg/ml for 
MIP-2 and KC respectively in SKH1 mice). Higher levels of cytokine induction was 
also found in younger mice and correlated with increased degrees of PVL injury. 
 
When this information is linked with the observation that culture medium composition 
greatly affects the expression of the genes encoding the LukF and LukS PVL subunits 
(Diep et al., 2008), with CCY resulting in higher expression of the PVL toxin than 
TSB, one would tend to agree with the suggestion put forward on the limitations of 
current in vitro models used for studying PVL (Loughman et al., 2009) and the need 
for a standardized protocol. 
 PVL Expression Studies 1.6.6
One other factor that could significantly affect the outcome of infection studies using 
PVL-positive S. aureus strains is the actual level of toxin expressed in vivo. Several of 
the initial studies attempting to link PVL and virulence had completely failed to 
address this factor. Approaches to the investigation of PVL expression have varied 
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both in the samples analysed and the method used to quantify the level of PVL 
expression. Different studies explored PVL expression both directly in skin abscess 
samples (Loughman et al., 2009, Badiou et al., 2008) and in vitro, in culture 
supernatants (Hamilton et al., 2007, Said-Salim et al., 2005). Additionally, one study 
quantified anti-PVL antibody titre in serum in a bid to relate this to the level of toxin 
present (Croze et al., 2009). Though Bronner and colleagues had previously expressed 
concern about the difficulty of leucotoxin quantification by ELISA, due to cross 
reactivity with other class S or class F components (Bronner et al., 2000), advances in 
research meant this issue has been resolved. Hence PVL expression in these studies 
was explored with one of two techniques: Enzyme linked immunosobent assay 
(ELISA) to detect the toxin itself, or reverse transcriptase RT-PCR which directly 
ascertained lukS/lukF mRNA transcript levels. 
 
In all these studies, PVL expression was detected in all strains harbouring the 
encoding genes, albeit with differing levels noted. Also, PVL expression in tissues 
was reported to be up-regulated when compared to in vitro levels of expression by the 
same strains (Loughman et al., 2009). However, separate studies found no correlation 
between in vitro levels of PVL expression and disease severity (Hamilton et al., 2007, 
Said-Salim et al., 2005). Additionally, PVL expression was found to be effected by 
the presence of neutrophils as noted by a 2009 study analysing lukS mRNA transcript 
levels in vitro (Loughman et al., 2009). This study reported an up-regulation of PVL 
expression when clinical strains of S. aureus were grown in media containing 
neutrophils as opposed to when the same strains were grown in media alone. These 
findings were in agreement with a later study (Tseng et al., 2009) which showed 
increased pathogenic effect of PVL-positive S. aureus in young mice with a more 
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aggressive immune response and hence a higher neutrophil level. In addition to the 
neutrophil level, several other factors have been shown to affect the expression of the 
lukF and lukS genes. Some of these include antibiotic concentration (Dumitrescu et 
al., 2008a) and the virulence global regulators agr and sae (Bronner et al., 2000, Wirtz 
et al., 2009). A reduction in sae expression was reported to result in decreased PVL 
production. In addition, the temporal expression of the PVL toxin has also recently 
been linked to the life cycle of the encoding phage and was also influenced by the 
genetic background of the S. aureus host (Wirtz et al., 2009). These various reports 
serve to highlight current gaps in the knowledge of factors affecting PVL expression, 
both in vivo and in vitro. 
 
Though progress is being made in relation to understanding the role of PVL in 
virulence and pathogenesis, a lot of unknowns still exist. In the meantime, the 
prevalence of PVL-positive CA-MRSA infections and colonisations, continue to 
increase. Several studies have proposed that several factors other than PVL may be 
responsible for the apparently enhanced virulence of community-acquired strains of  
S. aureus. These include alpha haemolysin and the phenol soluble modulins (PSMs). 
 
 Alpha Haemolysin/Toxin 1.6.7
Unlike PVL which came into recent prominence due to the rise in CA-MRSA, the role 
of the alpha toxin (HLA) in virulence had been established as far back as 1991. As 
evidenced by studies from 1940 aimed at enhancing the production of HLA (Casman, 
1940), and research on its composition (Bernheimer and Schwartz, 1963), the 
potential importance of this toxin was clearly recognised and a debate on its role in 
pathogenesis begun as early as 1963 (Taubler et al., 1963). 
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This pore forming toxin, which is a prototype of the beta barrel toxin family and the 
first pore forming bacterial cytolysin identified, is the most widely studied of the 
staphylococcal toxins. By 1991, several researchers had extensively studied this 
molecule and provided most of the background knowledge summarized below 
(Bhakdi and Tranum-Jensen, 1991). 
 
The alpha toxin, initially thought to be as large as 44 kDa, is a 33.2 kDa monomer 
which binds to a specific target membrane, assembles to form a mushroom shaped 
heptamer and subsequently undergoes conformational changes to form a 1 – 2 nm 
functional pore. This toxin is active on a wide variety of cell types such as 
lymphocytes, erythrocytes, platelets, endothelial cells, macrophages, fibroblasts and 
keratinocytes. These may differ in susceptibility. Human platelets and rabbit 
erythrocytes have been noted to exhibit a higher sensitivity than human erythrocytes. 
These are significantly resistant, requiring up to 400-fold more toxin to induce lysis 
(Bernheimer and Schwartz, 1963). Based on the concentration of toxin present, 
binding of the alpha toxin monomer may occur either via specific or nonspecific 
interactions. Pore formation often leads to membrane injury and a bidirectional flow 
of ions, water and molecules of low molecular weight such as ATP and ultimately, 
cell lysis (Bhakdi and Tranum-Jensen, 1991, Walev et al., 1993). Secondary effects 
such as alteration of activities of immune cells, stimulation of pro-inflammatory 
mediators (Dragneva et al., 2001) and induction of programmed cell death (apoptosis) 
have also been described (Menzies and Kourteva, 2000, Jonas et al., 1994). 
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Over the years, alpha toxin has been confirmed as a staphylococcal virulence factor in 
a wide variety of infection types (Bramley et al., 1989, Patel et al., 1987, Callegan et 
al., 1994, Kielian et al., 2001). In addition, its toxoid has been demonstrated to offer 
protection against infection (Hume et al., 2000). It was only recently though that this 
staphylococcal virulence factor began to be linked specifically with CA-MRSA, and 
suspected of playing a role in the virulence of these strains. Specifically in relation to 
S. aureus pneumonia, S. aureus LAC hla mutants failed to produce disease in a mouse 
host and immunisation with anti-hla antibodies was shown to protect from infection 
(Bubeck Wardenburg et al., 2007a, Bubeck Wardenburg et al., 2007b, Ragle and 
Bubeck Wardenburg, 2009). 
 
The gene encoding the alpha toxin in contrast to the PVL encoding genes, is found on 
the chromosome of about 99% of S. aureus strains. Expression of this gene may vary 
under different growth conditions, and is influenced by the presence of specific 
antibiotics such as β-lactams and clindamycin as well as quinupristin/dalfopristin 
(Ohlsen et al., 1998, Koszczol et al., 2006, Herbert et al., 2001, Ohlsen et al., 1997). 
Furthermore, expression is controlled by regulatory systems such as the accessory 
gene regulator (agr), staphylococcal accessory gene regulator (sar), extracellular 
protein regulator (xpr), S. aureus exoprotein expression (sae), repressor of toxin (rot) 
and multiple gene regulator (mgr) (Novick et al., 1993, Hart et al., 1993, Cheung et 
al., 1992, Giraudo et al., 1997, McNamara et al., 2000, Luong et al., 2003). The 
specific role of alpha haemolysin in disease caused by community-acquired strains of 
S. aureus has however not yet been verified. 
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 Phenol Soluble Modulins (PSMs) 1.6.8
Phenol soluble modulins (PSMs) belong to a relatively novel class of virulence factors 
‗the modulins‘. These modulins stimulate cytokine production in host cells 
(Henderson et al., 1996). PSMs were specifically named due to their solubility in 
phenol and were initially described in S. epidermidis. These factors exhibit pro-
inflammatory characteristics similar to other modulins previously described, thereby 
indicating a possible role in pathogenesis (Mehlin et al., 1999, Liles et al., 2001). 
 
In 2007, a group of researchers described a novel α-type PSM (PSMα) related to the 
PSM found in S. epidermidis (Wang et al., 2007). While the genes encoding PSMα 
were found to be carried on the genome of all sequenced S. aureus strains, the level of 
in vitro production of the peptides differed. Wang and colleagues noted a higher 
expression of PSMα in CA-MRSA compared to HA-MRSA. Furthermore, this study 
reported that PSMα deletion mutants resulted in reduced mortality in a mouse 
bacteraemia model and exhibited a reduced capacity to induce the lysis of human 
PMNs. These findings led these researchers to propose a role for PSM as the major 
factor associated with the leucocytic ability of CA-MRSA strains and hence their 
virulence. This role has however been questioned by a more recent report which 
observes that, though CA-MRSA isolates produce increased amounts of PSM, the 
concentrations of PSM produced are not sufficient to cause cell lysis (Hongo et al., 
2009). The study by Hongo and colleagues did however note an enhancement of lysis 
of human PMNs by PVL in the presence of PSMα. 
 
This research into the role of PSMs in CA-MRSA is however still in its preliminary 
stages. 
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 S. aureus typing 1.7
To better understand the role of PVL in virulence of community-acquired strains of  
S. aureus, as well as the effect of sequence variations in the lukF and lukS genes on 
epidemiology and spread of these strains, the ability to accurately type, identify 
related isolates and adequately discriminate between variants has been key. 
 
Strain characterisation is important in understanding the epidemiology (spread, 
relatedness and significance) of a particular group of organisms, as well as helping in 
the prevention and control of outbreaks. Over the years, several typing systems have 
been used in strain characterisation. These typing systems have evolved from 
phenotypic systems to the more recent genotypic typing systems and differ in their 
discriminatory power, reproducibility and relevance to specific isolate (Jones et al., 
1974, Kashbur et al., 1974, Cookson et al., 1992, Old et al., 1980, Scherer and 
Stevens, 1987, Colding et al., 1999, Singh et al., 2006). The most important S. aureus 
typing systems will now be considered in detail. 
 
 PFGE 1.7.1
With respect to S. aureus typing, pulsed field gel electrophoresis (PFGE) is the gold 
standard. PFGE which was first described by Schwartz and Cantor in 1984 is a 
modification of the standard agarose gel electrophoresis method which enables the 
resolution of much larger DNA molecules (up to 2,000 kb), by alternating the 
orientation of the electrical currents applied during electrophoresis (Schwartz and 
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Cantor, 1984). This method which was originally used in eukaryotic studies, was first 
applied as a S. aureus typing method in 1991 (Prevost et al., 1991). PFGE involves the 
separation of DNA fragments generated following a restriction enzyme digestion, to 
give a distinct restriction pattern for each isolate. Though several restriction enzymes 
were initially tested, digestion of S. aureus genomic DNA prior to PFGE is routinely 
carried out using the SmaI enzyme. The SmaI enzyme was found to produce the best 
outcome, resulting in 15 – 20 fragments, ranging in size from 30 to 1,500 kb. Other 
enzymes tested, resulted in fragments which were either too many or too few (Prevost 
et al., 1991, Ichiyama et al., 1991, Struelens et al., 1992, Schlichting et al., 1993). 
Following PFGE, isolates can then be typed as same or different by visual comparison 
of the restriction patterns produced. 
 
PFGE was found to have very high discriminatory powers and mainly proving useful 
in short term epidemiology studies, with its ability to distinguish between isolates 
which were evolutionary related but epidemiologically independent (Arbeit et al., 
1990). Several studies have since confirmed the superiority of PFGE to other typing 
techniques including phenotypic analysis, plasmid profiling, phage typing, ribotyping, 
multilocus enzyme electrophoresis (MLEE) and random amplification of polymorphic 
DNA (RAPD) (Prevost et al., 1992, Saulnier et al., 1993). PFGE however has the 
disadvantage of being technically demanding, labour intensive and often difficult to 
interpret, which may result in poor inter-laboratory reproducibility. Hence alternative 
approaches to typing S. aureus strains have been investigated. 
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With DNA sequencing technology becoming more commonplace, sequence based 
typing systems have been developed in recent years. Two such systems are multilocus 
sequence typing (MLST) and spa typing. 
 
 Multilocus Sequence Typing (MLST) 1.7.2
The multilocus sequence typing method which was first described in 1998 (Maiden et 
al., 1998), is derived from the cumbersome MLEE. MLEE uses allele specific 
variation in the electrophoretic mobilities of several housekeeping enzymes to 
generate strain fingerprints. Like PFGE, MLEE was a standard method in eukaryotic 
population genetics before its adaptation to bacterial genetics. The MLEE method 
detects enzyme variants based on differences in enzyme mobility, and is based on the 
principle that this variation relates directly to allelic variations in the encoding genes. 
As these genotypic differences were not expected to always result in enzyme variants, 
this technique involved the analysis of a large number of loci (15 – 25 enzymes) to 
provide sufficient discrimination. While MLEE enabled strain characterisation 
providing global epidemiology the technique was often laborious, technically 
demanding and subjective, making inter-laboratory comparison difficult (Selander et 
al., 1986, Musser et al., 1990, Musser and Kapur, 1992). 
 
Rather than looking at variations in electrophoretic mobility of enzymes, MLST 
focuses directly on variations in the DNA sequences of internal fragments (≈450 bp) 
of housekeeping genes. Thereby allowing the study of fewer loci and resulting in the 
classification of isolates into sequence types (STs). As these genes evolve slowly over 
time, MLST gives a picture of the evolutionary history and global epidemiology for 
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individual strains. Currently, the MLST protocol has been developed for 29 
microorganisms (http://www.mlst.net/databases/default.asp, assessed 11
th
 September 
2012) including many of the major pathogens. The protocol developed for typing 
strains of S. aureus, found that variations in just seven key housekeeping genes are 
enough to class isolates into groups of related ancestry (Enright et al., 2000). The 
housekeeping genes used, and their corresponding gene products are arcC (carbamate 
kinase), aroE (shikimate dehydrogenase), glpF (glycerol kinase), gmk (guanylate 
kinase), pta (phosphate acetyltransferase), tpi (triosephosphate isomerase) and yqiL 
(acetyl coenzyme A acetyltransferase). In MLST, following amplification and 
sequencing of fragments of the seven genes, each isolate is assigned an allele number 
at each of the loci. The information from each individual locus is combined to form 
what is termed an allelic profile which then corresponds to a sequence type (ST). For 
example, an isolate belonging to sequence type (ST) 1 has an allele number of one for 
each locus and hence an allelic profile of 1-1-1-1-1-1-1.  
 
The fact that the MLST technique monitors several genes which evolve slowly over 
time, eliminates the possibility of a chance occurrence when two isolates have the 
same allelic profile. This same characteristic is also a disadvantage of the technique as 
studying a number of genes makes the technique cumbersome and rather expensive to 
perform. One of the major advantages of the MLST method is that it is a nucleotide 
sequence based method with the results available online. As such, it is highly portable, 
allowing both reproducibility and inter-laboratory comparison, quite unlike PFGE. 
With several studies clearly demonstrating similar discriminatory abilities as PFGE, 
(Peacock et al., 2002a, Melles et al., 2007, Grundmann et al., 2002), MLST is now 
one of the major systems used for typing of S. aureus isolates. 
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 spa Typing 1.7.3
A second typing technique routinely used in studying the epidemiology, prevalence 
and spread of S. aureus, is the spa typing method. Use of variations in the spa gene 
which encodes the staphylococcal protein A (Spa) as an epidemiologic tool was 
proposed initially in 1994 (Frenay et al., 1994). Protein A, one of the major surface 
proteins of S. aureus is a cell wall protein covalently linked to the peptidoglycan. Spa 
consists of an IgG binding region and a polymorphic X region (Figure 1.4) made up 
of a variable number of 24 bp repeats (Guss et al., 1984). The variations in this region 
often arise from deletions, duplications and point mutations in the repeats (Kahl et al., 
2005). The 1994 Frenay study found a correlation between the number of 24 bp 
repeats in the X region of protein A and the epidemic status of the strain. Most 
epidemic strains were found to have > 7 repeats while non-epidemic strains contained 
7 or less repeats. The actual spa typing technique involves the amplification and 
sequencing of the polymorphic X region using primers located in the well conserved 
flanking regions (Frenay et al., 1996). Spa types are then assigned based on the 
sequence, number and arrangement of repeats found. 
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Figure 1.4: Illustration of the spa gene showing the polymorphic X region (Xr) used in spa typing and the positioning 
of the primer sequences used for both amplification and sequencing.  
Reproduced from: Shopsin et al. (1999) 
 
The numbered arrows indicate the 5′ start location of the forward and reverse primers on a S. aureus (GenBank accession No: J01786) forward 
strand. The spa gene segments are indicated by the lettered boxes (not to scale): S: Signal Sequence; A – D: Immunoglobulin G-binding regions; 
E: Region homologous to A – D; Xc: Cell wall attachment sequence. 
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Prior to 2003 and the development of the Ridom StaphType software 
(http://spaserver.ridom.de/) (Harmsen et al., 2003), several programs had been used 
for the identification and assignment of new repeats. These programs, unlike the 
Ridom StaphType, described spa types using alpha numeric codes and differed 
between researchers, often leading to non-uniform assignment of spa types (Shopsin 
et al., 1999, Tang et al., 2000). With the introduction of the open access internet-based 
Ridom StaphType software this limitation has been overcome and portability and 
uniformity of the technique has been established. 
 
Further validation of this technique as a molecular tool has deemed it comparable to 
other current techniques with a discriminatory power lower than PFGE but higher than 
MLST (Shopsin et al., 1999). Thus, spa typing has proved quite useful in the 
investigation of local outbreaks especially but has also been shown to be valuable in 
the analysis of the long term evolutionary history of S. aureus strains (Shopsin et al., 
1999, Khandavilli et al., 2009, Mellmann et al., 2008). In addition to speed, other 
advantages include ease of use, interpretation and inter-laboratory comparison. 
Currently, MLST is a more widely used technique in relation to S. aureus 
epidemiology but, due to its cost advantage, spa typing is becoming more commonly 
used with researchers applying spa typing to larger panels of isolates and MLST to 
only a subset of such strains (Ellington et al., 2009, Alp et al., 2009, Witte et al., 
2007). 
 
So far over six thousand (6,000) spa types have been described containing a total of 
364 unique repeats with the number of repeats in each spa type ranging from 2 to 16 
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(http://spaserver.ridom.de/). Though a few exceptions occur, most spa types are 
unique to an MLST clonal complex (Basset et al., 2009, Deurenberg et al., 2007, 
Cookson et al., 2007) making both techniques comparable. 
 
 High Resolution Melt Analysis 1.7.4
Current typing methods though quite discriminatory, are however still quite 
cumbersome, expensive and time consuming. High resolution melt (HRM) analysis is 
an extension to the traditional melting curve capabilities of real-time PCR systems and 
is one recently introduced technology which may have useful application as a rapid 
diagnostic tool, providing useful typing information. The first reports of HRM in 
2003, used labelled primers in a closed-tube system to identify sequence variants of 
the β-globin gene without any additional manipulations prior to performing the melt 
analysis (Gundry et al., 2003). The use of labelled primers however meant that 
variations in the sequence could only be detected if they occurred within the same 
melt domain as the labelled primer. A subsequent advancement to this method 
published in the same year overcame this limitation. This method involved the use of 
a novel dye (LCGreen) that unlike SYBR Green, bound to DNA but did not inhibit the 
PCR at high concentrations (Gundry et al., 2003, Wittwer et al., 2003). 
 
Since then, HRM has been widely applied in both gene scanning – often leading to 
disease detection – (Krypuy et al., 2006, Takano et al., 2008a, White et al., 2007, 
Slinger et al., 2007) and genotyping of different isolates based on variations in 
specific genes. Examples include the detection and identification of several clinically 
important bacterial species by variations in their 16S rRNA gene (Cheng et al., 2006), 
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the differentiation of influenza A virus subtypes based on the viral matrix gene (Lin et 
al., 2008), and Mycoplasma pneumoniae typing (Schwartz et al., 2009). 
 
HRM combined improved dye chemistry and machine resolution with novel software 
technologies to detect differences in amplicon melt curves with a high degree of 
sensitivity and specificity. Originally, dyes used in the detection of double stranded 
DNA such as SYBR Green I, were non-saturating and showed an inhibitory effect on 
DNA amplification at high concentrations. The development of saturating ds-DNA 
binding dyes was pivotal in HRM development. These dyes unlike SYBR Green I are 
non-inhibitory and may therefore be used at saturating concentrations, thus enabling 
binding to each base pair of the target amplicon. This property also possibly prevents 
dye redistribution during the melting process and results in improved sensitivities and 
accuracies (Wittwer et al., 2003). LCGreen was the first saturating dye to be described 
and others developed over the years include SYTO9, LCGreen Plus, EvaGreens and 
resolight dye (Wittwer et al., 2003, Monis et al., 2005, Vossen et al., 2009). HRM is 
currently available on several platforms, examples of which include the ABI 7300, 
Eppendorf Mastercycler RealPlex4S, Idaho Technology LightScanner, Roche 
LightCycler480 and Corbett Rotor-Gene 6500HRM. In comparison to the real time 
platforms, these instruments have an improved ability to measure amplicon melt 
behaviour due to an increase in temperature precision and improved data acquisition. 
The accompanying software is a third factor contributing to HRM sensitivity. This 
software allows the generation of a difference curve from the melt curve, usually 
following a temperature shift to correct for subtle temperature differences across the 
plate, and a normalization process which corrects for variations in starting template 
concentration (Herrmann et al., 2007, Herrmann et al., 2006).  
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HRM is capable of detecting a single base pair difference in an amplicon of up to 
1,000 bp in length (Reed and Wittwer, 2004). This capability of HRM however 
depends in part on amplicon length. Several studies have reported a higher degree of 
sensitivity for shorter length products (Reed and Wittwer, 2004, Gundry et al., 2003, 
Liew et al., 2004, Krypuy et al., 2006, Herrmann et al., 2006). Best results were 
obtained when analysing HRM products of less than 300 bp in length. In addition to 
amplicon length, the SNP class affects the outcome of HRM analysis. SNP classes 
describe the grouping of the six possible binary combinations of base mutations 
(where a G – T mutation is equivalent to a T – G mutation) based on the type of base 
change (Liew et al., 2004). Class 1 SNPs represent a C – T or G – A transition 
mutation (i.e. purine to purine change or pyrimidine to pyrimidine change). On the 
other hand, class 2 SNPs represent the C – A or G – T transversion mutation (i.e. 
purine to pyrimidine change). Class 3 SNPs specifically refer to a G – C mutation and 
class 4, a T – A mutation. While all SNPs can potentially be detected, class 3 and 4 
SNPs produce relatively small Tm differences (0.25°C) compared to the class 1 and 2 
SNPs (0.8 – 1.4°C) and hence often result in more problematic genotyping. 
 
 Typing approaches used to study evolution of S. aureus 1.8
One major contribution made by the several typing systems utilized in the study of  
S. aureus, was to the understanding of the evolution of this group of isolates, 
particularly the meticillin resistant strains. While the initial phenotypic typing systems 
simply enabled the classification of isolates as either same, different or possibly 
related, the early molecular based systems MLEE and PFGE went a step further. 
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MLEE defined genetic distance between two groups of isolates using the average 
linkage method described by Selander and colleagues (Selander et al., 1986). In this 
method, isolates which differed at all loci had a genetic distance of 1 and identical 
isolates a distance of 0. When combined with the assumption for PFGE that one SNP 
in chromosomal DNA could create a three fragment variation in restriction profile 
(Bannerman et al., 1995), both methods recognized that the relationship of isolates 
with a profile similarity of 85% or more (corresponding to a genetic distance of 0.20) 
was such that this high degree of similarity could not have occurred by chance. Hence 
such strains represent subtypes of the same clone with a common ancestor. 
 
For MLEE and PFGE which type isolates based on 15 to 20 variables, this could 
simply be interpreted thus: isolates with a maximum allelic variation of 3 were 
considered clonal but were classed as different if the number of mismatches exceeded 
this number (Selander et al., 1986, Musser and Kapur, 1992, Struelens et al., 1992, 
Bannerman et al., 1995, Dominguez et al., 1994). Tenover and colleagues went on to 
further propose that since 2 independent genetic events could possibly result in a 4 – 6 
band difference, isolates differing at less than 7 bands were probably of the same 
genetic lineage but only less closely related (Tenover et al., 1995). These guidelines 
were however only applied in an outbreak setting. 
 
The development of MLST (Enright et al., 2000) enabled major breakthroughs in the 
understanding of how these bacterial clones evolved. For this technique in which 
isolates were typed based on genetic variations at 7 housekeeping genes (which by 
their nature evolve relatively slowly over time), isolates identical at all loci were 
thought to have evolved from a common ancestor and classed as a sequence type (ST). 
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Those differing at one locus were however considered closely related and grouped 
together to form a clonal complex (Feng et al., 2008). One study went on to 
demonstrate how well the evolutionary events as defined by MLST agreed with that 
previously proposed by Tenover and colleagues based on PFGE band variation 
(Enright et al., 2000). Isolates belonging to the same sequence type were found to 
differ at 4 bands or less while members of the same clonal complex generally had a 
maximum of 7 band differences. Conversely, highly dissimilar STs possessing 
variations in 6 of the 7 MLST loci were found to have at least a 20 band difference. 
 
Perhaps the major success of MLST as a technique was in its ability to provide a 
framework to work out the process whereby various lineages evolved from each other. 
The putative ancestral ST for each clonal complex was usually the predominant 
member of the group. This had long been defined as the genotype which varied from 
most other members of the CC at only a single locus. Hence, subsequent members of 
each clonal complex were thought to have evolved from these putative ancestral STs 
(Enright et al., 2002). This hypothesis was validated by the findings of Feil and 
colleagues published in 2003 (Feil et al., 2003). In this study, single locus variants 
(SLVs) were shown to possess only a single nucleotide difference from the putative 
ancestral ST. Furthermore, the resulting variant locus was generally not represented 
among any other ST but unique to the specific SLV, clearly demonstrating that these 
STs had evolved directly from the putative ancestral genotype via point mutations 
rather than recombination. At that time, two groups of isolates (ST34 and ST40) were 
found to appear as exceptions to this model of evolution. Both groups contained 
allelles not unique to their clonal complexes and hence could only have arisen via 
recombination between two different clonal complexes (Feil et al., 2003). 
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 eBURST 1.8.1
One tool which proved useful in studying the evolution of S. aureus, was the eBURST 
(based upon related sequence types) algorithm described in 2004 (Feil et al., 2004). 
This algorithm was a new implementation of the previously described BURST 
program (Enright et al., 2002) which was designed primarily for the analysis of MLST 
data. The principle of the eBURST algorithm is based on the simplest model which 
explains the emergence of clonal complexes. This model proposes that the emergence 
of a clonal complex results following an increase in the frequency of a ‗founding 
genotype‘ within a population. This increase, results in genetic diversification of the 
founding genotype such that descendants which differ from this ‗founding genotype‘ 
at one of seven MLST loci accumulate, resulting in a clonal complex. The eBURST 
algorithm has three major functions. First, eBURST divides the STs in the MLST 
database into mutually exclusive groups of related genotypes based on a user defined 
parameter. This defines members of an eBURST group as STs with a minimum 
number of identical alleles as at least one other member of the group. The minimum 
number of identical alleles may be user defined, but more commonly a default setting 
is used. The default setting defines an eBURST group as STs which are identical at 6 
or 7 of the MLST alleles as at least one other member of the group. Based on this 
definition, STs which differ at two or more alleles from every other ST in the 
population cannot be assigned a group and are referred to as singletons. Within the 
eBURST groups, the algorithm then further identifies a ST which serves as the 
putative ancestral genotype or primary founder from which the other STs diverged. 
The primary founder is defined as the ST with the largest number of SLVs within the 
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group. Importantly, this process does not depend on the number of isolates in each ST 
and hence, is independent of sampling bias. 
 
Furthermore, the level of confidence in the accuracy of the predicted primary founder 
is represented by a bootstrap value. These values represent the percentage of times a 
specific sequence type is predicted as the primary founder following a bootstrap 
resampling procedure. This need for statistical confidence in the predicted primary 
founder is important because of the third function of eBURST. This algorithm predicts 
and displays the most likely pattern of evolutionary descent of the isolates in the 
clonal complex from this primary founder. This information is presented as a radial 
diagram whereby the primary founder is linked to its SLVs, which then link to double 
locus variants (DLVs) of the primary founder and so on. 
 
Despite the current widespread use of this algorithm, it must be noted that the pattern 
of evolutionary descent described by eBURST is inferred and does not take into 
account any additional data, be it phenotypic, genotypic or epidemiological. An 
example of a possible misrepresentation of evolutionary relationship by the eBURST 
algorithm was reported in the initial eBURST publication (Feil et al., 2004). ST239 
was described as a primary founder of a group containing ST8, on the basis of ST239 
possessing one SLV more than ST8. This grouping however, contrasted with a 
previous study (Enright et al., 2002). The study by Enright and colleagues, assigned 
ST8 as the primary founder of this group of isolates based on the absence of meticillin 
sensitive strains in ST239 and the observation that ST239 carried a type III SCCmec 
element found only in an MRSA ST8 strain within this grouping. Feil and colleagues 
had however reported a similarly high bootstrap value for ST239 and ST8 (70% and 
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66% respectively). This finding highlighted a possible issue in assigning ST239 as 
primary founder and emphasized the importance of taking the bootstrap value into 
consideration when interpreting the data generated by eBURST. 
 
 MRSA Evolution 1.8.2
The genotypic typing systems also proved quite invaluable in understanding the 
evolution of MRSA, especially in deciding between the single and multi–clone 
theories of MRSA evolution. Prior to 2002, several studies had put forward evidence 
in support of either different MRSA clones emerging from a single MSSA clone 
which acquired the SCCmec element once (the single clone theory), or the multiple 
acquisition of SCCmec elements by the different S. aureus lineages (multi clone 
theory) (Lacey and Grinsted, 1973, Carles-Nurit et al., 1992, Musser and Kapur, 1992, 
Kreiswirth et al., 1993, Crisostomo et al., 2001). The extensive study by Enright and 
colleagues in 2002, however, showed the multi clone theory to be the more likely 
theory (Enright et al., 2002). This study, which analysed over 900 isolates, noted the 
presence of both MSSA and MRSA within the same ST. This finding thereby pointed 
at the development of MRSA following the acquisition of a SCCmec element by 
meticillin sensitive strains. In addition to this, the detection of multiple SCCmec types 
in strains belonging to a single ST pointed at a case of multiple acquisitions. An 
exception to this model of MRSA evolution was however described with ST259 and 
ST247. These two groups of isolates lack meticillin sensitive members but rather are 
composed entirely of meticillin resistant strains. Hence ST259 and ST247 are thought 
to have evolved from point mutations in MRSA variants of their parent clones. 
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 Restriction-Modification Systems 1.9
One factor which may come into play in the evolution of S. aureus strains is the 
bacterial restriction-modification (RM) system. RM systems were initially described 
in the early 1950s (Luria and Human, 1952, Maio and Zahler, 1958, Bertani and 
Weigle, 1953) and are mainly found in bacteria but also present among other 
prokaryotes (Boyer, 1971, Patterson and Pauling, 1985, Wilson, 1991). RM systems 
are thought to serve as some sort of primitive bacterial immune system whereby they 
create a barrier that restricts the uptake of foreign DNA. These systems are thought to 
have evolved primarily to protect bacteria from viral infection. Bacterial RM systems 
are so named due to their mode of action. They act mainly by degrading foreign DNA 
fragments following the detection of a specific sequence, while a modification of the 
hosts own DNA by methylation protects it from restriction. In some cases though, 
restriction only occurs on modified foreign DNA (Bickle and Kruger, 1993). 
 
Several RM systems exist and differ in their composition and exact mechanism of 
action. RM systems may contain up to three distinct subunits, the R, M and S subunits 
(Wilson and Murray, 1991, Wilson, 1991, Bickle and Kruger, 1993, Boyer, 1971). 
The S or specificity subunit recognises a specific sequence to be modified or 
restricted, the M or modification subunit methylates the host DNA and the R or 
restriction subunit facilitates the cleavage of un-methylated DNA. The type I RM 
system is the most complex (Wilson and Murray, 1991) and has all three subunits 
present. In this system, the recognition site/sequences are not symmetrical but rather 
made up of two elements ranging from three to five nucleotides in length separated by 
a non-specific region ‗the spacer‘. This is often six to eight nucleotides long, as seen 
in the case of E. coli EcoBI which recognises the sequence TGA(N8)TGCT (Dryden et 
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al., 2001). This recognition site however differs from the cleavage site, with restriction 
enzymes acting at a significant distance away from it. On the other hand, the type II 
system is often described as the simplest. This is more commonly found in nature and 
serves as the source of quite a number of the restriction enzymes employed in 
biological research. In this case both recognition and cleavage occur at the same 
sequence. The sequences are specific and cleavage takes place within the sequence in 
a symmetric manner (Pingoud et al., 2005). Other RM types include the type IIs which 
have a non-symmetric recognition sequence and an endonuclease that acts a distance 
from this. In addition to this, the rarely occurring type III and type IV systems have an 
asymmetric and uninterrupted recognition sequence (Janulaitis et al., 1992). The type 
IV differs simply from the type III in that it does not require ATP for its activity. 
 
Several restriction modification systems have been described in strains of S. aureus 
and while these predominantly belong to the type II class, these systems are not 
widespread and are often carried on mobile genetic elements (Sussenbach et al., 1976, 
Iordanescu and Surdeanu, 1976, Sussenbach et al., 1978, Seeber et al., 1990, Godany 
et al., 2004, Dempsey et al., 2005). Recently however, a chromosomally located type I 
RM system (Sau1) has been described (Waldron and Lindsay, 2006). This Sau1 
system is found to be widely distributed among strains of S. aureus and includes a 
single restriction gene (hsdR), two copies of the modification gene (hsdM and hsdM1) 
and two copies of the sequence specificity gene (hsdS1 and hsdS2). Three of these hsd 
genes (hsdR, hsdM and hsdM1), exhibited a high degree of homology (>95%). 
Variations in both copies of the specificity gene (hsdS and hsdS1) however, appear 
linked with S. aureus lineage and hence may have contributed to the development and 
maintenance of these lineages. 
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 Conclusion 1.10
Since the first reports of CA-MRSA infections in the mid 1990s, the threat it poses has 
not diminished but rather increased. These strains are now routinely isolated in health 
care settings with the CA-MRSA USA300 strain reported as the most frequent cause 
of hospital-acquired MRSA infections in the USA (Seybold et al., 2006). Taken 
together with the increase in multi-drug resistance observed in these strains (Boyle-
Vavra et al., 2005, Takizawa et al., 2005), the very definitions of CA-MRSA are being 
challenged, blurring the lines between community-acquired and hospital-acquired 
isolates. The need therefore to define and understand factors which play a role in both 
the virulence and pathogenesis of these isolates remains ever pressing. Though recent 
reports confirming a role of PVL in CA-MRSA infections (particularly necrotising 
pneumonia) have brought the scientific community a step forward in relation to these 
strains, a lot of questions are still left unanswered. 
 
 Aims and Objectives 1.11
This first aim of the present study was to explore the genetic diversity of a group of 
local PVL-MSSA clinical isolates in order to contribute to the limited current data and 
provide insight into the evolution and emergence of PVL-MRSA isolates. In addition, 
as current typing systems are cumbersome and time consuming, the present study was 
also aimed at the development of a rapid high resolution melt (HRM) typing system 
for the characterisation of PVL-isolates. Thirdly, an enzyme-linked immunosorbent 
assay (ELISA) system was developed for the detection and quantification of both PVL 
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and alpha haemolysin which could be used as a research tool and potentially in 
clinical diagnosis to provide prompt diagnosis and hence improve patient care.
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Chapter Two 
 
2 General Materials and Methods 
 Media 2.1
Unless otherwise stated all growth media were purchased from either Fisher Scientific 
(Loughborough, UK), Oxoid (Basingstoke UK) or Sigma-Aldrich (Dorset UK), 
prepared according to manufacturer‘s instructions and sterilised by autoclaving at 
121°C at 15 psi for 20 min. 
 
The media used in the present study include Luria Bertani (LB) broth, LB agar, Brain 
Heart Infusion (BHI) broth, Trypticase Soy Broth (TSB) and CYGP (Casamino acids-
yeast extract-glycerophosphate) broth. The composition of these media is as indicated 
in Appendix 1. 
 
100 µg/ml of ampicillin was added to the media where required to select for the 
growth of ampicillin-resistant cultures. 
 
 Chemicals 2.2
All chemicals used in the present study were obtained from either Sigma-Aldrich 
(Dorset, UK) or BD Biosciences (Oxford, UK), unless otherwise stated. 
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 PVL-positive test isolates. 2.3
The PVL-positive S. aureus used in the present study consisted of two groups, both of 
which contained MSSA and MRSA isolates. The first group contained recent clinical 
isolates recovered between November 2008 and May 2009 from Nottingham 
University Hospitals (NUH) NHS Trust and confirmed as PVL positive by the Health 
Protection Agency (HPA) Staphylococcus Reference Unit (SRU) (Table 2.1). The 
second group contained all of the PCR confirmed, PVL-positive strains available in 
the University of Nottingham S. aureus strain collection. These had been obtained 
from two sources which are indicated in Table 2.2. All of the isolates were stored 
frozen at -80°C in trypticase soy broth (TSB) containing 10% v/v glycerol. 
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Table 2.1: NUH NHS Trust PVL-positive S. aureus clinical isolates 
S/No Strain ID Meticillin Status Source  
1.  TS1 MSSA NUHa 
2.  TS2 MRSA NUH 
3.  TS5 MSSA NUH 
4.  TS6 MSSA NUH 
5.  TS7 MSSA NUH 
6.  TS8 MSSA NUH 
7.  TS9 MSSA NUH 
8.  TS12 MSSA NUH 
9.  TS13 MSSA NUH 
10.  TS14 MSSA NUH 
11.  TS15 MSSA NUH 
12.  TS16 MSSA NUH 
13.  TS17 MSSA NUH 
14.  TS18 MSSA NUH 
15.  TS19 MSSA NUH 
16.  TS20 MSSA NUH 
17.  TS21 MSSA NUH 
18.  TS23 MSSA NUH 
19.  TS24 MSSA NUH 
20.  TS25 MSSA NUH 
21.  TS26 MRSA NUH 
22.  TS27 MRSA NUH 
23.  TS28 MRSA NUH 
24.  TS29 MRSA NUH 
25.  TS30 MRSA NUH 
a
NUH: Nottingham University Hospital. 
Isolates were recovered between November 2008 and May 2009 at NUH and confirmed 
as PVL positive by the Health Protection Agency (HPA) Staphylococcus Reference 
Unit (SRU) 
 
86 
 
Table 2.2: PVL-positive S. aureus isolates from the University of 
Nottingham S. aureus strain collection. 
S/No Isolate ID Meticillin Status Source 
1.  NRS123 MRSA NARSAa 
2.  NRS157 MSSA NARSA 
3.  NRS158 MSSA NARSA 
4.  NRS162 MSSA NARSA 
5.  NRS185 MSSA NARSA 
6.  NRS192 MRSA NARSA 
7.  NRS194 MRSA NARSA 
8.  NRS227 MSSA NARSA 
9.  NRS229 MSSA NARSA 
10.  NRS248 MRSA NARSA 
11.  NRS255 MRSA NARSA 
12.  RSS289 MSSA RSb 
13.  RSS290 MSSA RS 
a
NARSA strains had previously been purchased from the Network on Antimicrobial 
Resistance in Staphylococcus aureus strain collection 
 
b
RS: Richard Spence strain collection comprised of clinical strains isolated from the 
Nottingham University Hospitals between January 2003 and October 2005 (Spence, 
2007). 
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 Growth of Staphylococcus aureus and Escherichia coli 2.4
Strains used in the present study were propagated at 37°C aerobically, unless 
otherwise stated. Growth on solid media was routinely carried out statically by 
overnight incubation, while liquid cultures were grown overnight in a G25 orbital 
shaker incubator (New Brunswick Scientific Co Inc. Edison, New Jersey USA) with 
shaking at 200 rpm. 
 
 Genomic DNA Extraction 2.5
DNA extraction from S. aureus cultures was carried out using the DNeasy® blood and 
tissue kit (Qiagen, Crawley UK) according to manufacturer‘s instructions with some 
modifications. Firstly, bacterial cells were harvested from 3 ml of overnight culture by 
centrifugation at 13,000 rpm for 2 min using a benchtop centrifuge (Pico, Biofuge). 
Cells were subsequently lysed by resuspending in 180 µl enzymatic lysis buffer 
(20 mM Tris [pH 8.0], 2 mM EDTA and 1.2% v/v Triton X-100) supplemented with  
5 μl of 5 mg/ml lysostaphin in water and 5 μl of 1 mg/ml RNase A in water and 
incubated for 30 min at 37°C. This was followed by addition of 25 µl of 600 mAU/ml 
of proteinase K and 200 µl of buffer AL (both supplied with the Qiagen kit) and a 30 
min incubation at 56°C. Following this, 200 µl of 100% ethanol was added to the 
sample and the whole mixture applied to a DNeasy spin column, from which it was 
purified by a series of washes and centrifugation as described in the manufacturer‘s 
instructions. Finally, the DNA was eluted from the column using 200 µl of sterile 
distilled water and stored at -20°C. 
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 Plasmid DNA Extraction from E. coli 2.6
For plasmid extraction, 3 ml of overnight culture was harvested by centrifugation at 
13,000 rpm for 1 min and extraction carried out using the Qiaprep miniprep kit 
(Qiagen, Crawley UK) according to the manufacturer‘s instructions. Cell pellets were 
resuspended in 250 µl of Buffer P1. Following this, 250 μl of Buffer P2 and 350 μl of 
Buffer N3 were added to complete the lysis process and denature genomic DNA. Cell 
debris and precipitated genomic DNA were then removed by centrifugation at  
13,000 rpm for 10 min. Plasmid DNA in the supernatant was then applied to a 
Qiaprep spin column from which it was purified by a series of washes and 
centrifugation as instructed. Finally, the DNA was eluted using 50 µl of sterile 
distilled water and stored at -20°C. 
 
 DNA quantification 2.7
The quantity and purity of extracted DNA was determined using a NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Wilmington USA). The purity of 
the DNA sample was determined from the ratio of sample absorbance at 260 nm and  
280 nm with ratios between 1.8 and 2.0 indicating pure DNA samples. 
 
 Primer Design and Synthesis 2.8
Primers were designed using Primer 3 input 
(http://frodo.wi.mit.edu/http://frodo.wi.mit.edu/) with the aid of DNA sequences 
obtained via the NCBI database and their specificity ascertained using the NCBI 
BLAST tool  
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(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome). 
Unless otherwise stated, primer synthesis was carried out by Sigma-Aldrich Ltd 
(Dorset, UK) on a 0.05 M synthesis scale with purification by desalting. The 
exception to this was in the case of primers used in the HRM assays where higher 
purity primers are required. These were purified by HPLC. 
 
 Polymerase Chain Reaction (PCR) 2.9
A 10 mM dNTP solution was prepared from 100 mM stock solutions of dATP, dCTP, 
dGTP and dTTP (Promega, Southampton UK) by combining 50 µl of each dNTP 
stock with 300 µl of sterile distilled water. 
 
Unless indicated, all DNA amplification reactions were carried out on a Techne TC-
312 cycler (Barloworld Scientific, Staffordshire UK) in a 50 µl volume made up of 1 
× Phusion High-Fidelity DNA Polymerase buffer (New England BioLabs, Herts, UK), 
200 µM dNTPs, 0.5 µM of each primer, 0.5 µl of template DNA and 0.5 µl of 2 U/µl 
Phusion High-Fidelity DNA Polymerase (New England BioLabs, Herts, UK) and 
sterile distilled water. Thermal cycling conditions consisted of an initial denaturation 
at 98°C for 5 min, followed by 30 cycles of denaturation at 98°C for 10 s, annealing at 
55°C for 30 s and elongation at 72°C for 30 s with a single final extension at 72°C for 
5 min. 
 
 DNA Electrophoresis 2.10
DNA fragments were visualised following agarose gel electrophoresis using 1 – 1.5% 
w/v agarose gels prepared in 1 × TAE buffer (Appendix 2) containing 5 µg/ml 
90 
 
ethidium bromide (EtBr). Aliquots of DNA samples and a 1 kb standard ladder 
(Promega, Southampton, UK) were added to 5 × loading buffer and then loaded into 
wells in the set agarose gel. Following electrophoresis for 45 – 60 min at 80 – 100 V 
(BioRad PowerPac 200/2.0), visualisation of dsDNA was then carried out using a UV 
transilluminator and the image was captured using the attached Uvitec gel image 
capture equipment (Uvi Tec, Cambridge, UK). 
 
 Purification of PCR products 2.10.1
Where necessary, purification of PCR products was carried out to remove excess 
primers and PCR components in order to prevent potential interference with 
downstream applications. This was done using either a QIAquick PCR Purification 
Kit or a QIAquick Gel Extraction Kit (Qiagen, Crawley UK) according to the 
manufacturer‘s protocols. Elution of pure DNA was then carried out using 50 µl 
sterile water after a series of washes to remove contaminants. 
 
 DNA Sequencing 2.10.2
All DNA sequencing in the present study was carried out at the Biopolymer Synthesis 
and Analysis Unit (BSAU) of the School of Biomedical Sciences (University Of 
Nottingham) with 3130xl ABI PRISM Genetic Analyzer and the BigDye version 3.1, 
dye terminator chemistry. Sequences were analysed using Chromas Lite 2.0 software 
(http://chromas-lite.software.informer.com/2.0/). The primers employed for each 
sequencing reaction are described in the relevant result chapter of this thesis. 
 
91 
 
 Methods used in DNA manipulation 2.11
 A-tailing 2.11.1
In order to insert blunt ended DNA fragments generated using Phusion High-Fidelity 
DNA Polymerase into the pGEM
®
-T plasmid vector (Promega, Southampton UK), it 
was first necessary to create a dATP tail at both 5′ ends of the fragment. The A-tailing 
procedure was carried out as described in the Promega pGEM-T and pGEM-T Easy 
vector systems technical manual. This involved the incubation of 10 µl of purified 
DNA fragment in a 20 µl reaction mixture composed of 2 mM MgCl2, 0.2 mM dATP, 
2 µl Taq DNA polymerase (5 U/ml) and 1 × Taq DNA buffer at 70°C for 25 min. 
 
 DNA Ligation 2.11.2
Ligation of DNA fragments was carried out using Promega T4 DNA ligase in a 10 µl 
ligation mixture. This consisted of 1 × ligation buffer (30 mM Tris-HCl pH 7.8, 10 
mM MgCl2, 10 mM DTT and 1 mM ATP), 1 µl of 1000 U/ml T4 DNA ligase and 
varying volumes of DNA insert and vector and sterile distilled water. The ligation 
reaction was carried out overnight at 16°C. 
 
Following this, the ligation mixture was dialysed for 15 min against sterile distilled 
water using a 0.025 µm filter (Millipore) prior to transformation or storage at -20°C. 
 
 Restriction Enzyme (RE) Digestion 2.11.3
Digestion of plasmid DNAs using XhoI and NcoI (New England Biolabs, Herts, UK) 
restriction enzymes was carried out in a 20 µl reaction volume containing 1 × NEB 
Buffer 4 (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 
92 
 
1 mM DTT pH7.9), 2.5 µl of DNA, 1 µl of each enzyme (20,000 U/ml) and distilled 
water which was incubated for 1 h at 37°C. 
 
 Preparation of Competent E. coli 2.11.4
In order to prepare competent cells, an overnight bacterial culture of the appropriate 
strain of E. coli grown in LB broth was diluted 1:100 into 500 ml fresh LB broth. This 
was incubated at 37°C with shaking until an OD600nm of 0.5 was reached. Bacterial 
cells were then centrifuged at 4°C for 15 min at 4000 × g using an Allegra X-22R 
(Beckman Coulter, High Wycombe, UK). Harvested cells were subsequently washed 
by a series of resuspensions and centrifugation steps using 1 × and 0.5 × original 
culture volumes of sterile cold water. Following a final wash and centrifugation step 
using 20 ml of cold 10% v/v glycerol in water, competent cells were recovered into  
1 ml of 10% v/v glycerol in water, aliquoted, fast frozen using liquid nitrogen and 
stored at -80°C. 
 
 Transformation of E. coli by electroporation 2.11.5
10 µl of plasmid DNA was added to 40 µl of thawed electrocompetent cells on ice 
without mixing. This mixture was then transferred into a 2 mm cuvette (Geneflow 
Staffordshire, UK) and electroporated using a MicroPulser Electroporator (BioRad, 
Hemel Hempstead UK) by applying 2.5 kV at 200 Ω and 25 µFD. This was followed 
by the immediate addition of 800 µl of LB broth. Following a 2 h incubation at 37°C, 
200 µl of culture was then plated onto LB agar plates supplemented with 100 µg/ml 
ampicillin. Plates were incubated overnight at 37°C to select for transformants. 
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 Protein Separation and Visualisation 2.12
 Preparation of E. coli cell lysates by sonication 2.12.1
Lysis of E. coli BL21/DE3 cells expressing recombinant proteins was carried out by 
sonication. Cell pellets resuspended in PBS (or appropriate buffer for column 
purification) were cooled on ice for 10 min prior to sonication. Cells were sonicated at 
an amplitude of 5 microns for 60 s using a Soniprep 150 (Sanyo). Sonication was 
repeated 3 - 5 times with cooling on ice between cycles to prevent overheating of the 
samples. 
 
 Cell Fractionation 2.12.2
The presence of expressed proteins in soluble and insoluble E. coli fractions was 
investigated following fractionation of sonicated whole cell lysates. Following 
centrifugation of lysates at 13,000 rpm for 10 min, the resulting supernatant 
corresponding to the soluble fraction was removed and retained. The pellet which 
represents the insoluble fraction was then washed in PBS to remove any remaining 
soluble fraction and re-centrifuged. Cell fractions were stored at -20°C. 
 
 Sample Preparation for SDS-PAGE 2.12.3
Protein samples for SDS-PAGE were denatured by a combined effect of sample buffer 
and heat. This was done by adding the appropriate volumes of single or double 
strength SDS sample buffer (Appendix 2). 2 × SDS sample buffer was added to the 
whole cell lysate and soluble fractions, while the insoluble fraction was resuspended 
in 1 × SDS sample buffer. All samples were boiled for 5 min. Samples were 
subsequently centrifuged at 13,000 rpm for 3 min to remove debris. 
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 SDS-PAGE  2.12.4
SDS-PAGE is a technique which enables the separation of proteins based entirely on 
differences in molecular weight/mass and was initially described in 1970 (Laemmli, 
1970). In the present study 15 µl of protein sample prepared as described in Section 
2.12.3 was loaded into each well of a discontinuous SDS-PAGE gel (11.5% w/v 
acrylamide resolving gel and 4% w/v acrylamide stacking gel) using a BioRad Mini 
Protean II gel system and electrophoresed at 200 V for 42 min (BioRad PowerPac 
200/2.0). The composition of the gels and running buffer are shown in Appendix 2. 
Low range molecular weight markers (BioRad, Hemel Hempstead UK) were 
electrophoresed on each gel. 
 
Protein bands were subsequently visualised following fixation, by staining with 
Coomassie brilliant blue (BioRad, Hemel Hempstead UK) according to the 
manufacturer‘s instructions and destaining with Methanol/Acetic acid (Appendix 2). 
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Chapter Three 
 
3 Molecular characterization and PVL typing of community-
acquired meticillin-sensitive S. aureus clinical isolates 
3.1 Introduction 
Following the firmly established epidemiological link between PVL and CA-MRSA 
(Chheng et al., 2009, Diep et al., 2004, Enany et al., 2007, Liassine et al., 2004, Linde 
et al., 2005, Miklasevics et al., 2004, Tsai et al., 2008, Vandenesch et al., 2003, Witte 
et al., 2005), and the subsequent reports of worldwide spread, significant research has 
been aimed at the typing and characterisation of PVL-positive S. aureus isolates. 
Despite the fact that PVL-MSSA has been reported to pose an equal clinical threat as 
PVL-MRSA (Schefold et al., 2007, Mongkolrattanothai et al., 2003, Perbet et al., 
2010, Swaminathan et al., 2006, Lorenz et al., 2007, Ramos et al., 2009), most 
research has however focused on PVL-MRSA rather than PVL-MSSA. A general lack 
of knowledge therefore exists about this subset of isolates, especially with regards to 
its genotypic characteristics. In the past 5 years, the rise in number of PVL-positive  
S. aureus in the United Kingdom (as referred to the HPA) has surprisingly been due to 
meticillin susceptible rather than resistant isolates (HPA, 2011a). This observation has 
also been reported in several other countries (Tong et al., 2010, Breurec et al., 2011). 
PVL-MSSA may therefore present a previously unrecognised public health risk. In 
addition to this, a second possible role exists for this group of isolates in respect of 
evolution of S. aureus. 
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CA-MRSA are generally accepted to have evolved following the acquisition of 
SCCmec elements by strains of S. aureus in the community (Daum et al., 2002). For 
the actual evolution of PVL-MRSA however, two possibilities exist (Figure 3.1). 
Uptake of genes encoding PVL by these community strains could either have occurred 
prior to the acquisition of the SCCmec elements or these genes might have been 
introduced after SCCmec acquisition. The acquisition of PVL encoding genes prior to 
SCCmec acquisition is however the more widely accepted model for the evolution of  
PVL-MRSA (Monecke et al., 2007b). This view has often been supported by studies 
describing PVL-MSSA strains which are highly similar to PVL-MRSA strains but 
differ in SCCmec carriage (Boyle-Vavra and Daum, 2007, Mongkolrattanothai et al., 
2003, Monecke et al., 2007b, Diep et al., 2006a). In addition, a significantly higher 
genetic diversity has been reported within PVL-MSSA than in PVL-MRSA 
(Vandenesch et al., 2003, Rasigade et al., 2010). This finding further supports the 
possible emergence of PVL-MRSA via PVL-MSSA as opposed to the PVL-MSSA 
strains resulting from a possible loss of a SCCmec element. However, the hypothesis 
that PVL-MSSA isolates serve as precursors for PVL-MRSA has not yet been proven. 
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Figure 3.1: Hypothetical pathways for the evolution of PVL-MRSA 
Acquisition of genes encoding PVL by the MSSA strain shown on the left of the figure could either occur 1. Prior to 
SCCmec acquisition as shown in the top half of the figure or. 2. Subsequent to SCCmec acquisition, as shown in the 
bottom half of the figure. 
 
 
 PVL-MSSA 
MRSA  
PVL-MRSA 
98 
 
 
Very few studies have however focused on the genetic background of PVL-MSSA 
strains, PVL phage variant carried, and variations within the lukSF-PV locus, to see 
how these all fit in with these evolutionary theories. Some studies simply 
characterised the isolates using MLST and/or spa typing (Udo et al., 2008, Holmes et 
al., 2005, Nimmo et al., 2006) and others went on to look at the virulence gene 
profiles and antibiogram (Tristan et al., 2007, Witte et al., 2005, Bartels et al., 2007, 
Denis et al., 2005). However, PVL gene polymorphisms and their possible 
implications had not been addressed at the start of the present study. Being able to 
show that a PVL-MSSA strain shares not just the same MLST and spa profile as its 
MRSA counterpart, but also contains identical PVL sequence variation and phage 
types would prove invaluable to understanding the evolution of these organisms. This 
represents a key aim of the work described in this chapter. 
 
In addition to contributing to the limited available molecular typing data on PVL-
MSSA strains, the work described in this chapter set out to explore PVL gene 
polymorphisms and phage distribution in a group of clinical isolates and how these 
relate to those previously observed in PVL-MRSA strains. This would aid current 
understanding of the evolution and emergence of PVL-positive CA-MRSA isolates 
and help to more accurately assess the current threat posed by these often overlooked 
PVL-positive MSSA strains. 
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3.2 Materials and Methods 
3.2.1 Bacterial Isolates 
Test isolates used in the present study were previously characterized clinical isolates 
of S. aureus collected by Dr. Tim Sloan from Nottingham University Hospitals NHS 
Trust (NUH) (Table 2.1). The clinical isolates were selected as likely to be PVL 
producers based upon (a) clinical suspicion due to the type of infection, or (b) an 
antibiotic susceptibility profile (gentamicin/trimethoprim resistance) that had 
previously been found to be characteristic of PVL-MSSA strains in NUH. The 
presence or absence of thirteen toxin genes (sea, seb, sec, sed, see, seg, seh, sei, sej, 
tst, eta, etb and etd) in these isolates had previously been determined by the Health 
Protection Agency (HPA) Staphylococcus Reference Unit (SRU), using multiplex 
PCRs as previously described (Becker et al., 1998, Monday and Bohach, 1999). 
 
3.2.2 Strain Characterisation 
To determine the relatedness and genetic origins of these isolates, sequence based 
molecular techniques were employed to determine the spa type, MLST type and 
presence of allelic variations in the two genes that encode the PVL toxin. In addition, 
characterisation of the PVL phage type was carried out. All of these methods are 
similar in comprising a PCR DNA amplification using specific primers, amplicon 
purification, quantification and a sequencing step. 
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Genomic DNA employed in these tests was extracted from overnight cultures of test 
isolates grown in LB broth using the Qiagen DNeasy® blood and tissue kit as 
previously described (Section 2.5). 
 
3.2.2.1 spa typing 
The first step in spa typing is the amplification of the polymorphic X region of the spa 
gene. This was carried out as previously described (Section 2.9) using primers 
described in a previous study (Aires-de-Sousa et al., 2006) and listed in Table 3.1. 
Following purification and quantification, the PCR products were sequenced using the 
same forward and reverse primers as used for amplification. Analysis of the spa gene 
sequence was performed manually, based on the process described by Harmsen and 
colleagues (Harmsen et al., 2003), using data presented on the Ridom GmbH spa 
website (www.spaserver.ridom.de). 
 
The first step in this process involved the identification of specific 5′ and 3′ signature 
sequences (http://spa.ridom.de/submission.shtml). These signature sequences serve as 
markers for the start and end of the polymorphic X region used in spa typing and 
ensure that no repeat is omitted. Following the identification of the signature 
sequences, a manual analysis of the test sequence was carried out in order to identify 
the individual repeats. First, the 24 bases immediately adjacent to the 5′ signature 
sequence were cross-matched against the spa repeats database 
(http://spa.ridom.de/repeats.shtml) to assign the repeat identities. This process was 
repeated until the ‗ending‘ repeat was identified. The ‗ending‘ repeat is the last repeat 
and this can be found 18 – 19 bases from the 3′ signature sequence. Though not a 
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common occurrence, repeat sequences 21 bases and 27 bases in length have also been 
reported (http://spa.ridom.de/repeats.shtml). This possibility was therefore taken into 
consideration during the cross-matching process. 
 
Next, spa types were assigned for each test sequence. A spa type is a unique identifier 
given to a particular repeat succession. For example, spa type 001 (t001), is the unique 
identifier for the repeat succession 26-30-17-34-17-20-17-12-17-16. In the present 
study, spa types were assigned by manually cross-matching the repeat succession for 
each test sequence against the spa-type database (http://spa.ridom.de/spatypes.shtml). 
In the case of a suspected novel spa type, i.e. where the spa sequences failed to match 
up with any of the previously described spa types, the sequence chromatogram was 
then submitted to the spaserver (http://spa.ridom.de/submission.shtml). This was to 
enable the spa curator to verify the accuracy of the reads, presence of the signature 
sequences and to assign a novel spa type identity directly from the chromatogram. 
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Table 3.1: Primers Used In DNA amplification in the present study 
Target 
Gene 
5′ – 3′ Primer sequences Product 
Length (kb) 
Reference 
SPA    
spa Forward: TAAAGACGATCCTTCGGTGAGC 
Reverse: CAGCAGTAGTGCCGTTTGCTT 
 
Variable (Aires-de-Sousa et al., 
2006) 
MLST    
arc Forward: TTGATTCACCAGCGCGTATTGTC 
Reverse: AGGTATCTGCTTCAATCAGCG 
570 (Enright et al., 2000) 
aroE Forward: ATCGGAAATCCTATTTCACATTC 
Reverse: GGTGTTGTATTAATAACGATATC 
536  
glpF Forward: CTAGGAACTGCAATCTTAATCC 
Reverse: TGGTAAAATCGCATGTCCAATTC 
576  
gmk Forward: ATCGTTTTATCGGGACCATC 
Reverse: TCATTAACTACAACGTAATCGTA 
488  
pta Forward: GTTAAAATCGTATTACCTGAAGG 
Reverse: GACCCTTTTGTTGAAAAGCTTAA 
575  
tpi Forward: TCGTTCATTCTGAACGTCGTGAA 
Reverse: TTTGCACCTTCTAACAATTGTAC 
475  
yqiL Forward: CAGCATACAGGACACCTATTGGC 
Reverse: CGTTGAGGAATCGATACTGGAAC 
 
598  
PVL    
lukS Forward: ATGGTCAAAAAAGACTATTAGCTG 
Reverse: TCAAATTCACTTGTATCTCCTGAG 
764 The present study 
lukF Forward: TCAGTAAACGTTGTAGATTATGCACC 
Reverse: ATTTTCATCTTTATAATTATTACCTATC 
 
535  
HRM    
lukS Forward: GTGGTCCATCAACAGGAGGT 
Reverse: TGAAGGATTGAAACCACTGTGT 
272 The present study 
lukF Forward: CGGTAGGTTATTCTTATGGTGGA 447 The present study 
 Reverse: TCCAGTGAAGTTGATTCCAAAA   
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3.2.2.2 Multilocus Sequence Typing (MLST) 
Selected isolates were further typed using the MLST technique which involves the 
amplification and sequence comparison of fragments of seven housekeeping genes as 
previously described (Enright et al., 2000), using primers listed in Table 3.1. In brief, 
DNA amplification was carried out at each locus. PCR products were then purified, 
quantified and sequenced as previously described. Each sequence was edited to 
correspond to the specific region of internal fragment used to define an allele using 
information contained in the S. aureus MLST database 
(http://saureus.mlst.net/sql/concatenate/default.asp). Next, the allelic profile for each 
isolate was assigned by comparing the sequence data for each locus against sequences 
contained in the S. aureus MLST database 
(http://saureus.mlst.net/sql/multiplelocus.asp). Finally the unique sequence type 
represented by each allelic profile was determined by comparing against the allelic 
profiles contained in the S. aureus MLST database 
(http://saureus.mlst.net/sql/allelicprofile_choice.asp). 
 
Alternatively, sequence types were established from spa types via the spa database 
http://spa.ridom.de/mlst.shtml, which enables mapping of MLSTs based on spa types. 
 
3.2.2.3 PVL characterization and PVL phage typing 
As PVL typing simply involves an analysis of specific allelic variations on both the 
lukF and lukS genes, two sets of primers (Table 3.1) were designed to amplify the 
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variable regions in the lukSF-PV locus. The first set of primers was designed to 
generate a 764 bp fragment of the lukS gene starting at nucleotide 1 of the lukSF-PV 
locus. The second set of primers was designed to generate a 535 bp fragment of the 
lukF gene starting at nucleotide 1,288 of the lukSF-PV locus. Amplification products 
were generated using the same cycling conditions as previously described (Section 
2.9) and purified PCR products sequenced. The PVL types were determined based on 
the gene sequence (O'Hara et al., 2008). 
 
PVL phage typing was carried out as previously described (Ma et al., 2008), using 
additional information provided by Boakes and colleagues (Boakes et al., 2011a). In 
brief, this method designed to detect the six PVL encoding phages so far described 
(øPVL, ø108PVL, ø2958PVL, øSLT, øSa2mw and øSa2USA), involves the use of 
nine different amplification reactions (PCR-1 to PCR-9). Primers for PCR-1 to PCR-8 
were described by Ma and colleagues. These were based on the nucleotide sequences 
of five PVL phages (øPVL, ø108PVL, ø2958PVL, øSLT and øSa2mw) with GenBank 
accession numbers of AB009866, AB009866, AP009363, NC_002661 and 
BA000033, respectively. 
 
PCR-1 and PCR-2 were specifically designed to differentiate the different phage 
morphologies. PCR-1 (Table 3.2) was composed of two sets of primers specific for 
DNA fragments unique to the icosahedral-head type PVL phages. The two sets of 
primers in PCR-2 were however specific for DNA fragments unique to PVL phages 
with elongated-head types. PCR-3 and PCR-4 were then designed to amplify specific 
linkage genes to the lukSF-PV locus. These reactions were to confirm that the phage 
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morphologies detected were indeed associated with carriage of the genes encoding for 
PVL. PCR-3 detected linkage genes in icosahedral-head type PVL phages while  
PCR-4 detected linkage genes in elongated-head type PVL phages. Finally, the last 
five amplification reactions (PCR-5 to PCR-9), were designed to detect phage specific 
fragments. PCR-6, PCR-7, PCR-8 and PCR-9 detected DNA fragments unique to 
ø2958PVL, øSLT, øSa2mw and øSa2USA respectively. PCR-5 however, was 
designed to identify both øPVL and ø108PVL. While this reaction contained primers 
which could amplify phage specific fragments from both of these phages, the product 
lengths were however distinct for each phage (Figure 3.2). 
 
These nine amplification reactions were expected to generate amplicons ranging in 
length from 468 bp to 10,497 bp. The amplification protocol used was similar to that 
previously described (Section 2.9) but had a longer elongation step (2 min), thirty five 
cycles and DMSO was added to reaction mixtures to facilitate generation of the longer 
product lengths expected. 
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Table 3.2: Primers used for detecting and typing PVL phages 
 
Reaction ID Primer name 5′ – 3′ Primer Sequence Product 
Length 
(bp) 
Phages 
Identified 
PCR-1 portal-1F 
portal-1R 
 
tail-1F 
tail-1R 
 
ACACGTGATAAAACAGGAGAA 
TCTAAATTAGCATCCGTGATAC 
 
ATAATTGGGATAGCAACGCAA 
CTTGATTAGACTCAACCAAACT 
569 
 
 
489 
 
ø108PVL 
øPVL 
PCR-2  portal-2F 
portal-2R 
 
tail-2F 
tail-2R 
 
GATGGCTAGTTTGCCCTTGA 
CTGAGGGCAATTGAAAAACG 
 
CATAGCGCTAATGTCGCAAA 
AGCCTCCATTGTTTGTTTGG 
656 
 
 
468 
ø2958PVL 
øSa2mw 
øSLT 
PCR-3  lukSR1 
teil-ico-F 
 
ACGAAGTAGCAATAGGAGTGA 
AGATTTAGAAGAGGAGGCACGA 
10,497 
 
ø108PVL 
øPVL 
PCR-4  lukSR1 
teilE-F2 
ACGAAGTAGCAATAGGAGTGA 
ATTGATTCAAACTGTTTCTTCT 
9,483 
 
ø2958PVL 
øSa2mw 
øSLT 
 
PCR-5 intF2 
108-aR 
PVL-aR 
 
ATGTTTTCGAGTTTTTGAGTTAG 
TCAAATCCGTAATCACTCATTCT 
TTCACTAACTAAACCTATCATTGT 
 
4,340 
1,411 
 
ø108PVL 
øPVL 
PCR-6  intF2 
2958-aR 
ATGTTTTCGAGTTTTTGAGTTAG 
TGGTAATCAACCATTCACTTATGA 
2,238 ø2958PVL 
 
 
PCR-7  intF2 
MW2-aR 
ATGTTTTCGAGTTTTTGAGTTAG 
TAAGTTCCTGGTGTCATTCCTAAT 
4,065 øSa2mw 
 
 
PCR-8  intF2 
SLT-aR 
ATGTTTTCGAGTTTTTGAGTTAG 
TCTTACCAAATGCAACACAACGAAT 
8,770 øSLT 
 
 
PCR-9 Sa2USA_F 
Sa2USA_R 
GGTATTACCCAACAACACAACAATTACG 
CCTCAGGCGCCATCACCAATA 
680 øSa2USA 
 
The primer sequences were compiled from (Ma et al., 2008) and (Boakes et al., 2011a) 
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Figure 3.2: A representative example of expected product 
sizes for PVL phage amplification reactions. 
The primers used in each reaction are as described in Table 3.2. The PCR 
products were generated as described in Section 3.2.2.3. The expected PCR 
product sizes (bp): PCR-1: 489 and 569; PCR-2: 468 and 656; PCR-3: 
10,497; PCR-4: 9,483; PCR-5
a
: 4,340; PCR-5
b
: 1,411; PCR-6: 2,238; PCR-
7: 4,065; PCR-8: 8,770. 
 
PCR-5 is designed to amplify phage specific regions of two different 
phages. 
a
4,340 bp product expected when reaction is positive for ø108PVL. 
b
1,411 bp product expected when reaction is positive for øPVL. 
 
The figure was reproduced from Ma et al., (2008). 
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Following amplification of the phage genes, determination of the specific phage 
present could then be made based on the unique combination of amplicons obtained 
(Table 3.3). Phages which could not be completely typed could however still be 
classified as either icosahedral or elongated head types. 
 
Table 3.3: Key to PVL phage typing 
S/No Phage PCR 
1 2 3 4 5 6 7 8 9 
1.  øPVL + - + - +* - - - - 
2.  ø108PVL + - + - +** - - - - 
3.  øSa2958 - + - + - + - - - 
4.  øSa2mw - + - + - - + - - 
5.  øSLT - + - + - - - + - 
6.  øSa2USA - + - + - - - - + 
 
The table shows the various PVL phages and the unique combination of positive 
results which indicate each phage 
 
+: Represents the presence of amplification products of the expected sizes 
+
*
: Represents ≈1.4 kb PCR-5 amplification product 
+
**
: Represents ≈4.3 kb PCR-5 amplification product 
-: Represents a lack of amplification product of expected size 
 
Expected PCR product sizes (bp): PCR-1: 489 and 569; PCR-2: 468 and 656; 
PCR-3: 10,497; PCR-4: 9,483; PCR-5: 4,340 or 1,411; PCR-6: 2,238; PCR-7: 
4,065; PCR-8: 8,770. 
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3.3 Results 
3.3.1 Characteristics of PVL-MSSA 
The 19 PVL-positive MSSA strains analysed comprised both hospital and community-
acquired isolates recovered between November 2008 and May 2009 at NUH. Isolates 
were obtained from a range of sample types, from patients with varying clinical 
histories and ages (Table 3.4). These isolates were mostly community-acquired 
(15/19; 80%), i.e. either sent from the GP or recovered at A/E and were associated 
mainly with skin and soft tissue infection. One strain (TS1) however was isolated 
from a fatal case of necrotizing pneumonia. This strain collection was noted to have a 
low prevalence of virulence/toxin genes. While 89.5% (17/19) of isolates carried the 
seg and sei genes, 31.6% (6/19) of isolates also carried one or two additional toxin 
genes (sea, sec or sed). Two isolates carried four of the thirteen toxin genes 
investigated (Table 3.4). The majority of toxin genes (seb, see, seh, sej, tst, eta, etb 
and etd) were however not detected in this population. 
 
89.5% (17/19) of isolates were trimethoprim resistant with additional gentamicin 
resistance observed in 57.9% (11/19) of isolates. This high prevalence of 
gentamicin/trimethoprim resistance was probably a reflection of the selection criteria. 
Most isolates (11/19; 57.9%) were resistant to a maximum of 2 antibiotics. The 
highest resistance (to four antibiotics) was observed in a single ST30 isolate (TS12). 
All the isolates were susceptible to clindamycin, rifampicin, linezolid, vancomycin, 
fusidic acid and teicoplanin. 
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Table 3.4: Clinical characteristics of Panton-Valentine leucocidin positive S. aureus test isolates. 
S/No Isolate ID /Source of 
Isolation 
a
 
Toxin gene 
profile 
b
 
Age Clinical details Antibiotic resistances 
c, d
 
1.  TS 1/CA None 30 Necrotising pneumonia, fatal FULLY SENSITIVEe 
2.  TS 5/CA sea, sei, sec, seg 39 Axillary boil TMP, CIP, ERY 
3.  TS 6/HA sei, seg 80 Wound infection post hip surgery GEN, TMP 
4.  TS 7/CA sea, sei, seg 35 Nasal carriage TMP, DOX 
5.  TS 8/CA sea, sei, sec, seg 17 Facial abscess TMP, ERY, CIP 
6.  TS 9/HA sei, seg 89 Wound infection post hip surgery GEN, TMP 
7.  TS 12/CA sei, seg 6 Wound, no details given GEN, TMP, CIP, ERY 
8.  TS 13/CA sei, seg 35 Leg abscess GEN, TMP 
9.  TS 14/HA sei, seg 87 Leg ulcer GEN, TMP 
10.  TS 15/CA sei, seg 39 Recurrent boils FULLY SENSITIVE 
11.  TS 16/CA sea, sei, seg 27 Thigh abscess TMP 
12.  TS 17/CA sei, seg 55 Nasal carriage GEN, TMP 
13.  TS 18/CA sei, seg 83 Foot wound GEN, TMP 
14.  TS 19/CA sei, seg 26 Back abscess GEN, TMP 
15.  TS 20/CA sei, seg 64 Bursitis, knee GEN, TMP 
16.  TS 21/HA None 3 Empyema TMP 
17.  TS 23/CA sei, seg 24 IVDU, cellulitis, bacteraemia GEN, TMP 
18.  TS 24/CA sei, seg 83 Cellulitis foot, bacteraemia GEN, TMP 
19.  TS 25/CA sei, sed, seg 55 Severe pneumonia, post-viral TMP 
 
a
Source of Isolation, HA, isolated after 48 h of admission; CA, isolated either at the general practice or accident and emergency department or 
within 48 h of admission 
b
Total toxin genes analysed for include; sea, seb, sec, sed, see, seg, seh, sei, sej, tst, eta, etb and etd 
c
GEN: Gentamicin, TMP: Trimethoprim, CIP: Ciprofloxacin, ERY: Erythromycin, DOX: Doxycycline. 
d 
All isolates were susceptible to clindamycin, rifampicin, linezolid, vancomycin, fusidic acid and teicoplanin 
e
Fully sensitive to the listed antibiotics 
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3.3.2 spa typing of test isolates 
Following amplification of the spa gene from various isolates, and purification using a 
QiaQuick PCR purification kit, DNA sequencing resulted in noisy chromatograms 
(Figure 3.3) as defined by irregularly spaced reads. Multiple peaks were observed for 
a single base in some cases. This was considered unacceptable as sequences could not 
be accurately assigned. To overcome this problem, amplicons were instead purified 
following electrophoresis by gel extraction using a QiaQuick gel extraction kit 
(Section 2.10.1) prior to sequencing. This eliminated the DNA smearing which had 
been previously observed when products were analysed (Figure 3.4) and resulted in 
clean sequencing reads with reduced baseline noise (Figure 3.5). 
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Figure 3.3: Example of a noisy sequence chromatogram generated following sequencing of the spa amplicons 
purified with a QiaQuick PCR purification kit.  
The sequence data was generated (using the recommended spa typing primers listed in Table 3.2) following purification of a spa amplicon using 
the QiaQuick PCR purification kit as described in Section 2.10.1. The arrows indicate examples of multiple peaks generated for a single 
nucleotide resulting in a noisy chromatogram producing a potentially ambiguous sequencing result. 
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Figure 3.4: Representative gel images indicating purity of the spa gene fragments following amplicon purification 
by gel extraction. 
The agarose gel images were generated following DNA electrophoresis of purified spa gene fragments as described in Section 2.10. The left 
hand gel image (Panel A), shows a smearing (as indicated by the arrows) associated with several spa gene fragments following purification 
using a QiaQuick purification kit i.e. directly on amplified DNA as described in Section 2.10.1. The right hand image (Panel B), shows the 
lack of smearing associated with results of purification of spa gene fragments using a QiaQuick extraction kit as described in Section 2.10.1. 
A B 
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Figure 3.5: Example of a clean sequence chromatogram generated following sequencing of the spa 
amplicons purified with a QiaQuick gel extraction kit.  
The sequence data was generated (using the recommended spa typing primers listed in Table 3.2) following purification of a spa 
amplicon using the QiaQuick gel extraction kit as described in Section 2.10.1. A clean sequence chromatogram is indicated by 
the lack of multiple peaks and reduced baseline to noise. 
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For each spa sequence, repeat identities and spa types were mapped only after the 
detection of the 5′ and 3′ signature sequences that are essential for reliable results 
(http://spa.ridom.de/submission.shtml). An example of the elements identified 
following sequence analysis is shown in Figure 3.6. The results of the spa typing 
showed that eleven different spa types were present in the strain collection. The 
number of repeat sequences ranged from five to twelve (Table 3.5). These eleven 
types clustered into two spaCCs (CC005 and CC345/657) and five singletons based 
on the BURP algorithm (StaphType Software; Ridom GmbH, Wurzburg, Germany).  
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TAGTTTCTTCAAAGCTAAAAAGCTAAACGATGCTCAA-GCACCAAAA-
GAGGAAGACAACAAAAAACCTGGT-(26)-AAAGAAGACGGCAACAAACCTGGC-(23)-
AAAGAAGACAACAACAAACCTGGT-(13)-AAAGAAGACGGCAACAAACCTGGC-(23)-
AAAGAAGATGGCAACAAACCTGGC-(31)-AAAGAAGACAACAAAAAGCCTGGC-(05)-
AAAGAAGACGGCAACAAGCCTGGT-(17)-AAAGAAGATGGCAACAAACCTGGT-(25)-
AAAGAAGACGGCAACAAGCCTGGT-(17)-AAAGAAGATGGCAACAAACCTGGT-(25)-
AAAGAAGACGGCAACAAACCTGGT-(16)-AAAGAAGATGGTAACAAACCTGGC-(28)-
AAAGAAGACGGCAACGGGG-TACATGTCGT-
TAAACCTGGTGATACAGTAAATGACATTGCAAAAGCAAACGGCACTACTGCTGAA 
 
 
 
Figure 3.6: Representation of sequence analysis and the spa type allocation process for TS13 
The spa sequence was generated following amplification, purification and sequencing of a spa gene fragment 
(Figure 3.2.2.1). The assignment of spa types depends on the presence of signature sequences (highlighted in 
yellow) which serve as markers for the start and end of the polymorphic X region used in spa typing. The spa 
repeats identified by cross-matching each 24 base cluster against the spa repeats database 
(http://spa.ridom.de/repeats.shtml) are represented as figures in brackets. 
 
5′ signature – 0 
bp from repeat 
3′ signature – 19bp 
from repeat 
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Types t005 and t021 occurred most frequently (42.1%) while seven other spa types 
were represented by only a single clinical isolate. Three spa types which have not 
previously been described were identified and submitted to the Ridom SpaServer 
(http://spa.ridom.de/submission.shtml), and assigned as spa types t6642, t6643 and 
t6769. Both t6642 and t6643 were found to be associated with ST22 isolates. t6642 
with a repeat succession of 26-23-13-23-31-05-22-17-25-17-25-114 was of the same 
length as the prototype t005 (identified by the BURP algorithm). These however 
varied in the composition and arrangement of repeat sequences (t005 had a repeat 
succession of 26-23-13-23-31-05-17-25-17-25-16-28). Type t6643 (26-23-13-23-31-
05-17-25-16-390) however differed in length with 2 repeat deletions noted. Similarly, 
type t6769 was of the same length as type t186 (an ST88 related spa type) with single 
point mutations occurring in three repeats leading to an r34 to r13 change (Figure 
3.7). 
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Table 3.5: Results of spa typing. 
S/No Test Isolate Repeat Succession
a
 spa Type
b
 
1.  TS13, TS14, TS18, TS20, TS24 26-23-13-23-31-05-17-25-17-25-16-28 t005 
2.  TS7, TS12, TS15, TS16  15-12-16-02-16-02-25-17-24 t021 
3.  TS19 26-23-31-05-17-25-17-25-16-28 t310 
4.  TS8 26-23-13-21-17-34-34-33-34 t345 
5.  TS2, TS5 26-23-13-21-17-34-33-34 t657 
6.  TS17 07-23-13-23-31-05-17-25-17-25-16-28 t852 
7.  TS1 07-56-12-17-17-16-16-33-31-57-12 t1941 
8.  TS25 07-23-21-17-13-33-13 t3342 
9.  TS6, TS9 26-23-13-23-31-05-22-17-25-17-25-114 t6642 
10.  TS23 26-23-13-23-31-05-17-25-16-390 t6643 
11.  TS21 07-12-21-17-13-13-13-13-33-13 t6769 
The spa typing data presented in this table was generated as described in Section 3.2.2.1. The table shows the spa repeat 
succession detected in each isolate and the corresponding spa types. 
 
a
Repeat succession represents the sequence of repeats as identified from the spa repeats database 
(http://spa.ridom.de/repeats.shtml). 
b
The spa type represents a unique identifier for each specific repeat succession as determined from the spa-type database 
(http://spa.ridom.de/spatypes.shtml). 
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Figure 3.7: Depiction of the relationship between the new spa types 
described in the present study and their existing clonal prototypes as 
defined by the BURP algorithm 
The relationship between the new spa types t6642 and t6643 and the existing clonal 
prototype t005, and between t6769 and the clonal prototype t186 is shown, Yellow 
highlights indicate repeat variations, whilst red highlights depict the single nucleotide 
variation between repeats r13 and r34. 
 
spa type Repeat Succession 
t005 26-23-13-23-31-05-17-25-17-25-16-28 
t6642 26-23-13-23-31-05-22-17-25-17-25-114 
t6643 26-23-13-23-31-05-17-25-16-390 
SET 1 
spa type Repeat Succession 
t186 07-12-21-17-13-13-34-34-33-34 
t6769 07-12-21-17-13-13-13-13-33-13 
SET 2 
r13: AAAGAAGACAACAACAAACCTGGT 
r34: AAAGAAGACAACAAAAAACCTGGT 
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3.3.3 Multilocus Sequence Typing 
Typing of the clinical isolates using the MLST technique (Enright et al., 2000) 
revealed further strain diversity. Six multilocus STs (ST1, ST22, ST30, ST88, ST772 
and ST1518) were detected (Table 3.6). These were grouped by eBURST analysis 
(Section 1.8.1) (Feil et al., 2004) into five CCs of known MRSA lineages (CC1, 
CC22, CC30, CC88 and CC152). Of these, ST1518 was described for the first time 
ever in the present study. The associated isolate (TS1) was isolated from a fatal case 
of necrotising pneumonia. ST1518 is a single locus variant of ST152, differing by a 
single mutation in the glp allele. ST22 isolates occurred most frequently (9/19; 47.4%) 
in this collection of clinical isolates. 
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Table 3.6: MLST allelic profiles and corresponding STs 
S/No Test Isolate Allelic Profile
a
 Sequence Type
b
 
1.  TS25 1-1-1-1-1-1-1 1 
2.  TS6, TS9, TS13, TS14, TS17, TS18, TS19, TS20, TS23, TS24 7-6-1-5-8-8-6 22 
3.  TS7, TS12, TS15, TS16 2-2-2-2-6-3-2 30 
4.  TS21 22-1-14-23-12-4-31 88 
5.  TS5, TS8 1-1-1-1-22-1-1 772 
6.  TS1 46-75-207-44-13-68-60 1518 
MLST of clinical isolates was carried out as described in Section 3.2.2.2 
a
Allelic profiles were determined based on the DNA sequence of each locus using the S. aureus MLST database 
(http://saureus.mlst.net/sql/multiplelocus.asp) 
b
Sequence Type corresponding to each specific allelic profile was determined from the S. aureus MLST database 
(http://saureus.mlst.net/sql/allelicprofile_choice.asp) 
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3.3.4 SNP analysis of the PVL-encoding genes 
When compared with the sequence of øSLT, the proposed lukSF-PV progenitor 
(Wolter et al., 2007), a total of seven SNPs were noted in the PVL encoding gene 
sequences generated in the present study. Five of these occurred in the lukS gene 
(Table 3.7). Most isolates (17/19; 89.5%) generated sequences of the H variant as 
previously defined (O'Hara et al., 2008), with both H1 and H2 isoforms present 
among this panel of isolates. The non-synonymous A – G SNP which occurs at 
nucleotide 527 and defines the R variant, occurred only in a single isolate (TS1). 
Similar to previous reports as summarised in Table 1.4, the resulting PVL SNP 
profiles were generally multilocus ST specific. The H2 variant of the genes encoding 
PVL was detected in all ST22 isolates despite their epidemiological differences. This 
relationship of PVL SNP profile to multilocus ST is not exclusive as demonstrated by 
the detection of the H2 variant in both ST772 isolates. Two different PVL SNP 
profiles (H1 and H2) were however detected in ST30 isolates. The outlier H1 variant 
carried by TS12 was identical to that of ST22 and ST88 and overall was found in 
63.2% (12/19) of this panel of isolates. 
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Table 3.7: Single nucleotide polymorphisms detected in the lukSF-PV 
locus of the study population 
S/No Isolate ID (ST) lukS 
 
lukF Isoforms 
  
33 105 181 216 345 470 527 663  1396 1729 
 1.  TS 1 (1518) G T T C C T G T  A G R 
2.  TS 5 (772) G T T C C T A G  A A H2 
3.  TS 6 (22) G T T C C T A G  G A H1 
4.  TS 7 (30) G T T C C A A G  A A H2 
5.  TS 8 (772) G T T C C T A G  A A H2 
6.  TS 9 (22) G T T C C T A G  G A H1 
7.  TS 12 (30) G T T C C T A G  G A H1 
8.  TS 13 (22) G T T C C T A G  G A H1 
9.  TS 14 (22) G T T C C T A G  G A H1 
10.  TS 15 (30) G T T C C A A G  A A H2 
11.  TS 16 (30) G T T C C A A G  A A H2 
12.  TS 17 (22) G T T C C T A G  G A H1 
13.  TS 18 (22) G T T C C T A G  G A H1 
14.  TS 19 (22) G T T C C T A G  G A H1 
15.  TS 20 (22) G T T C C T A G  G A H1 
16.  TS 21 (88) G T T C C T A G  G A H1 
17.  TS 23 (22) G T T C C T A G  G A H1 
18.  TS 24 (22) G T T C C T A G  G A H1 
19.  TS 25 (1) A T T C T T A G  A A H2 
 
The SNPs in the genes encoding PVL were detected as described in Section 3.2.2.3. The 
SNPs highlighted in yellow indicate point mutations that were used in defining the H1, H2 
and R PVL sequence isoforms. 
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3.3.5 PVL Phage typing 
Initial PCR amplification of phage sequences resulted in inconsistent amplification of 
the linkage genes (PCR-3 and PCR-4) which were expected to generate long PCR 
products (≈10 kb). This inconsistency was however found to be rectified by the 
addition of 2% v/v dimethyl sulfoxide (DMSO) to the PCRs as indicated using two 
independent isolates (Figure 3.8). DMSO is an organic solvent which has been 
demonstrated to improve PCR amplification based on its ability to prevent secondary 
structure formation (Jensen et al., 2010). This analysis shows the absence of PCR 
products of approximately 10,000 bp without DMSO addition (Figure 3.8 1A and 
Figure 3.8 2A) and their subsequent generation on addition of DMSO (Figure 3.8 1B 
and Figure 3.8 2B). 
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Figure 3.8: Representative gel images depicting the effect of DMSO on generation of amplicons for PVL phage typing.  
The figure shows PCR amplification products generated following PVL phage typing as described in Section 3.2.3.3. Panel 1A shows the 
amplification products generated from TS14 genomic DNA, with no DMSO added. Panel 1B shows the amplification products generated from 
TS14 genomic DNA with DMSO added. Panel 2A shows the amplification products generated from TS18 genomic DNA with no added DMSO and 
Panel 2B shows the amplification products generated from TS18 genomic DNA with DMSO added.  
The arrows on panel 1B and panel 2B indicate the extra PCR amplification product generated on addition of DMSO. 
Expected PCR product sizes (bp): PCR-1: 489 and 569; PCR-2: 468 and 656; PCR-3: 10,497; PCR-4: 9,483; PCR-5: 1,411 or 4,340; PCR-6: 2,238; 
PCR-7: 4,065; PCR-8: 8,770; PCR-9: 680. 
DMSO: Dimethyl sulfoxide
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A common feature of the PVL phage amplification process in the present study, was 
the presence of products of unexpected size as exemplified by the faint, circled bands 
seen in Figure 3.9. A possible lack of specificity of the primers employed in the assay 
was considered and the primer sequences were assessed using both a primer BLAST 
analysis (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and in silico PCR analysis 
(http://insilico.ehu.es/PCR/) against the collection of staphylococcal DNA sequences 
held at the National Center for Biotechnology Information (NCBI). Both tools are 
designed to provide theoretical PCR results. Results of in silico PCR however 
correlate with high specificity amplification reactions while the primer BLAST may 
provide information on non-specific products generated due to primer mismatches 
(Bikandi et al., 2004, Ficetola et al., 2010). These analyses provided a possible 
explanation for the presence of the faint products. Using the more stringent in silico 
PCR analysis which uses sequenced bacterial genomes and allows for only one 
mismatch, a single primer pair (PCR-6) was found to generate an unexpected 1,307 bp 
product. This was confirmed following a primer BLAST which allowed for only one 
mismatch. In addition, the primer pair for PCR-5A generated a hypothetical product of 
unexpected size (4,579 bp) using in silico PCR. Assaying for less stringent 
amplification conditions by increasing the mismatch parameter in the primer BLAST 
software to two bases however resulted in a different outcome. Possible non-specific 
amplification products were identified for three additional reactions (PCR-1, PCR-2 
and PCR-4) (Data not shown). The expected size of these theoretical products did not 
however match the observed size of the non-specific products generated following 
PVL phage typing in the present study.  
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Figure 3.9: Agarose gel image showing examples of non-specific 
amplification products following PVL phage typing 
Circled on the figure are examples of non-specific PCR amplification products 
generated following PVL phage typing of clinical isolate TS1 (as described in Section 
3.2.3.3). 
Expected PCR product sizes (bp): PCR-1: 489 and 569; PCR-2: 468 and 656; PCR-3: 
10,497; PCR-4: 9,483; PCR-5: 1,411 or 4,340; PCR-6: 2,238; PCR-7: 4,065; PCR-8: 
8,770; PCR-9: 680. 
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The algorithm for the interpretation of phage type (Ma et al., 2008) was not 
followed strictly as PCR-5, which is designed to generate specific phage products 
only from icosahedral-head type PVL phage yielded a product of similar length 
even for elongated-head type PVL phages. This finding had similarly been reported 
in a previous study (Otter et al., 2010). Hence, if the PCR results for both 
icosahedral-head type morphology (PCR-1) and linkage genes (PCR-3) were 
negative, a positive result for PCR-5 was not taken into consideration in 
interpretation of the PVL phage typing data. 
 
In total, four of the known PVL-phage types (øPVL, ø108PVL, øSa2USA and 
øSa2mw) were detected in the present study population (Table 3.8). The majority 
of isolates (12/19; 63.2%) carried PVL-phage types with icosahedral-head type 
morphologies. Both of the ST772 isolates in the present study however, failed to 
generate any PCR product of expected size (Figure 3.10) in all nine PCRs. Though 
a single faint DNA band was observed in PCR-1, this product was not of the 
expected size. This complete lack of amplification could perhaps indicate carriage 
of an uncharacterised PVL phage type by the ST772 isolates. 
 
The phage present in TS21 could also not be fully characterised as no PCR product 
was generated in the PVL phage specific reactions (i.e. PCR-5 to PCR-9). This 
result indicates that the PVL phage carried by TS21 does not belong to any of the 
currently characterised PVL phage types. Unlike the PVL phage carried by ST772 
isolates, the PVL phage carried by TS21 could be partially characterised as an 
elongated-head type PVL phage, based on the positive amplification reactions of 
PCR-2 and PCR-4. 
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Table 3.8: Results of PVL-phage typing of the clinical isolates 
S/No Isolate PCR PVL Phage 
1 2 3 4 5 6 7 8 9  
1.  TS 1 - + - + +
*
 - - - + øSa2USA 
2.  TS 5 - - - - - - - - - Not Detected 
3.  TS 6 + - + - +
*
 - - - - øPVL 
4.  TS 7 + - + - +
*
 - - - - øPVL 
5.  TS 8 - - - - - - - - - Not Detected 
6.  TS 9 + - + - +
*
 - - - - øPVL 
7.  TS 12 + - + - +
*
 - - - - øPVL 
8.  TS 13 + + + - +
*
 - - - - øPVL 
9.  TS 14 + - + - +
*
 - - - - øPVL 
10.  TS 15 + - + - +
**
 - - - - ø108PVL 
11.  TS 16 + - + - +
*
 - - - - øPVL 
12.  TS 17 + - + - +
*
 - - - - øPVL 
13.  TS 18 + - + - +
*
 - - - - øPVL 
14.  TS 19 + - + - +
*
 - - - - øPVL 
15.  TS 20 + - + - +
*
 - - - - øPVL 
16.  TS 21 - + - + +
*
 - - - - Elongated Head
***
 
17.  TS 23 + - + - +
*
 - - - - øPVL 
18.  TS 24 + - + - +
*
 - - - - øPVL 
19.  TS 25 + + - - +
*
 - + - - øPVL/ øSa2mw 
DNA amplification reactions to detect the PVL-phage type were set-up as described in 
Section 3.2.2.3. The PVL-phage typing data was interpreted based on the key outlined in 
Table 3.3 with the modification outlined in Section 3.3.5.  
 
+: Represents the presence of amplification products of expected sizes 
+
*: Represents ≈1.4 kb PCR-5 amplification product 
+
**: Represents ≈4.3 kb PCR-5 amplification product 
-: Represents a lack of amplification product of expected size 
***
: Elongated head indicates a PVL-phage which could not be fully characterised 
 
Expected PCR product sizes (bp): PCR-1: 489 and 569; PCR-2: 468 and 656; PCR-3: 
10,497; PCR-4: 9,483; PCR-5: 4,340 or 1,411; PCR-6: 2,238; PCR-7: 4,065; PCR-8: 
8,770. 
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Figure 3.10: Agarose gel image depicting lack of expected 
amplification products following PVL-phage typing of an ST772 
isolate. 
The PCR amplification products were generated following PVL phage typing of TS8 
(ST772) as described in Section 3.2.3.3. The arrow indicates a faint band of 
unexpected size indicative of a non-specific amplification product. 
Expected PCR product sizes (bp): PCR-1: 489 and 569; PCR-2: 468 and 656; PCR-3: 
10,497; PCR-4: 9,483; PCR-5: 1,411 or 4,340; PCR-6: 2,238; PCR-7: 4,065; PCR-8: 
8,770; PCR-9: 680. 
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3.3.6 Summary of Results 
Overall, the typing results show a clear link between the clonal lineage of an isolate 
and additional factors such as the antibiotic resistance profiles generated by the NUH, 
toxin genes detected by HPA, and the presence of specific PVL-phage types as 
described in the present study (Table 3.9). The exception to this was observed among 
the ST30 isolates. Despite having identical spa types, these differed greatly in 
antibiotic resistance, toxin genes present, PVL gene polymorphisms and the PVL 
phage carried. In contrast, a good correlation between the clonal lineage of an isolate 
and additional genes was observed with the ST22 isolates. Despite being recovered 
from a wide variety of skin and soft tissue infections both in the community and the 
hospital, these isolates showed almost identical antibiotic resistance and toxin profiles 
and PVL genotypes. They however differed in the spa types they represented. 
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Table 3.9: Molecular characterization of 19 PVL-positive S. aureus clinical isolates
a
. 
Strain Date/ Source of  ST(CC) spa
c
  Antibiotic resistances
d
 Virulence lukS lukF Sequence PVL Phage Typing PCR result
e PVL-phage PVL-phage 
ID Isolation
b
 
 
Type  Profile 33 105 181 216 345 470 527 663 1396 1729 Isoform 1 2 3 4 5 6 7 8 9 Type Isoform 
TS 13 17/03/09 (CA) 22(22) t005 GEN, TMP seg, sei G T T C C T A G G A  (H1) + + + - +
*
 - - - - øPVL  (H1) 
TS 14 04/03/09 (HA) 22(22) t005 GEN, TMP seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL (H1) 
TS 18 11/11/08 (CA) 22(22) t005 GEN, TMP seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 20 03/02/09 (CA) 22(22) t005 GEN, TMP seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 24 06/11/08 (CA) 22(22) t005 GEN, TMP seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 19 30/12/08 (CA) 22(22) t310 GEN, TMP seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 17 04/12/08 (CA) 22(22) t852 GEN, TMP seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 6 06/05/09 (HA) 22(22) t6642 GEN, TMP seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 9 07/04/09 (HA) 22(22) t6642 GEN, TMP seg, sei G T T C C T A G G A (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 23 16/12/08 (CA) 22(22) t6643 GEN, TMP seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 1    18/03/09 (CA) 1518(152) t1941 FULLY SENSITIVE None  G T T C C T G T A G  (R)  - + - + +
*
 - - - + øSa2USA  (R) 
TS 5 23/04/09 (CA) 772(1) t657 TMP, CIP, ERY sea, sec, seg, sei G T T C C T A G A A  (H2) - - - - - - - - -   
TS 8 08/04/09 (CA) 772(1) t345 TMP, CIP, ERY sea, sec, seg, sei G T T C C T A G A A  (H2) - - - - - - - - -   
TS 25 05/12/08 (CA) 1(1) t3342 TMP sed, seg, sei A T T C T T A G A A  (H2) + + - - +
*
 - + - - øPVL / 
øSa2mw  
(H1)/(R) 
TS 7 04/04/09 (CA) 30(30) t021 TMP, DOX sea, seg, sei G T T C C A A G A A  (H2) + - + - +
*
 - - - - øPVL  (H1) 
TS 12 18/03/09 (CA) 30(30) t021 GEN, TMP, CIP, ERY seg, sei G T T C C T A G G A  (H1) + - + - +
*
 - - - - øPVL  (H1) 
TS 15 12/02/09 (CA) 30(30) t021 FULLY SENSITIVE seg, sei G T T C C A A G A A  (H2) + - + - +
**
 - - - - ø108PVL  (H2) 
TS 16 11/02/09 (CA) 30(30) t021 TMP sea, seg, sei G T T C C A A G A A  (H2) + - + - +
*
 - - - - øPVL  (H1) 
TS 21 11/02/09 (HA) 88(88) t6769 TMP None G T T C C T A G G A  (H1) - + - + +
*
 - - - - Elongated head 
Phage (GenBank accession no)                         
øSLT (NC_002661)  
 
G T T C C T A G A A  - + - + - - - + - øSLT (H2) 
ø108PVL (AB243556.1) 
 
G T T C C T A G A A  + - + - +
**
 - - - - ø108PVL (H2) 
øPVL (AB009866.2)  
 
G T T T C T A G G A  + - + - +
*
 - - - - øPVL (H1) 
ø2958PVL (AP009363.1) 
 
G T T C C T A G G A  - + - + - + - - - ø2958PVL (H1) 
øSa2mw (BA000033)  
 
G T T C C T G T A A  - + - + - - + - - øSa2mw (R) 
øSa2USA (CP000730.1) 
 
G T T C C T G T A G  - + - + - - - - + øSa2USA (R) 
aTotal toxin genes analysed for include; sea, seb, sec, sed, see, seg, seh, sei, sej, tst, eta, etb, and etd. ID, identifier; HA (hospital associated), isolated after 48 h of admission; CA, isolated either at the general practice or accident and emergency 
department or within 48 h of admission. 
b Date of isolation presented as: Day/mo/yr. 
cThe spa types underlined were described for the first time in the present study. 
dGEN: Gentamicin, TMP: Trimethoprim, CIP: Ciprofloxacin, ERY: Erythromycin, DOX: Doxycycline / All isolates were susceptible to clindamycin, rifampicin, linezolid, vancomycin, fusidic acid and teicoplanin  
e ―*‖ and ―**‖ indicate 1,411 bp and 4,340 bp, products respectively. Yellow highlights indicate SNPs 
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3.4 Discussion 
While the molecular epidemiology of CA-MRSA has been explored extensively 
(Deleo et al., 2010, David and Daum, 2010) and interest in CA-MSSA is on the 
increase, there exists a dearth of detailed knowledge on PVL-MSSA, particularly in 
relation to the genetics of the lukSF-PV locus. Despite the fact that initial reports of 
PVL-positive isolates were described among meticillin susceptible rather than 
resistant isolates (Lina et al., 1999, Hsu et al., 2005, Prevost et al., 1995a), few studies 
focused specifically on the typing of these strains. Generally, early typing studies on 
PVL-MRSA involved identifying their clonal lineages using either PFGE or MLST 
(Vandenesch et al., 2003, Holmes et al., 2005, Ma et al., 2006, Nimmo et al., 2006, 
Krziwanek et al., 2007, David et al., 2008, Fang et al., 2008, Goering et al., 2008, Udo 
et al., 2008, Yu et al., 2008). Some studies went further to associate these with 
specific spa types (Denis et al., 2005, Tristan et al., 2007, Witte et al., 2007, Bartels et 
al., 2007, Zhang et al., 2008, Otter and French, 2008, Ellington et al., 2009, Vourli et 
al., 2009). PVL-MSSA strains were not however entirely left out in the 
characterisation process. Four studies made mention of PVL-MSSA (Afroz et al., 
2008, Karahan et al., 2008, Severin et al., 2008, Orscheln et al., 2009), but none of 
these carried out a complete typing process on the test isolates. 
 
During the course of the present study, other researchers have also recognised the 
obvious gaps in knowledge of PVL-MRSA epidemiology and hence, more recent 
studies have focused on both PVL-MSSA and MRSA strains, often employing both 
MLST and spa typing. Several studies looked at different populations of PVL-S. 
aureus isolates (Tong et al., 2010, Blanco et al., 2011, Schaumburg et al., 2011, 
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Brown et al., 2012, Rolo et al., 2012, Zhao et al., 2012), while others simply analysed 
various sub-groups of PVL-MRSA isolates (Ellington et al., 2010, Holzknecht et al., 
2010, Otter et al., 2010, Boakes et al., 2011a, Aschbacher et al., 2012). A few 
however, focused on PVL-MSSA only (Rasigade et al., 2010, Breurec et al., 2011). 
Only two of these studies however (Otter et al., 2010, Boakes et al., 2011a), analysed 
both PVL sequence variation and PVL phage type in relation to strain typing. 
 
PVL-MSSA strains have recently been noted to have an even more diverse genetic 
background than PVL-MRSA strains and yet the same predominant clonal lineages 
are represented in both cases (Muttaiyah et al., 2010, Rasigade et al., 2010, Tong et 
al., 2010). Rather interestingly, in spite of the limited number of isolates analysed in 
this present study (Table 3.4), a similarly diverse genetic background was detected 
and the major sequence types associated with PVL-MRSA clones were represented 
(ST22, ST88, ST30 and ST1). Both ST1 and ST30 are pandemic clones with 
worldwide distribution. These have routinely been isolated in the UK where they have 
been reported at one time or the other as one of the major circulating MRSA clones 
(Ellington et al., 2009, Grundmann et al., 2010, Monecke et al., 2007b, Otter et al., 
2009). ST30 is often referred to as the Oceania or South West Pacific clone due to its 
original isolation from Australia, New Zealand and Western Samoa. In contrast, ST1, 
a USA400 PFGE related clone was initially described in the USA, though currently its 
prevalence is in decline (Vandenesch et al., 2003, Tristan et al., 2007). 
 
The PVL-MRSA ST22 isolates, though related to the pandemic HA-MRSA ST22 
EMRSA-15 clone are in themselves not pandemic but rather have been described 
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predominantly in Europe and the UK (Ghebremedhin et al., 2005, Holmes et al., 2005, 
Krziwanek et al., 2007, Monecke et al., 2007b). In the UK, while the majority of  
PVL-MRSA circulating clones belong to either ST8, ST30 or ST80 (Holmes et al., 
2005, Ellington et al., 2009, Otter and French, 2008), isolates belonging to ST22, the 
predominant sequence type found in the present study (Table 3.9), also constitute a 
significant burden of infection (Ellington et al., 2009). Of the other clones identified in 
the present study, ST772 was first described in Asia (Afroz et al., 2008, D'Souza et al., 
2010), and has an MLST allelic profile of 1-1-1-1-22-1-1. This is a single locus 
variant of ST1 and belongs to the same clonal complex, CC1. Recently, an increase in 
the number of ST772 isolates was noted (Ellington et al., 2010) in the UK. These 
isolates are known as the ‗Bengal Bay clone‘ in England, due to an association with 
importation from India and Bangladesh. Our test isolates (Table 3.9) therefore appear 
to reflect the current distribution of S. aureus strains in England. 
 
The new ST identified in the present study, ST1518 with an MLST allelic profile of 
46-75-207-44-13-68-60, is a single locus variant of ST152 (46-75-49-44-13-68-60). 
ST152 is a multilocus ST which is not commonly found in the UK, but has been 
reported in several European and African countries. In addition, it is thought to be 
associated with travel, specifically of immigrants from ex-Yugoslavian countries 
(Blanc et al., 2007, Monecke et al., 2007a, Berglund et al., 2005, Okon et al., 2009). 
ST152 is interesting because all isolates so far identified are PVL-positive, and it has 
generally been associated with carriage and skin and soft tissue infections (Muller-
Premru et al., 2005, Perez-Roth et al., 2010, Ruimy et al., 2008), rather than severe 
life threatening infection. In contrast, the TS1 Nottingham strain which belongs to 
CC152 was isolated from a patient who died from necrotising pneumonia. 
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Where MLST provides a snapshot of global epidemiology by looking at strain 
relatedness based on long term changes, the information it provides is sometimes 
inadequate as highlighted in a 2009 study (Larsen et al., 2009a). In this study, two 
rather distinct clones presented with identical PFGE and MLST profiles (USA300, 
ST8). These clones were however associated with clearly different clinical profiles, 
varying in age of patients infected and location of acquisition. The isolates also varied 
in the type of MGEs carried and antibiotic susceptibility profiles (Larsen et al., 
2009a). The two clones corresponded to two different spa types, t008 and its single 
repeat variant t024. The t008 clone was found to be PVL-positive while the t024 clone 
was PVL-negative. This identical delineation of spa type and PVL encoding genes 
between t008 and t024 strains had also previously been reported during a study 
characterising a group of isolates from Denmark (Bartels et al., 2007). 
 
Another group of isolates (the ST22) further highlight the need for spa typing as an 
essential adjunct to the characterisation of S. aureus. Over the years, various studies 
analysing different collections of S. aureus isolates described an apparent association 
between PVL and the ST22, EMRSA-15 strains (Udo et al., 2006, Coombs et al., 
2009, Nadig et al., 2010). These reports of the presence of PVL encoding genes in a 
highly successful hospital acquired clone raised concerns at the potential implications 
if this phenomenon became widespread, with respect to increase in virulence and 
severity of infection. In these three studies, isolates were described as EMRSA-15 
based on PFGE pattern, phage typing, production of SEC, non-production of urease 
and resistance to erythromycin and/or ciprofloxacin (Udo et al., 2006), or MLST and 
type of SCCmec element (Coombs et al., 2009), or MLST and spa type (Nadig et al., 
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2010). Two other studies which described an association between the PVL toxin and 
ST22 isolates more cautiously referred to these isolates as EMRSA-15 related clones 
(Holmes et al., 2005, Goering et al., 2008) presumably based on the meticillin 
susceptible status of the strains. 
 
A closer analysis of the literature shows that like the t008 and t024 spa types of ST8, 
the presence of the lukSF-PV locus in ST22 isolates varies depending on the spa type. 
Among the ST22 isolates, PVL encoding genes have only been rarely described in the 
two spa types which are more commonly associated with EMRSA-15 (t032 and t022) 
(Aires-de-Sousa et al., 2008, Boakes et al., 2011b, Otter and French, 2008). Therefore, 
despite reports of PVL-positive ST22 isolates, PVL encoding genes are rare in 
EMRSA-15 associated spa types. This was demonstrated in a recent study exploring 
the molecular diversity of CC22 PVL-MRSA strains in the UK (Boakes et al., 2011b). 
None of the 47 test isolates belonged to either spa type t032 or t022 but represented 
among these strains were spa types t005, t852, t1516, t2816, t1760, t849 and t1790. 
This absence of spa types t032 and t022 was similarly maintained within our 
population of PVL-MSSA ST22 strains (Table 3.9). spa typing analyses the variable 
region of the spa gene which is highly polymorphic. Unlike both PFGE and MLST 
typing, spa typing generally reflects local, more recent, variations. It has a higher 
discriminatory power than MLST, as clearly demonstrated in the present study 
whereby five different spa types (t005, t310, t852, t6642 and t6643) were represented 
within ST22 alone. 
 
Furthermore, in this present study, the ST22 isolates analysed were genetically similar 
in susceptibility and toxin profile as well as spa type to the recently described ST22 
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PVL-positive MRSA UK strains (Ellington et al., 2010), rather than to the 
predominant HA-MRSA ST22 EMRSA-15 clone (O'Neill et al., 2001, Wolter et al., 
2008, Grundmann et al., 2010). This is in agreement with the observation by Boakes 
and colleagues (Boakes et al., 2011b), who further went on to assert that PVL-ST22 
strains in the UK are evolving independently rather than by EMRSA-15 acquiring the 
PVL encoding genes. 
 
The genes encoding the Panton Valentine leucocidin may be carried by several 
temperate bacteriophages, of which at least five have been described in the literature 
(Kaneko et al., 1998, Kaneko et al., 1997, Narita et al., 2001, Baba et al., 2002, Diep 
et al., 2006b, Ma et al., 2006, Ma et al., 2008). Notwithstanding the differences in 
genetic background of the genes encoding the PVL toxin, the sequence of both lukF 
and lukS genes is relatively conserved with 12 major single nucleotide polymorphisms 
(SNPs) observed in total (Takano et al., 2008b). This previously described highly 
conserved nature of the genes encoding the PVL toxin (O'Hara et al., 2008) was also 
observed in the present study (Table 3.7). A total of 7 SNPs were detected and no 
additional polymorphisms described. In agreement with reports made from previous 
studies on lukSF-PV locus polymorphism (Otter et al., 2010, Takano et al., 2008b), 
PVL typing of select isolates showed that specific clonal lineages harboured the same 
PVL encoding gene sequences despite the variations in spa types within these clones 
(Table 3.9). A comparison of the lukSF-PV gene sequences from the present study 
with the current literature revealed that while specific clones appear to be associated 
with a specific sequence, the same lukSF-PV gene sequence variant may be carried by 
more than one lineage (Table 3.9). 
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These sequence polymorphisms have acted as the basis for the haplotypes previously 
defined by O‘Hara and colleagues (O'Hara et al., 2008). Both geographical and clonal 
bias has been shown to exist in the distribution of the two haplotypes defined by these 
polymorphisms. The R haplotype traditionally occurs within a limited number of 
lineages predominantly in the USA and more recently Australia (O'Hara et al., 2008, 
Tong et al., 2010). Due to previous reports of isolates carrying R haplotypes being 
found in the UK in significant numbers (Otter et al., 2010, Boakes et al., 2011a), the 
low incidence of R haplotypes in this small study population may reflect more on the 
meticillin susceptibility of the isolates rather than geographical location. No 
significant functional and structural differences are thought to result from the arginine 
(R) to histidine (H) mutation present in this haplotype (Besseyre des Horts et al., 
2010, Berglund et al., 2008b), however it is of interest that the only R haplotype found 
in this present study was linked with a fatal case of necrotizing pneumonia in a 
healthy adult. By 2011, this appeared to be the first reported case of an isolate 
carrying the R isoform described outside the previously noted clonal complexes (CC1, 
CC5, CC8 and ST93). Two recent publications have however reported this isoform in 
three isolates which belonged to ST30, ST121 and CC377 respectively (Li et al., 
2012, Brown et al., 2012). This increased detection of the R isoform in novel 
backgrounds may simply reflect the recent increase in PVL typing of S. aureus strains. 
 
One evolutionary pathway postulated for the development of CA-MRSA is the 
acquisition of PVL encoding genes prior to that of the SCCmec element. To lend 
credence to this theory, one would expect to find strains of both PVL-MSSA and 
PVL-MRSA which are more or less similar but simply differ in the presence of the 
mec gene and perhaps other resistance genes. Of the 11 unique MLST/spa clones 
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described in the present study, 4 (36.4%) of these were described for the first time 
(ST22/t6642, ST22/t6643, ST1518/t1941 and ST88/t6769), and one other had only 
just been described in 2009 (ST1/t3342). Of the 6 remaining profiles, limited typing 
data was available in the literature with regards to ST22/t310 and ST30/t021 isolates, 
therefore, there was no basis for comparison. A single study identified two fully 
sensitive MSSA ST30/t021 strains from Ireland with the same virulence profile as 
found in TS15 in the present study (Ellington et al., 2007). ST22/t005, ST22/t852, 
ST772/t345 and ST772/t657 were however found to possess spa and toxin profiles 
identical to clones of circulating CA-MRSA in the UK (Ellington et al., 2009, 
Ellington et al., 2010). These varied only in susceptibility profile, with the CA-MRSA 
strains generally presenting a more resistant profile, thereby lending support to the 
evolution of PVL-MRSA from PVL-MSSA. 
 
The number of MSSA isolates in the present study having identical PVL isoforms as 
their previously described MRSA counterparts also lends further credence to the 
hypothesis of PVL-MRSA evolving from PVL-MSSA (Berglund et al., 2008b, 
Boakes et al., 2011a, Dumitrescu et al., 2008b). This process may however not be 
limited to a single evolutionary event. The detection of several PVL phage types 
observed in the ST30 lineage in the present study, and described by Boakes and 
colleagues in two separate studies (Boakes et al., 2011b, Boakes et al., 2011a), hints at 
the possibility of multiple phage acquisitions and hence evolutionary events, though 
this remains to be verified. 
 
While the data generated in the present study, appears to favour evolution of PVL-
MRSA from PVL-MSSA, it is important to note that in contrast, several PVL-negative 
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CA-MRSA clones (as described by MLST and spa data) have been reported, which 
appear to have similar profiles to PVL-MRSA strains (Bartels et al., 2007, Otter and 
French, 2008, Zhang et al., 2008, Rivero-Perez et al., 2012). Otter and French 
described two MRSA clone groups (ST1/t127 and ST8/t008) which contained both 
PVL-positive and PVL-negative strains and hence an argument could be made for the 
acquisition of the mec genes prior to the genes encoding the PVL toxin. Antibiogram 
data in these studies though were not directly linked with each specific isolate thereby 
preventing any further comparisons or conclusions to be drawn. Another study 
highlights the possibility of acquisition of mec genes prior to genes encoding the PVL 
toxin (Zhang et al., 2008). In this study, similar PVL-positive and PVL-negative 
variants of USA400/t128 were detected. These strains however, simply differed in the 
carriage of fnbB and cnaA virulence genes. These findings may therefore suggest that 
evolution of PVL-MRSA can take place by several pathways. Thus, further research 
will be required to ascertain if all clones evolve by either pathway, or if several clones 
favour a certain pattern of evolution. 
 
Despite the increase in discriminatory power of the initial PVL-phage typing method 
with the recent description of additional primers enabling øSa2USA detection (Boakes 
et al., 2011a), the inability of this technique to detect the ST772 PVL phages highlight 
its limitations and the need for constant updating to encompass evolving novel phages. 
 
In conclusion, due to the gentamicin/trimethoprim resistance bias in isolate selection, 
the present study provides one of the most comprehensive in-depth analysis of PVL-
MSSA ST22 isolates incorporating data on the PVL encoding genes to date. It also 
highlights the important role PVL-MSSA strains generally play as reservoirs for the 
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emergence of PVL-MRSA strains due to their direct evolutionary links suggested by 
the typing results. The data emphasise the need for increased surveillance which may 
form the basis for intervention strategies against PVL-MSSA to help curb the 
emergence and clonal expansion of PVL-MRSA. 
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Chapter Four 
 
4 Development and validation of a high resolution melt based 
method for the rapid typing/identification of PVL-positive strains 
of S. aureus 
 
 Introduction 4.1
Despite the wealth of information provided by the typing systems employed in the 
initial part of this research, these current typing methods for S. aureus are often 
cumbersome, expensive and time consuming. This can be illustrated by an analysis of 
the process for the sequence based typing systems (Figure 4.1). A number of the 
typing systems are simply based on sequence comparison. This involves the need to 
ascertain the presence, integrity and purity of a PCR product by visualisation on an 
agarose gel following both the amplification and purification processes. All these 
steps combine to increase the complexity and timescale of the technique before the 
actual sequencing take place. As the MLST procedure involves the analysis of seven 
unique loci per isolate, significant manpower and time resources are consequently 
involved in obtaining the essential typing information, highlighting the need for an 
alternative. 
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Figure 4.1: Process flowchart for sequence based typing systems  
The approximate timings of each stage in the process of the sequence based 
typing systems are indicated in brackets 
 
DNA Product Amplification 
DNA Product Visualisation 
DNA Product Purification 
DNA Product Visualisation 
DNA Product Quantification 
Sequencing 
Sequence Data Analysis 
(1 h) 
(1 h) 
(20 min) 
(1 h) 
(10 min) 
(48 h) 
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 High Resolution Melt (HRM) 4.1.1
The recently described high resolution melt (HRM) technique is a real time PCR 
based method. This method eliminates the need for product detection via the 
traditional post amplification processes such as agarose gel electrophoresis. 
Furthermore it enables PCR amplicon differentiation based on variations in DNA melt 
characteristics (Gundry et al., 2003, Wittwer et al., 2003). Since its development, 
HRM has found wide application mainly in SNP detection and as a gene scanning 
tool. A few studies have employed this technique as a bacterial typing tool based on 
variations in a single gene. These variations in application are clearly highlighted by a 
comparison of two publications (Price et al., 2007, Schwartz et al., 2009). Whereas 
one study applied HRM to genotyping of Campylobacter jejuni based on size 
variations in a class of short sequence repeats (CRISPRs) (Price et al., 2007), a second 
study (Schwartz et al., 2009) identified different Mycoplasma pneumoniae isolates 
based on SNPs in a single constant length gene fragment. 
 
The ≈1.9 kb lukSF-PV locus which encodes both LukF and LukS subunits of the 
Panton-Valentine leucocidin is a highly conserved region in which 12 major SNPs 
have been described to date (Section 1.6.3) (Takano et al., 2008b, Berglund et al., 
2008b, Dumitrescu et al., 2008b). Only four of these SNPs are however commonly 
found within PVL-positive isolates. These occur at positions 527 and 663 of lukS and 
1396 and 1729 of lukF and represent two major allelic variations per gene. A527/G663 
and G527/T663 in the lukS gene and G1396/A1729 and A1396/A1729 in the lukF gene (Table 
4.1). Furthermore, the lukS locus is unique in the fact that the two predominant 
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variants (A527/G663 and G527/T663) potentially balance each other out 
thermodynamically. 
 
These four SNPs serve as the basis for the designation of previously described H and 
R isoforms of lukSF-PV (O'Hara et al., 2008). These allelic variations in both lukF and 
lukS genes have been shown to be specific (though not exclusive) to the different  
S. aureus clones as defined by STs (Table 1.4). The potential therefore exists for the 
use of these variations in HRM based genotyping of PVL-positive S. aureus isolates. 
 
The use of HRM in detecting all previously described classes of single base pair 
changes within a specific amplicon has been well documented (Krypuy et al., 2006, 
Toi and Dwyer, 2008, Sinthuwiwat et al., 2008, Norambuena et al., 2009). Shorter 
amplicons ranging in size from 45 – 190 bp were generally employed to improve 
result specificity. Only a limited number of studies have however made mention of the 
detection of a double mutation within an amplicon (Pietzka et al., 2009, van der Stoep 
et al., 2009, De Leeneer et al., 2008). 
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Table 4.1: The four major SNP combinations used to define PVL isoforms 
lukSF-PV sequence variants 
527* 663* 1396* 1729* Main STs** 
A G G A 22, 59, 88 
A G A A 30, 50, 80, 121, 772 
G T A G 8, 93, 1, 5 
G T A A 1 
 
*
These values indicate nucleotide positions of the allelic variations within the lukSF-PV locus 
**
Specific STs associated with each variant combination as compiled from (Takano et al., 
2008b, Berglund et al., 2008b, Otter et al., 2010, Wolter et al., 2007) 
 
The four major SNPs shown are as described by O'Hara et al. (2008) 
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The present study therefore set out to analyse the ability of HRM to differentiate 
between allelic variations including those which potentially balance each other out 
thermodynamically (as seen in the lukS locus). This technique was then explored as a 
possible tool for rapid molecular characterisation of PVL-positive S. aureus isolates 
based on the specific allelic variations present in the lukSF-PV locus. If successful, 
this method could significantly reduce turnaround typing time and improve outbreak 
investigation and epidemiological studies. 
 
Studies presented in this chapter aimed to answer the following questions. 
1. Could the HRM technique be used to differentiate between both A527/G663 and 
G527/T663 variants of the lukS gene as well as the lukF gene variants? 
2. Could the HRM technique be used to class isolates of differing spa types as 
either same or different? 
3. Could this technique then be applied as a genotyping tool for a group of 
blinded isolates? 
4. Are the results generated by this technique consistent and accurate? 
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 Materials and Methods 4.2
 Primers 4.2.1
To explore the use of HRM analysis in the rapid typing of PVL-positive S. aureus 
isolates at both the lukSF-PV and spa loci, three sets of primers were used (Table 3.1). 
The lukSF-PV primers were designed to capture allelic variations at positions 527 and 
663 of the lukS gene and at positions 1396 and 1729 of the lukF gene, thereby 
generating PCR products of 272 bp and 447 bp in length respectively. Previously 
described primers were used for the spa locus (Aires-de-Sousa et al., 2006). 
 
 Standard S. aureus Isolates 4.2.2
Four standard NARSA (Network on Antimicrobial Resistance in S. aureus) isolates  
NRS123, NRS157, NRS158 and NRS162 with known allelic variations of G527/T663-
A1396/A1729; A527/G663-G1396/A1729; A527/G663-G1396/A1729; and G527/T663-G1396/A1729 
respectively at positions of the lukSF-PV locus indicated above were used in the 
development of the lukSF-PV HRM (Table 4:2). Development of the spa HRM was 
similarly carried out using five PVL-positive S. aureus isolates with known spa types 
(Table 4.3), from our own strain collection. 
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Table 4.2 Allelic variation of standard isolates used for the 
development of the lukSF-PV HRM assay 
S/No Strain ID
*
     Allelic Variation
**
 
lukS          –       lukF 
1. NRS123 G527/T663       A1396/A1729 
2. NRS157 A527/G663       G1396/A1729 
3. NRS158 A527/G663       G1396/A1729 
4. NRS162 G527/T663       G1396/A1729 
 
*
Standard isolates were obtained from the Network on Antimicrobial Resistance in  
S. aureus (NARSA) collection. 
**
Allelic variations are as described in Table 4.1 representing variations at positions 
527, 663, 1396 and 1729 of the lukSF-PV locus. 
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Table 4.3: spa type and repeat sequence of isolates used for the development of spa HRM 
 
S/No Isolate ID
*
 spa type Repeat Sequence 
1.  TS6 t6642 26-23-13-23-31-05-22-17-25-17-25-114 
2.  TS9 t6642 26-23-13-23-31-05-22-17-25-17-25-114 
3.  TS14 t005** 26-23-13-23-31-05-17-25-17-25-16-28 
4.  TS18 t005 26-23-13-23-31-05-17-25-17-25-16-28 
5.  TS17 t852** 07-23-13-23-31-05-17-25-17-25-16-28 
 
*
The isolates chosen represented spa types generating amplicons of identical lengths (as indicated by number of repeats) but varying in 
nucleotide composition (Isolates were obtained from the NUH Trust between 2008 and 2009). 
**
spa types t005 and t852 differ at only a single base pair. 
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 HRM 4.2.3
Using the Roche LC480 High resolution mastermix, samples were set up for PCR 
amplification in a 25 µl final volume containing 1 × MasterMix, 1 µl template DNA, 
300 nM each primer and 2.5 mM MgCl2 on a Roche LightCycler® 480 Real-Time 
PCR System, using a 96-well plate. The amplification protocol involved a 5 min hold 
at 95°C followed by 45 amplification cycles comprising of 95°C denaturation for 10 s, 
annealing at 60°C for 10 s and elongation at 72°C for 10 s. The HRM reactions were 
carried out in triplicate for each isolate tested. 
 
After amplification, high resolution melting (Section 1.7.4) was carried out on the 
PCR amplicons generated. The first part of the melting process involved a brief 
denaturation of samples at 95°C for 1 min and rapid annealing. Following this, the 
temperature was again slowly increased and HRM curve data obtained from 65°C to 
97°C with 5 fluorescence acquisitions per degree centigrade (1°C). 
 
Finally, HRM analysis involving normalisation, temperature shift and difference curve 
generation was carried out on the melt data using the automatic settings of the Gene 
Scanning Software Version 1.5.0 (Roche Diagnostics) except were indicated. 
Normalisation involves the conversion of raw fluorescence data of the active melt 
region into a relative fluorescence signal ranging from 0% (≈ lowest fluorescence 
value) to 100% (≈ highest fluorescence value). Conversely, temperature shift involves 
shifting on the X – axis to show up the relative rather than absolute temperature 
difference between the curves (Reja et al., Wittwer et al., 2003). Difference curves are 
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generated by subtracting the normalised and temperature shifted curves from that of a 
reference ‗base curve‘. This process makes it easier to visualise small variations 
between amplicons. 
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 Results 4.3
 lukSF-PV locus HRM Analysis 4.3.1
An analysis of the melt profile of the four NARSA isolates at the 272 bp lukS locus 
revealed four distinct but similar melt profiles and peaks (Figure 4.2 A), with melting 
temperatures (Tm) ranging from 76.25°C to 76.68°C. Subsequent HRM analysis 
involving normalisation and temperature shift using the Roche Gene Scanning 
Software version 1.5.0, classed the four standard isolates into two distinct groups 
(Figure 4.2 B). The variations within these two groups were then more clearly 
represented by the generation of a difference curve using the Roche Gene Scanning 
Software (Figure 4.2 C) using the automatic settings. 
 
The melt profile of the 447 bp lukF product differed from that of the 272 bp lukS locus 
with the product melting in two steps (Figure 4.2 D). Unlike the HRM profiles 
produced following analysis of the lukS locus, a visual inspection of the lukF HRM 
profiles did not provide clear cut demarcation into distinct groups. This inability to 
visually separate the lukF profiles into groups did not however have an effect on the 
final outcome of the analysis process. The gene scanning software was able to 
automatically cluster the lukF amplicons into two distinct groups after normalisation 
and temperature shift.  
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Figure 4.2: Representation of different melt curves generated during the HRM analysis of four S. aureus NARSA isolates. 
Panel A presents the initial melt profiles of the four standard isolates at the lukS locus showing no obvious clear groupings. Panel B presents the 
normalised and temperature shifted melt profiles of the same four standard isolates showing a clear demarcation of the two allelic variants represented 
within the four isolates into two groups. Panel C presents the difference curves of the four standard isolates at the lukS locus highlighting the difference 
in high resolution melt profile between the variants. Panel D presents the lukF normalised and temperature shifted melt profile showing multiple melt 
domains which were assigned into two groups by the HRM software as represented by the two colours. 
NRS162 
NRS123 
NRS123 / 162 (S1) 
NRS157 / 158 (S2) 
A B 
C D 
F1 
F2 
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The four different allelic variations G527/T663; A527/G663; A1396/A1729 and G1396/A1729 
present in these NARSA isolates were hence designated S1, S2, F1 and F2 
respectively.  
 
The next step in the process was to explore the ability of the HRM software to 
accurately predict the genotypes of unknown isolates based on known standard 
genotypes. To do this, melt profiles of NRS123 and NRS157 with genotypes S1 and 
S2 respectively, were used as positive internal standard controls. Based on the 
genotypes of these two isolates, the gene scanning software was able to accurately 
class isolates NRS158 and NRS162 which were used as the unknowns, as S2 and S1 
(Figure 4.3). This result therefore demonstrated the ability of the technique to 
determine the genotypes of unknown isolates based on HRM profiles of standard 
isolates. 
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Figure 4.3: Automatic grouping of NRS158 and NRS162 as S2 and S1 variants (circled) respectively 
Grouping of standard strains NRS158 and NRS162 following HRM analysis was automatically performed by the Gene Scanning 
Software Version 1.5.0 based on the data obtained from the specified internal control isolates NRS123 and NRS157. 
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 Pilot study to characterise a subset of isolates using HRM analysis 4.3.1.1
Following the demonstration of the ability of the HRM technique to distinguish 
between both lukS and lukF variants, a test run was carried out to further explore the 
potential of the technique as a genotyping tool. The result of this analysis using 20 
previously characterised PVL-positive S. aureus test isolates, highlighted the potential 
of this method (Table 4.4). 
 
HRM analysis of the lukS locus resulted in 100% typeability. All isolates were 
assigned to either group S1 or S2. At the lukF locus, 95% (19/20) of isolates could be 
assigned to one of the two previously described groups i.e. F1 or F2. A single isolate 
(TS1) was classed as ‗unknown‘ (FU). Isolate TS1 differed from both the F1 and F2 
control genotypes by having an allelic profile of A1396/G1729, further highlighting the 
specificity of the HRM assay. 
 
A total of three profiles (S1:FU, S2:F1, and S2:F2) were therefore generated for the 
twenty isolates (Table 4.4) corresponding to the six STs present within this collection. 
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Table 4.4: HRM profiles of isolates generated following HRM based typing 
S/NO HRM Profile
*
 Test Isolate ST
**
  Nucleotide positions of lukSF-PV 
sequence variations captured in 
study 
     lukS  lukF 
     527 663  1396 1729 
1.  S1:FU TS1 1518  G T  A G 
2.  S2:F1 TS25 1  A G  A A 
3.  ″ TS7 30  A G  A A 
4.  ″ TS15 30  A G  A A 
5.  ″ TS16 30  A G  A A 
6.  ″ TS2 772  A G  A A 
7.  ″ TS5 772  A G  A A 
8.  ″ TS8 772  A G  A A 
9.  S2:F2 TS6 22  A G  G A 
10.  ″ TS9 22  A G  G A 
11.  ″ TS13 22  A G  G A 
12.  ″ TS14 22  A G  G A 
13.  ″ TS18 22  A G  G A 
14.  ″ TS17 22  A G  G A 
15.  ″ TS19 22  A G  G A 
16.  ″ TS20 22  A G  G A 
17.  ″ TS23 22  A G  G A 
18.  ″ TS24 22  A G  G A 
19.  ″ TS12 30  A G  G A 
20.  ″ TS21 88  A G  G A 
*
The HRM profile was generated for each isolate by combining HRM data from both the lukS and 
lukF loci. 
**
MLST sequence type. 
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 spa locus HRM analysis 4.3.2
Despite the promising typing results obtained in Section 4.3.1.1, the level of 
discrimination produced was 50% lower than that provided by MLST. HRM analysis 
of DNA fragments of the lukSF-PV locus generated three genotypes as opposed to the 
six STs represented within the test population (Table 4.4). Therefore, the next step in 
the present study was to explore the use of HRM in genotyping S. aureus isolates 
based on variations in spa types. This step was taken in a bid to improve the potential 
utility of HRM as a typing tool by possibly combining data from the lukSF-PV and 
spa loci. 
 
 Test strain characteristics 4.3.2.1
Five isolates representing three different spa types were used for the development of 
the spa HRM technique (Table 4.3). These spa types were chosen to demonstrate the 
ability of the technique to differentiate spa amplicons with identical lengths but 
variable nucleotide composition. The amplicons from all three spa types represented 
were 288 bp in length (Table 4.3). Additionally, isolate TS17 (t852) was included in 
the analysis to explore the ability of the HRM technique to differentiate between spa 
types t852 and t005 which differ by only a single base pair. 
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 HRM analysis of isolates of differing spa type 4.3.2.2
Initial analysis of the spa HRM data using the automatic settings of the Roche Gene 
Scanning Software, generated complex shaped difference curves with more than one 
peak (indicated by the arrows in Figure 4.4 A). These complex shaped plots 
negatively affected discrimination as crossing over and overlapping of the difference 
curves (indicated by the circle) limited visual interpretation (Figure 4.4 A). This 
limitation was overcome by carrying out HRM analysis with a temperature shift of 
zero (0°C) on the data. The process resulted in single peaks and no overlaps (Figure 
4.4 B). Hence all further analysis was carried out with a temperature shift of zero. 
 
162 
 
 
 
 
 
 
Figure 4.4: Normalised and temperature shifted difference curves of five S. aureus isolates representing three 
different spa types using temperature shifts of 5°C or 0°C. 
The HRM profiles which were generated as described in Section 4.2.3 show the effect of temperature shift on HRM analysis of the spa locus. 
Panel A presents the complex shaped difference curves generated with the automatic temperature shift of 5°C in place. Panel B presents the 
clearly resolved difference curves when a temperature shift of 0°C was used. 
 
Colour code: Blue = TS17 (t852); Yellow = TS14 (t005); Orange = TS18 (t005); Pink = TS6 (t6642); Red = TS9 (t6642). The spa types are 
shown in bracket 
A B 
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 spa HRM Data Interpretation 4.3.2.3
Following HRM analysis, assignment of the different spa types as same or different 
was carried out using previously defined criteria (Stephens et al., 2008). Isolates 
generating similar shaped difference curves falling within 4 relative signal difference 
(RSD) units of each other were grouped as identical. RSD is the unit of measurement 
generated when a difference curve is created. 
 
Both t6642 isolates (TS6 and TS9) consistently (over 5 repeat experiments) produced 
similar difference curves with RSD values which differed by <4 (Figure 4.5). This 
enabled both isolates to be grouped as same. Interpretation of results for the t005 
isolates (TS14 and TS18) however proved more problematic. While generating similar 
shaped difference curves, these consistently had RSD values which differed by >4 
(≈18). In contrast, TS17 (t852) and TS14 (t005) produced more similar curves with 
differences in RSD values closer to 4 (≈5). This similarity was highlighted by the 
automatic classification of these two isolates as same by the gene scanning software 
(Figure 4.6). 
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Figure 4.5: Normalised and zero temperature shifted difference curves of five 
S. aureus test isolates representing three different spa types. 
 
The HRM profiles were generated as described in Section 4.2.3 with a 0°C temperature shift. The 
figure shows similar HRM profiles generated by t6642 isolates (TS6 and TS9) with a difference in 
RSD values of <4. Additionally, t005 isolates (TS14 and TS18) generated similar shaped HRM 
profiles but a difference in RSD value of ≈18. t852 (TS17) generated a HRM profile similar to TS14 
with a difference in RSD value of ≈5 
 
Colour code: Blue = TS17 (t852); Yellow = TS14 (t005); Orange = TS18 (t005); Pink = TS6 
(t6642); Red = TS9 (t6642). The spa types are shown in bracket 
  
TS14 (t005) 
TS17 (t852) 
TS18 (t005) 
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Figure 4.6: Automatic classification of normalised and zero temperature shifted 
difference curves of five S. aureus test isolates into three groups. 
The HRM profiles were generated as described in Section 4.2.3 with a 0°C temperature shift. The 
figure shows the automatic classification of HRM profiles of both t6642 isolates (in blue) as same, 
misclassification of the t005s (in red and green respectively) as different and t852 (T17) wrongly 
classed as identical to t005 (TS14). Each individual group as defined by the gene scanning software 
is represented by a different colour.  
TS14 (t005) 
TS17 (t852) 
TS18 (t005) 
TS6 and TS9 (t6642) 
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In order to explore the discrepancies noted between the t005 isolates in Figure 4.6, 
further HRM analysis of a total of five isolates of spa type t005, was carried out. This 
analysis resulted rather interestingly in their classification into more than one group. 
While all the difference curves corresponding to the five t005 isolates were similar in 
shape, they differed greatly in RSD. Of the five isolates, TS13, TS14 and TS18, 
produced difference curves which clustered together (Figure 4.7), with a difference in 
RSD values of >4 (≈38.2, 36.2 and 34.5 respectively). HRM data for these three 
isolates was obtained from the first 6 columns of the 96-well plate. TS20 and TS24 
produced similar difference curves. These curves however had RSD values which 
differed by >4 (≈24.2 and 11.3 respectively). As HRM data for these two isolates was 
obtained from columns 8 and 10 of the 96-well plate, this suggested a possible effect 
of well position on result outcome. 
 
This possible effect of well position on assay outcome was further highlighted in the 
case of TS14 and TS18, which produced HRM profiles with a difference in RSD 
values <4. This result was in contrast to the results of the initial assay (Figure 4.4 B) 
whereby a difference in RSD value of ≈18 was noted between the isolates. The only 
variable between the two assays was the well position used in the microtitre plate. In 
the initial assay, TS14 and TS18 isolates were analysed in columns 6 and 10 
respectively while they were analysed in columns 4 and 7 respectively in the second 
assay. 
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Figure 4.7: High resolution melt profile of five S. aureus isolates with 
identical t005 spa types 
The HRM profiles were generated as described in Section 4.2.3 with a 0°C temperature 
shift. The figure shows HRM profiles of isolates to the right of the plate (colour coded 
blue and orange) presenting with differences in RSD values >4 and TS14 and TS18 
formerly classified as different presenting difference curves clustered together. Inset 
represents the different colour codes associated with each plate column. 
 
Colour code: Red = TS13; Pink = TS14; Yellow = TS18; Blue = TS20; Orange = TS24 
 
 
TS14 
TS18 
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 Effect of well position on results of HRM analysis 4.3.2.4
In order to further explore the possible effect of well position on HRM profiles, two 
randomly chosen strains, TS6 and TS9 of spa type t6642 were used. Twelve aliquots 
of a large scale PCR ―mastermix‖ created for each strain were dispensed into wells at 
various positions of a 96-well plate (Figure 4.8) and PCR amplification and HRM 
analysis performed. 
 
 
Figure 4.8: Aliquot positions used to assay for effects of well position 
on HRM profiles. 
The aliquot positions for TS6 are highlighted in red while the aliquot positions for 
TS9 are highlighted in black. 
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The amplification efficiency of the different aliquots of both TS6 and TS9 appeared to 
vary across the plate, resulting in variable amplification curves (Figure 4.9). These 
amplification curves which represent the fluorescence generated per amplification 
cycle, differed in the fluorescence value at which the curves entered the non-
exponential plateau phase. For most reactions of both isolates (7 of 12), a plateau 
phase was reached at fluorescence units ranging from 64 – 74. Of the 5 reactions with 
a plateau phase corresponding to fluorescence units over 74, four occurred in columns 
1 and 12 of the 96-well plate. 
 
Similarly, well position appeared to impact on the outcome of HRM analysis (Figure 
4.10). Samples in columns 11 and 12 of the 96-well plate gave RSD values which 
differed by >4. This resulted in amplicons in these columns being grouped separately 
despite the similar shaped difference curves (Figure 4.10). This analysis provided a 
strong indication that the observed well/column based variability could be a reflection 
of temperature variability across the plate. 
 
In order to further explore this hypothesis, the automatic temperature shift function of 
the gene scanning software was restored (Figure 4.11). Temperature shift, one of 
three functions of the gene scanning software, is designed to correct for temperature 
variation across the plate. While restoring the automatic temperature shift function at 
this stage resulted in more complex shaped difference curves, it did result in a 
reduction in differences in RSD values between replicate samples analysed at different 
positions on the plate (Figure 4.11). A position dependent clustering (of samples) was 
however still maintained, highlighting the need to take into consideration sample 
position in the interpretation of spa HRM data generated by the Roche LC480. 
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Figure 4.9: Variable amplification profiles generated for aliquots of single master mixes for TS6 and TS9 
analysed at different well positions of the 96-well plate. 
The amplification curves were generated during amplification as described in Section 4.3.2. The figure shows differences in 
fluorescence units corresponding to non-exponential plateau phase with four out of the five samples producing fluorescence units >74 
located in columns 1 and 12. The inset represents the different colour code associated with each plate column Colour code: Blue = 
Column 1; Red = Column 2; Yellow = Column 6; Purple = Column 11; Green = Column 12 (Aliquots positions of TS6 are highlighted 
in red and TS9 in black). 
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Figure 4.10: Normalised and zero temperature shifted difference curves of a single sample (TS6) analysed at different 
positions of the 96-well plate.  
The HRM profiles were generated as described in Section 4.2.3 with a 0°C temperature shift. The figure shows HRM profiles of a single master 
mix dispensed at varying well positions clustering into two distinct groups dependent on sample location on the plate (as indicated by colour code). 
The inset represents the different colour code associated with each plate column Colour code: Blue = Column 1; Red = Column 2; Yellow = 
Column 6; Purple = Column 11; Green = Column 12 (Aliquots positions of TS6 are highlighted in red and TS9 in black) 
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Figure 4.11: Normalised and automatic temperature shifted difference curve clustering for aliquots of single master 
mixes for TS6 and TS9 analysed at different well positions of the 96-well plate. 
The HRM profiles were generated as described in Section 4.2.3 with a 0°C temperature shift. The figure shows HRM profiles of a single master 
mix dispensed at varying well positions showing a reduction in RSD and less defined difference curve grouping dependent on sample location 
on the plate (as indicated by colour code). The inset represents the different colour code associated with each plate column Colour code: Blue = 
Column 1; Red = Column 2; Yellow = Column 6; Purple = Column 11; Green = Column 12 (Aliquots positions of TS6 are highlighted in red 
and TS9 in black). The arrows indicate RSD values showing differences in values slightly greater than 4 between aliquots in column 11 and the 
aliquot showing the lowest RSD. 
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 Guidelines for the interpretation of spa HRM data 4.3.2.5
Based on the above findings and an awareness of the possible negative impact of 
temperature variation across the assay plate, the following guidelines for typing 
isolates as same or different based on the spa HRM analysis on the Roche LC480 
were formulated :- 
 
1. Following HRM analysis with a temperature shift of zero. 
A. Isolates should be classed as having the same spa type if generating difference 
curves which are identical or highly similarly in shape and peak which fall 
within an RSD <4. 
B. Isolates should be classed as having different spa types if generating difference 
curves which vary in shape and peak and have an RSD of >4. 
 
2. In case of ambiguous results i.e. 
Isolates presenting with difference curves identical or similar in shape 
and peak but an RSD <4 
OR 
Isolates with difference curves identical or similar in shape, an RSD 
<4 but slightly differing peaks 
 
A. Isolates may only be typed as same or different after further analysis of results 
following a restoration of the automatic temperature shift function of the gene 
scanning software to control for temperature variation across the plate. 
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 HRM analysis of a range of spa types 4.3.2.6
Using the above criteria for the interpretation of spa HRM data, several isolates of 
different spa types (Table 4.5) were then analysed. The results demonstrated the 
ability of the HRM technique to be used in genotyping of isolates via the spa locus 
(Figure 4.12). No ambiguous results occurred within these isolates which were 
classed by the HRM software into two groups of 2 and 3 isolates respectively and 
others occuring singly (singletons). 
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Table 4.5: List of isolates used to test the optimised spa HRM 
S/No spa type Isolate ID 
1.  t008 TS27; TS29; TS30 
2.  t1941 TS1 
3.  t128 NRS123; NRS248 
4.  t386 TS26 
5.  t125 NRS192 
6.  t127 NRS229 
7.  t021 NRS162 
 
 
Figure 4.12: Normalised and zero temperature shifted difference curves of S. 
aureus test isolates based on the proposed criteria for HRM data analysis. 
The HRM profiles were generated as described in Section 4.2.3 with a 0°C temperature shift. 
The figure shows accurate spa HRM genotyping with two groups of three and two isolates 
(indicated in black and red boxes respectively), and five singletons. 
 
Colour code: Red (NRS192); Green (TS29); Pink (NRS248); Grey (NRS123); Yellow (TS27); 
Brown (TS30); Light blue (TS26); Green-Blue (NRS229), Orange (NRS162); Purple (TS1). The 
isolate identities are indicated in bracket. 
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 Strain list for HRM Validation combining PVL and spa types 4.3.3
Following the demonstration of the ability of high resolution melting to be used as a 
typing tool based on specific variations in lukF, lukS and spa genes, the next step in 
the development of this technique was its validation using a larger panel of S. aureus 
isolates. In order to do this, forty isolates from our collection, were assigned new 
identities (1 – 40) by a laboratory colleague, so that assays could be performed in a 
blinded manner. These isolates will subsequently be referred to as ―blinded isolates‖. 
These isolates include a range of MLST groups, spa types and PVL status (Table 4.6) 
and were analysed to validate the sensitivity and specificity of this technique, as well 
as its potential to serve as a rapid diagnostic tool capable of determining the 
relatedness of PVL-positive S. aureus isolates. 
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Table 4.6: Relevant characteristics of isolates used to validate the 
HRM assay by combining PVL and spa type data. 
S/No Expected lukSF-PV Genotype
*
 
(Number of Isolates) 
MLST spa type Isolate ID 
1.  S1FU (5) ST8 
 
ST1518 
t008 
t211 
t1941 
TS27/TS29/TS30 
NRS158 
TS1 
2.  SIF1 (7) ST1  t125 
t127 
t128 
t175 
t386 
t3342 
NRS192 
NRS229 
NRS123/NRS248 
NRS194 
TS26 
TS25 
3.  S2F1 (12) ST30 
 
ST80 
ST121 
ST772 
t021 
 
t044 
t314 
t345 
t657 
TS7/TS12/TS15/TS16/NRS162/ 
RSS289/RSS290 
NRS255 
NRS185 
TS8 
TS2/TS5 
4.  S2F2 (14) ST22 
 
 
 
 
 
ST25 
ST88 
t005 
t310 
t852 
t3379 
t6642 
t6643 
t2554 
t690 
t6769 
TS13/TS14/TS18/TS20/TS24 
TS19 
TS17 
NRS157 
TS6/TS9 
TS23 
NRS227 
TS28 
TS21 
5.  None (2) ST22 
ST59 
t032 
t216 
RSS043 
RSS063 
*
These expected lukSF-PV types are based on previous associations of variations in the 
genes encoding the PVL toxin with specific STs as described in literature and 
summarised in Table 1.4. 
 
lukSF-PV genotype key: S1 = G527/T663; S2 = A527/G663; F1 = A1396/A1729; F2 = 
G1396/A1729; FU = A1396/G1729. 
S1 and S2 represent allelic variations at positions 527 and 663 while F1, F2 and FU 
represent allelic variations at positions 1396 and 1729 of the lukSF-PV locus. 
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 HRM validation of the lukS gene 4.3.4
HRM analysis at the lukS gene resulted in 38 of the isolates classed automatically as 
either G527/T663 or A527/G663 genotypes designated S1 and S2 respectively. A subset of 
this data is presented in Figure 4.13. Overall, the majority of isolates (70%; 28/40), 
belonged to the S2 group while only 25% (10/40) belonged to the S1 group.  
 
Following HRM analysis at the lukS locus however, two of the blinded isolates (37 
and 38) could not automatically be classed as either S1 or S2. For the blinded isolate 
38, while one assay duplicate was clearly identified as being ‗negative‘ for the lukS 
gene (Figure 4.13), the second duplicate was designated as an ‗unknown‘ lukS 
genotype. Both assay duplicates for isolate 37, were also designated as an ‗unknown‘ 
lukS genotype. As the blank no template control in this assay was also assigned an 
‗unknown‘ lukS genotype by the software, the amplification and melt profiles of all 
three assays (blinded isolates 37, 38 and blank) were further analysed. 
 
The melt profiles from these three assays revealed similar melt temperatures as the 
other blinded isolates in the test run (Figure 4.14) but significantly lower melt peaks 
were observed. 
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Figure 4.13: Representative Normalised and automatic temperature shifted difference curve profiles of the lukS locus. 
The HRM profiles which were generated as described in Section 4.2.3 show a clear difference in the S1 (blue), S2 (red) and Unknown (brown) lukS 
profiles. S1 represents the G527/T663 genotype while S2 represents the A527/G663 genotype. 
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Figure 4.14: Melt curves of lukS locus showing lower melt peaks of negative 
and blank samples. 
The melt curves were generated as described in Section 4.2.3. The figure shows lower melt 
peaks (circled in blue) of isolates 37 and 38 and assay blank no template control. Inset shows 
assignment of genotypes of the blinded isolates 37 and 38 (circled in red) and the blank no 
template control (circled in black) where brown = unknown and orange = negative 
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This information is in agreement with the higher crossing point (Cp) values observed 
for these isolates which are represented in Figure 4.15. When compared with the Cp 
values (range 16.50 – 18.97) associated with the majority of the other isolates, a sub-
group produced high Cp values (range 28.59 – 40.00). This sub-group included the 
blank no template controls and blinded isolates 37 and 38 which are PVL-negative 
(Figure 4.15). Cp values indicate the point at which each amplification mixture 
produces measurable fluorescence and is a function of the amount of DNA present at 
the beginning of the PCR cycling. Hence high Cp values (>30) indicate late 
amplification which is often non-specific – a finding that may explain discordant 
results in the present study. This finding highlights the need for proper monitoring and 
analysis of the entire amplification process and the need to take this into consideration 
during the interpretation of the HRM data. Proper monitoring would ensure accuracy 
in the downstream application as ignoring the discrepancies in melt peaks and Cp in 
this case would have clearly resulted in false positives. 
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Figure 4.15: Amplification curves showing variable crossing points generated from HRM analysis of 
lukS in a “blinded” panel of isolates.  
The amplification curves were generated as described in Section 4.2.3. The figure shows late non-specific amplification 
taking place in blinded isolates 37, 38 and blank no template control (to the right of the black line) this corresponds to the 
HRM profiles with lower melt peaks as observed in Figure 4.14. 
 
Cut-off between specific and 
non-specific amplification 
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 HRM validation of the lukF gene 4.3.5
For the lukF locus, the majority of PVL-positive isolates as expected had identical 
duplicates and were classed automatically as either F1 (A1396/A1729 genotype), F2 
(G1396/A1729 genotype) or unknown. Two isolates (4 and 9) however, had inconsistent 
assay duplicate results. These isolates are indicated by the circles on Figure 4.17. In 
both cases one assay duplicate was assigned to a known group and the other to an 
unknown group. This inconsistency was however found to be eliminated by altering 
the automatic pre-melt normalisation temperature (circled) from a range of 71.49 – 
72.49°C (Figure 4.16 A) to 71.19 – 72.39°C (Figure 4.16 B). This resulted in an 
equal distribution of positive isolates between both the F1 and F2 genotypes (47.5%; 
19/40 of each). 
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A 
 
B 
 
Figure 4.16: Effect of automatic (A) and adjusted premelt (B) values on the 
consistency of HRM profiles for duplicate assay wells for isolates 4 and 9. 
In A: Red circles indicate inconsistent profiles generated in duplicate wells for the same isolate 
before adjustment of the pre-melt normalisation temperature 
 
In B: Black circles indicate consistent profiles generated in duplicate wells for the same isolate 
after adjustment of the pre-melt normalisation temperature 
 
The premelt settings are indicated by blue circles on the melting curves. 
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 Summary of lukS and lukF HRM results 4.3.6
Overall, the 38 PVL-positive isolates could be grouped into one of four genotypes 
(Table 4.7) S1F1, S1F2, S2F1 and S2F2 subsequently represented as A, B, C and D 
respectively. The largest number of isolates (47.3%; 18/38) belonged to the S2F2 (D) 
genotype which from the literature, has been associated predominantly with the ST22, 
ST59 and ST88 lineages (Table 1.4). 
 
Table 4.7: Summary of lukS and lukF HRM results of 40 blinded 
isolates 
S/No Detected lukSF-PV Genotype Blind Identity (No of Isolates) 
1.  S1F1 (A) 1, 21, 22, 24, 25, 26, 31, 34, 35 (9) 
2.  S1F2 (B) 28 (1) 
3.  S2F1 (C) 4, 5, 6, 8, 10, 11, 13, 20, 29, 36 
(10) 
4.  S2F2 (D) 2, 3, 7, 9, 12, 14, 15, 16, 17, 18, 19, 
23, 27, 30, 32, 33, 39, 40 (18) 
 
lukSF-PV Genotype key: S1 = G527/T663; S2 = A527/G663; F1 = A1396/A1729; F2 = 
G1396/A1729; FU = A1396/G1729. 
S1 and S2 represent allelic variations at positions 527 and 663 while F1, F2 and FU 
represent allelic variations at positions 1396 and 1729 of the lukSF-PV locus. 
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 HRM validation of the spa locus 4.3.7
Based on data presented in Figure 4.17, classification of all 38 isolates using spa 
HRM was expected to generate a significant number of types, which could potentially 
make genotyping difficult. Therefore, further analysis of isolates was carried out by 
comparing difference curves within each of the PVL groupings (A, C and D) shown in 
Table 4.7. As group B only contained 1 isolate, this was omitted from this round of 
analysis. 
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Figure 4.17: HRM spa profiles for 20 isolates tested in triplicate. 
The HRM profiles were generated as described in Section 4.2.3. The figure shows the 
close proximity of the HRM profiles generated in triplicates for the 20 test isolates 
which creates an obvious difficulty in data interpretation. Each colour represents a 
different isolate. 
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 HRM spa interpretation for group A isolates 4.3.7.1
For group A (S1F1) isolates (Figure 4.18), interpretation of HRM data to differentiate 
isolates was relatively easy, with difference curves varying either in shape or peak 
maxima and clear subgroupings occurring. 
 
 
Figure 4.18: HRM spa profiles generated for group A (S1F1) isolates  
The HRM profiles were generated as described in Section 4.2.3. The HRM profiles 
show a single subgroup consisting of three isolates (22, 24 and 25) with other isolates 
presenting clearly distinct HRM profiles. 
 
Colour code: Red (21); Green (22); Pink (24); Grey (25); Yellow (26); Brown (31); 
Light blue (34); Blue-Green (35); Blue (1). The blinded isolate numbers are shown in 
brackets 
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 HRM spa interpretation for group C Isolates 4.3.7.2
For the group C isolates, two subgroups (C1 and C2) produced difference curves 
which were similar in shape and peak (indicated in Figure 4.19) which made 
differentiation of the isolates difficult or impossible. As the results were ambiguous, 
implementation of the guidelines described in Section 4.3.2.5 was subsequently 
carried out to enable successful genotyping of these subgroups. 
 
 
Figure 4.19: HRM spa profiles generated for group C (S2F1) isolates. 
The HRM profiles were generated as described in Section 4.2.3. The figure shows 
some clearly distinct HRM profiles. HRM profiles presenting similar shaped 
difference curves which could confound assignment of genotypes are indicated. 
 
Colour code: Blue (1); Red (4); Green (5); Pink (6); Grey (8); Yellow (10); Brown 
(11); Light blue (13); Blue-Green (20); Orange (29); Purple (36). The blinded isolate 
numbers are shown in brackets. 
  
Subgroup C1 
Subgroup C2 
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For subgroup C1 (Figure 4.20), while isolates 5 and 10 were obviously identical with 
nearly overlapping difference curves, isolate 8 also generated a difference curve which 
was similar in shape and peak. Isolate 36 on the other hand, though generating a curve 
similar in peak, differed slightly in shape. 
 
Despite the tendency to call isolates 5, 8 and 10 as same and isolate 36 different, a 
certain degree of uncertainty in the interpretation of these results still existed, hence 
the Section 4.3.2.5 guidelines were applied. Restoring the automatic temperature shift 
function at this point (as shown in Figure 4.21 B), further highlighted the relative 
signal difference, and showed that isolate 36 generated a >4 difference in RSD values 
when compared to the other three members of the cluster. 
 
Furthermore, as isolates of identical genotype are expected to generate a <4 difference 
in RSD values, isolate 5 was then set as the base curve to confirm that isolates 5, 8 and 
10 indeed belong to the same genotype. Without restoring the automatic temperature 
shift function (Figure 4.20 C), isolate 8 (coloured grey) gave a >4 RSD. Following a 
restoration of the automatic temperature shift function (to minimise any temperature 
variation across the plate), this wide difference in RSD was eliminated with all three 
isolates falling within a RSD of 4 (Figure 4.20 D). 
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Figure 4.20: HRM profiles of group C (S2F1) subgroup 1 isolates produced under varying conditions designed to 
clarify the genotype of closely related isolates. 
The HRM profiles were generated as described in Section 4.2.3. Panel A shows the normalised and zero temperature shifted difference curves of 
isolates 5, 8, 10 and 36, showing HRM profiles highly similar in shape and peak. Panel B shows normalised and automatic temperature shifted 
difference curves of isolates 5, 8, 10 and 36 with 36 clearly differentiated with >4 difference in RSD values. Panel C and D show HRM profiles 
using isolate 5 as the base curve to confirm genotype of isolates 5, 8 and 10 as identical. Showing isolate 8 with a >4 difference in RSD values 
with zero temperature shift (Panel C) but <4 with the automatic temperature shift applied (Panel D). 
 
Colour code: Green (5); Yellow (10), Grey (8) and Purple (36). The blinded isolate numbers are shown in brackets. 
A B 
C D 
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A similar interpretation procedure was carried out for the subgroup C2 of group C. 
This consisted of isolates 4, 6 and 13 in which isolates 4 and 6 were obviously the 
same, with isolate 13 being potentially different (Figure 4.21 A). In this case 
however, no further confirmation of relatedness could be made despite restoring the 
automatic temperature shift (Figure 4.21 B) and changing the base curve (Figure 4.21 
D). This was as a result of the highly complex nature of the signal differences 
generated following the changes. Hence isolate 13 was genotyped as different (but 
perhaps closely related to isolates 4 and 6) based on spa HRM analysis. 
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Figure 4.21: HRM profiles of group C (S2F1) subgroup 2 isolates produced under varying conditions designed to 
clarify the genotype of closely related isolates. 
The HRM profiles were generated as described in Section 4.2.3. Panel A shows normalised and zero temperature shifted difference curves of 
isolates 4, 6, and 13 showing profiles highly similar in shape and peak. Panel B shows the null effect on RSD value of restoring automatic 
temperature shift on HRM profile of isolates 4, 6, and 13. Panels C and D show HRM profiles using isolate 4 as the base curve to confirm 
genotype of isolates 4, 6 and 13. The data shows isolate 13 with a >4 difference in RSD value with zero temperature shift (Panel C) which could 
not be resolved due to the amorphous curves generated with the automatic temperature shift applied (Panel D). 
 
Colour code: Red (4); Pink (6) and Blue (13). The blinded isolate numbers are shown in brackets. 
A B 
C D 
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 HRM spa interpretation for group D isolates 4.3.7.3
With the exception of one subgroup, subgroup D3 (Figure 4.22), genotyping of group 
D isolates proved relatively straightforward with clear demarcations occurring 
between profiles generated by the different clusters of isolates (Figure 4.22). 
 
 
Figure 4.22: HRM spa profiles generated for group D (S2F2) isolates. 
The HRM profiles were generated as described in Section 4.2.3. The figure shows 
some clearly distinct HRM profiles. Circled are the HRM profiles for subgroup D3 
which required additional interpretation. 
 
Colour code: Red (2); Green (3); Pink (7); Grey (18); Yellow (12); Brown (40); Light 
blue (14); Blue-Green (9); Orange (17); Purple (32); Green 2 (19); Pink 2 (27); Grey 2 
(32); Yellow 2 (39); Brown 2 (23); Light blue 2 (15); Blue-Green 2 (16); Orange 2 
(30); Purple (36). The blinded isolate numbers are shown in brackets.  
Subgroup D3 
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Further analysis of subgroup D3 HRM profiles (Figure 4.23) provided some 
clarification with respect to their genotyping. An expanded view of the subgroup 
highlighted variations in the HRM profiles with differences in both shape and peak 
maxima apparent. 
 
 
Figure 4.23: HRM spa profiles of group D (S2F2) subgroup 3 only. 
The HRM profiles were generated as described in Section 4.2.3. The figure shows a 
more detailed analysis of HRM profiles of subgroup D3 further highlighting 
differences in shape and peak of the difference curves to enable further genotyping. 
 
Colour code: Green (3); Pink (7); Grey (18); Light blue (14); Green 2 (19); Pink 2 
(27); Light blue 2 (15); Blue-Green 2 (16); Orange 2 (30). The blinded isolate 
numbers are shown in brackets. 
 
While the remaining isolates in subgroup D3 (3, 7, 18, 19 and 27) produced obviously 
varied difference curves (Figure 4.24), the <4 difference in RSD values provided a 
strong indication of identical spa genotypes. Hence, the guidelines prescribed in 
Section 4.3.2.5 were applied. Restoring the automatic temperature shift function of 
the software at this point however, simply resulted in curves which were more 
complex and difficult to interpret (not shown). No further confirmation could 
therefore be carried out, hence the isolates were tentatively classed as same. 
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Figure 4.24: Subgroup D3 (S2F2) isolates showing complex HRM 
difference curves 
The HRM profiles were generated as described in Section 4.2.3. Figure shows 
complex HRM curves which could not be visually assigned to unique groups. 
 
Colour code: Green (3); Pink (7); Grey (18); Green 2 (19); Pink 2 (27); Orange 2 (30). 
The blinded isolate numbers are shown in brackets. 
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 Compilation of HRM results 4.3.8
Taking all of the above into consideration, the spa HRM resulted in 7 different spa 
types identified for PVL group A (S1F1). This was comprised of 1 subgroup of 3 
isolates and 6 singletons. PVL group B (S1F2) was composed of only a single isolate, 
hence 1 spa type. For PVL group C (S2F2), 7 spa types were identified. These were 
comprised of 2 subgroups of 2 and 3 isolates each and 5 singletons. PVL group D 
(S2F2) had 11 spa types. These were comprised of 3 subgroups of 2, 3 and 5 isolates 
respectively and 8 singletons (Table 4.8). Overall, employing HRM analysis as a 
rapid genotyping tool for the 38 PVL-positive isolates resulted in a total of 26 distinct 
genotypes (Table 4.9). The total number of genotypes detected by HRM analysis of 
both lukSF-PV and spa loci in the present study however, differed from the expected 
number of genotypes. Based on known spa types and STs, a total of 23 distinct 
genotypes were expected. These were expected to be contained within four PVL 
groups (S1F1, S2F1, S2F2 and S1FU) comprising 6, 5, 9 and 3 genotypes 
respectively. 
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Table 4.8: Compilation of lukSF-PV and spa HRM results to create 
unique code for each genotype 
lukSF-PV Genotype
*
 spa HRM groupings
**
 Corresponding Blinded Isolate 
identity 
S1F1 (A) A1 
A2-7 (Singletons
***
) 
22/24/25 
1/26/31/34/35/21 
S1F2 (B) B1 28 
S2F1 (C) C1 
C2 
C3-7 (Singletons) 
4/6 
5/8/10 
11/13/20/29/36 
S2F2 (D) D1 
D2 
D3 
D4-11 (Singletons) 
14/15 
12/39/40/ 
3/7/18/19/27 
2/9/16/17/23/30/32/33 
 
*
The lukSF-PV genotype is as detected in the present study and described in Table 4.7 
**
The spa groups summarise the results generated in Section 4.3.7, with subgroups 
within each lukSF-PV genotype numbered. 
***
Singletons indicate groups composed of only a single isolate 
 
lukSF-PV genotype key: S1 = G527/T663; S2 = A527/G663; F1 = A1396/A1729; F2 = 
G1396/A1729; FU = A1396/G1729. 
S1 and S2 represent allelic variations at positions 527 and 663 while F1, F2 and FU 
represent allelic variations at positions 1396 and 1729 of the lukSF-PV locus. 
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Table 4.9: Comparison of experimentally generated HRM genotypes 
with predicted results 
lukSF-PV 
genotype 
Expected
*
 Number of Isolates 
(No of spa types) 
Actual
**
 Number of Isolates 
(No of spa types) 
S1F1  7 (6) 9 (7) 
S1F2  0 (0) 1 (1) 
S2F1  12 (5) 10 (7) 
S2F2  14 (9) 18 (11) 
S1FU  5 (3) 0 (0) 
Total 38 (23) 38 (26) 
*
The expected types are predicted based on previous associations of variations in the 
genes encoding the PVL toxin with specific STs as described in published literature and 
summarised in Table 1.4. 
 
**
The actual predicted types are as generated in the present study 
 
lukSF-PV genotype key: S1 = G527/T663; S2 = A527/G663; F1 = A1396/A1729; F2 = 
G1396/A1729; FU = A1396/G1729. 
S1 and S2 represent allelic variations at positions 527 and 663 while F1, F2 and FU 
represent allelic variations at positions 1396 and 1729 of the lukSF-PV locus. 
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These results indicate that using HRM as a typing tool resulted in 100% typeability of 
the PVL-positive S. aureus isolates. HRM typing yielded a similar number of types 
and distribution within types (26 types in all) when compared with the combination of 
MLST and spa types (23 types in all). Furthermore, comparing the discriminatory 
power of both techniques as previously described (Hunter and Gaston, 1988) using 
Formula 1 revealed a comparable index of discrimination between both typing 
methods i.e. HRM and the MLST/spa typing. The indices of discrimination (D) were 
0.947 and 0.97 for the MLST/spa combination and HRM typing respectively. 
 
     
 
 (   )
∑  (    )
 
   
 
 
Formula 1: Parameters used to ascertain discriminatory power. 
 
(Where D is the index of discrimination, N is the population size; S is number of types 
and n is the distribution of strains within types) 
 
These figures were generated by applying the information from both typing schemes 
to the formula. In both cases the population size (N) was identical (38). 
 
With regards to the MLST/spa combination typing with number of types (s) equal to 
23 and strain distribution (n) varying from 7 to 1 (n1 = 7, n2 = 5, n3 = 3, n4 to n6 = 2 
and n8 to n25 = 1); D could therefore be calculated thus: 
 
1 – [(7 × 6 + 5 × 4 + 3 × 2 + 2 × 1 + 2 × 1 + 2 × 1 + 1 × 0 . . . . . . + 1 × 0)/(38 × 37)] = 
1 – (74/1406) = 0.947. 
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Similarly for the HRM data with s = 26 and n values ranging from 5 to 1 (n1 = 5, n2 to 
n4 = 3, n5 to n6 = 2 and n7 to n26 = 1) the D could therefore be calculated thus 
 
1 – [(5 × 4 + 3 × 2 + 3 × 2 + 3 × 2 + 2 × 1 + 2 × 1 + 1 × 0 . . . . . . + 1 × 0)/(38 × 37)] = 
1 – (42/1406) = 0.970. 
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 Data Correlation 4.3.8.1
With each blind isolate assigned a specific code based on a combination of lukS, lukF, 
and spa HRM data (represented by a letter and a number as described in Table 4.8), a 
further step was taken to validate the ability of HRM to be used as a rapid diagnostic 
tool. This involved matching up the blinded isolates to the original isolate list. Prior to 
this process however, sequencing of both lukS and lukF genes of all 38 PVL-positive 
isolates was carried out. The sequencing was done to confirm the current PVL data 
which had so far been inferred from the sequence type of isolates, based on published 
literature (Table 1.4). The sequences obtained from most isolates correlated with the 
expected data but some exceptions occurred. Of the 38 PVL-positive isolates, 9 
showed allelic variations in the lukSF-PV locus which differed from the expected 
genotype (Table 4.10). 
 
Based on the original and updated information (Table 4.6 and Table 4.10), the final 
step in this process involved predicting the actual isolate identity of each blinded 
isolate based on the experimental data obtained. This information is presented in 
Table 4.11. 
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Table 4.10: Variations from expected PVL genotypes detected via 
sequencing 
S/No ST (expected genotype
*
) Isolate identity Actual lukSF-PV genotype
**
 
1.  ST1 (S1F1) TS25 
TS26 
NRS229 
NRS194 
S2F1 
S1FU 
SIFU 
S2F2 
2.  ST8 (S1FU) NRS158 S2F2 
3.  ST30 (S2F1) TS12 
NRS162 
RSS289 
RSS290 
S2F2 
S1F2 
S2F2 
S2F2 
*
The expected genotypes are based on previous associations of variations in the genes 
encoding the PVL toxin with specific STs as described in literature and summarised in 
Table 1.4. 
 
**
The actual PVL genotype was determined by sequencing of the lukSF-PV locus 
 
lukSF-PV genotype key: S1 = G527/T663; S2 = A527/G663; F1 = A1396/A1729; F2 = 
G1396/A1729; FU = A1396/G1729. 
S1 and S2 represent allelic variations at positions 527 and 663 while F1, F2 and FU 
represent allelic variations at positions 1396 and 1729 of the lukSF-PV locus. 
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Table 4.11: Linking of blinded isolate identity to experimentally determined isolate identities 
lukSF-PV Genotype spa HRM groupings Blind Identity Proposed Isolate Identity
*
 
S1F1 (A) A1 
A2-7 (sgls) 
22/24/25 
1/26/31/34/35/21 
TS27/TS29/TS30 
TS1/TS26/NRS123/NRS192/NRS229/NRS248 
S1F2 (B) B1 28 NRS162 
S2F1 (C) C1 
C2 
C3-7 (sgls) 
4/6 
5/8/10 
11/13/20/29/36 
TS2/TS5 
TS7/TS15/TS16/ 
TS8/TS25/NRS185/NRS255 
S2F2 (D) D1 
D2 
D3 
D4-11 (sgls) 
14/15 
12/39/40/ 
3/7/18/19/27 
2/9/16/17/23/30/32/33 
TS6/TS9 
TS12/RSS289/RSS290 
TS13/TS14/TS18/TS20/TS24 
TS17/TS19/TS21/TS23/TS28/NRS157/NRS158/
NRS194/NRS227 
*
The proposed isolate identity shown in this Table is based on the information provided in Table 4.6 and the lukSF-PV sequencing data in 
Table 4.10. sgls: singletons 
 
lukSF-PV genotype key: S1 = G527/T663; S2 = A527/G663; F1 = A1396/A1729; F2 = G1396/A1729; FU = A1396/G1729. 
S1 and S2 represent allelic variations at positions 527 and 663 while F1, F2 and FU represent allelic variations at positions 1396 and 1729 of 
the lukSF-PV locus. 
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Combining the expected and predicted results at the lukSF-PV locus, the assay appears 
to be 100% sensitive and 81.58% specific. The assay was able to correctly identify all 
38 isolates as PVL-positive. However, the 6 isolates belonging to the S1FU group 
(based on data from Tables 4.7 and 4.11) were misclassified as belonging to group 
S1F1, while a single S2F1 isolate (TS17) was misclassified as S2F2. 
 
While combining the data from the analysis of the spa locus did improve the 
discriminative ability of this HRM based typing method and enabled further 
delineation within groups, the actual positive predictive value of this technique was 
however poor. The predictive value was ascertained by the ability to accurately link a 
blind identity to a known isolate. This low predictive value was highlighted with the 
six spa groups containing 2 or more isolates (Table 4.12). An accurate prediction of 
the actual strain identity of the blinded isolate was possible in only 2 of these 6 groups 
(33.3%). 
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Table 4.12: spa HRM predictive ability 
S/No Blind Identity 
groupings 
Proposed Isolate Identity Actual Isolate Identity 
1.  22/24/25 TS27/29/30 TS27/29/30 
2.  4/6 TS2/TS5 TS15/TS16 
3.  5/8/10 TS7/TS15/TS16 TS2/TS5/TS8 
4.  14/15 TS6/TS9 TS14/TS20 
5.  12/39/40 TS12/RSS289/RSS290 TS12/RSS289/RSS290 
6.  3/7/18/19/27 TS13/TS14/TS18/TS20/TS24 TS13/TS18/TS24 
TS19, NRS157 
 
*
The groupings for blinded isolates were ascertained experimentally from results of 
HRM analysis at both lukSF-PV and spa locus. 
**
The proposed isolate identity indicates the predicted identity of each blinded isolate 
based on results of the HRM analysis 
***
The actual isolate identity indicates the true strain identity of each isolate on the 
blinded list (Appendix 3) 
 
The two groups of isolates whose genotypes were accurately predicted are depicted in 
red. 
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In three of the seven expected spa groups (Table 4.13), all members of the group were 
correctly identified as belonging to the same group. For the TS2/TS5 (t657) group 
though, typing via HRM resulted in an isolate with an unrelated spa type (t345, TS8) 
misidentified as part of this group. A partially correct identification of group members 
belonging to the same spa type was however made in two cases. In the case of the 
TS7/TS15/TS16 group, a single member (TS7) was misidentified as being different. 
Isolates that were mistakenly assigned to the different spa groups belonged to the 
group C clusters whose HRM profiles had initially provided conflicting results that 
required further analysis (Figure 4.21 and Figure 4.22). 
 
These findings highlight the limitations of the use of the spa HRM. While the issue of 
temperature variability across the assay plate did not negatively impact on the 
discriminatory ability of the technique as a whole, the subjectivity introduced into the 
data interpretation due to temperature variation poses a significant problem in the 
predictive accuracy of this technique using the spa locus. 
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Table 4.13: Accuracy of spa HRM groupings compared to known spa 
types 
S/No Known spa groups Correctly grouped as same
*
 
1.  TS27/29/30 YES 
2.  TS12/RSS289/290 YES 
3.  TS2/TS5 YES 
4.  TS7/15/16 PARTIALLY 
5.  TS13/TS14/TS18/TS20/TS24 PARTIALLY 
6.  NRS123/248 NO 
7.  TS6/TS9 NO 
*Response key: ‗YES‘ = All members of the group identified as same; ‗PARTIALLY‘ 
= Some members identified as same and some misidentified as different; ‗NO‘ = All 
members misidentified as different 
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 Effect of mutation position on outcome of HRM analysis 4.3.9
Following the ability of the HRM analysis to differentiate the two lukS genotypes 
possessing two SNPs with potentially identical melt temperatures (a G – A SNP at 
position 527 and a T – G SNP at position 663), the present study went on to further 
explore the contribution of SNP position in differentiating between these potentially 
neutralising nucleotide changes in the lukS locus. 
 
To do this, four custom DNA sequences were synthesized (produced by DNA2.0) 
having an identical base pair composition overall but a G/T to A/G allelic variations at 
varying positions within the sequence (Table 4.14). These were subjected to HRM 
analysis using the original sequence as a control. The gene scanning software was able 
to again place the original A527/G663 allelic variant and the G527/T663 variant into two 
separate genotypes (Figure 4.25), thus affirming the high sensitivity and 
reproducibility of the initial HRM analysis. Interestingly however, all A/G variants 
(which have exactly identical base pair composition) were not classed together, 
suggesting a position dependent effect of allele variation on HRM sensitivity. 
 
The four A/G allelic variants were classed into three different groups by the gene 
scanning software. The lukS variant A was classed as identical with the original lukS 
G527/T663 sequence. While the lukS variant C and the original lukS A527/G663 variant 
were placed in the same genotype, the lukS variant B was grouped entirely on its own. 
A visual inspection of the normalised and automatic temperature shifted difference 
curve of this variant however shows a close relatedness to the lukS variant A group as 
noted by a similar shaped difference curve (Figure 4.25).
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Table 4.14: Single nucleotide polymorphisms in the 4 different test 
lukS sequences in comparison to a parent sequence
*
. 
lukS Variant A 
GTGGTCCATCAACAGGAGGTAATGATTCATTTAATTATTCAAAAACAATTAGTTA
TAATCAACAAAACTATATCAGTGAAGTAGAACGTCAAAATTCAAAAAGTGTTCAA
TGGGGAATAAAAGCTAATTCATTTATCACATCATTAGGTAAAATGTCGGGACATG
ATCCAAATTTATTTGTTGGATATAAACCATATAGTCAAAATCCGAGAGACTATTTT
GTTCCAGACAATGAATTACCCCCATTAGTACACAGTGGTTTCAATCCTTCA 
 
lukS Variant B 
GTGGTCCATCAACAGGAGGTAATGGTTCATTTAATTATTCAAAAACAATTAGTTA
TAATCAACAAAACTATATCAGTGAAGTAGAACGTCAAAATTCAAAAAGTGTTCAA
TGAGGAATAAAAGCTAATTCATTTATCACATCATTAGGTAAAATGTCTGGACATG
ATCCAAATTTATTTGTTGGATATAAACCATATAGTCAAAATCCGAGAGACTATTTT
GTTCCAGACAATGAATTACCCCCATGAGTACACAGTGGTTTCAATCCTTCA 
 
lukS Variant C 
GTGGTCCATCAACAGGAGGTAATGGTTCATTTAATTATTCAAAAACAATTAGTTA
TAATCAACAAAACTATATCAGTGAAGTAGAACGTCAAAATTCAAAAAATGTTCAA
TGGGGAATAAAAGCTAATTCATTTATCACATCATTAGGTAAAATGTCTGGACATG
ATCCAAATTTATTTGTTGGATATAAACCATATAGTCAAAATCCGAGAGACTATTTT
GTTCCAGACAATGAATGACCCCCATTAGTACACAGTGGTTTCAATCCTTCA 
 
Original lukS A527/G663 Variant
**
 
GTGGTCCATCAACAGGAGGTAATGGTTCATTTAATTATTCAAAAACAATTAGTTA
TAATCAACAAAACTATATCAGTGAAGTAGAACATCAAAATTCAAAAAGTGTTCAA
TGGGGAATAAAAGCTAATTCATTTATCACATCATTAGGTAAAATGTCTGGACATG
ATCCAAATTTATTTGTTGGATATAAACCATATAGTCAAAATCCGAGAGACTATTTT
GTGCCAGACAATGAATTACCCCCATTAGTACACAGTGGTTTCAATCCTTCA 
 
Original lukS G527/T663 sequence
*
 
GTGGTCCATCAACAGGAGGTAATGGTTCATTTAATTATTCAAAAACAATTAGTTA
TAATCAACAAAACTATATCAGTGAAGTAGAACGTCAAAATTCAAAAAGTGTTCAA
TGGGGAATAAAAGCTAATTCATTTATCACATCATTAGGTAAAATGTCTGGACATG
ATCCAAATTTATTTGTTGGATATAAACCATATAGTCAAAATCCGAGAGACTATTTT
GTTCCAGACAATGAATTACCCCCATTAGTACACAGTGGTTTCAATCCTTCA 
 
*
Sequence source: Strain NN1, GenBank accession no. AB186917 
**
Sequence source: Strain MW2, GenBank accession no. BA000033 
 
The yellow highlighting indicates the location of the primer binding sites for HRM analysis. 
The SNPA positions in the sequences are highlighted in blue and SNPB in red. 
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Figure 4.25: Normalised and automatic temperature shifted difference 
curves of lukS locus with identical DNA composition but varying SNP 
location  
The HRM profiles were generated as described in Section 4.2.3. Panel A shows the 
automatic classification of samples (each colour represents a unique group), 
maintaining the ability of the technique to differentiate between the original A527/G663 
allele from the G527/T663 allele (arrowed). Panel B shows the samples as originally 
colour coded prior to the automatic classification indicating the sample identities. 
 
Colour code for Panel B: Blue = Original lukS A527/G663 variant; Yellow = lukS Variant 
C; Pink = lukS Variant B; Red = lukS Variant A; Orange = Original lukS G527/T663 
sequence. 
 
No identifiable pattern appears to account for the grouping/genotyping of these five 
sequences, as HRM products with the most similar melt temperatures were not 
necessarily placed in the same group (Table 4.15). 
 
A B 
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Table 4.15: Variable characteristics of the lukS test sequences 
Sequence Types SNPA SNPB Tm (
o
C) 
 Proximal
*
 to 
forward primer 
GC rich
**
 
neighbours 
Proximal to 
Reverse primer 
GC rich 
neighbours 
 
Original lukS G527/T663 sequence NA NA NA NA 75.99 
Original lukS A527/G663 variant No No No No 76.03 
lukS Variant A Yes No No Yes 75.79 
lukS Variant B No Yes Yes No 75.73 
lukS Variant C No No Yes No 75.77 
 
*
Proximal is defined as a mutation occurring within 16 bp of the primer 
**
GC rich neighbours describe mutations of which 3 of the 4 immediate adjacent base pairs are either a G or a C 
NA: Not Applicable 
Mutation A: G to A mutation 
Mutation B: T to G mutation 
Tm (°C): Melt temperature of each sequence following HRM 
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 Discussion 4.4
HRM has been shown to exhibit a remarkably high level of sensitivity when compared 
to traditional melt curve analysis (Wittwer et al., 2003). This is thought to depend in 
part on improved dye chemistry. The saturating dyes used in HRM are neither toxic 
nor inhibitory at high concentrations and are therefore able to bind to saturation. This 
prevents dye relocation during the melting phase, hence leading to improved 
sensitivity (Wittwer et al., 2003, Erali et al., 2008). The present study therefore set out 
to explore the potential of HRM as a rapid diagnostic tool in the characterization of 
PVL-positive S. aureus isolates based on the premise that this technique would be able 
to accurately differentiate between the double mutations contained in the lukS and 
lukF gene fragments. 
 
In the present study, the totally different HRM curves generated for PCR amplicons 
from four standard NARSA isolates, which theoretically possess identical melt 
temperatures (Figure 4.2 A), confirmed the increased discriminatory power of this 
technique compared to that obtained using a traditional melt curve analysis. The HRM 
melt curves of PCR amplicons from the lukF locus however differed significantly 
from those of lukS. The lukF products specifically exhibited a complex melt profile 
composed of two melt domains. This phenomenon has previously been reported in 
amplicons >400 bp in length (Wittwer et al., 2003) and results from the melting of 
AT-rich regions at lower temperatures than the GC-rich regions. 
 
Improved dye chemistry alone is however insufficient to generate the additional 
information provided by the HRM technique, as observed by analysis of the raw HRM 
data (Figure 4.2 A). This data was only able to provide useful information after 
214 
 
further analysis using the Roche Gene Scanning Software Version 1.5.0 (Figure 4.1 
D). Most HRM instruments are designed to work with specific software which 
controls up to three functions – normalisation, temperature shift and difference curve 
generation. The normalisation function which corrects for varying template 
concentration can be described as a shifting on the Y – axis and enables comparison of 
the different melt curves, thereby highlighting subtle differences. The second function 
– temperature shift – corrects for slight temperature variations across the plate (Reja et 
al., Wittwer et al., 2003). Difference curves may then be generated by subtracting the 
normalised and temperature shifted curves from that of a reference ‗base curve‘, a 
process which makes it easier to visualise small variations between amplicons. 
 
Data generated by HRM analysis, was able to accurately distinguish the two allelic 
variants in the lukS locus which potentially balanced each other out 
thermodynamically (G527 – A527, T663 – G663). These results were obtained without any 
modifications to the automatic software settings. This finding is contrary to a previous 
report in which an amplicon with a possibly neutralising double mutation could only 
be detected following changes in instrument settings for normalization, temperature 
shift and sensitivity (Pietzka et al., 2009). Another study involving a C – T, A – C 
double mutation in an 88 bp fragment of the gyrA gene of Bacillus anthracis may 
suggest a possible variable effect of study sequence, as these mutations could not be 
detected using HRM analysis (Loveless et al., 2010). 
 
In the present study however, an extra T – A mutation at nucleotide 470 of lukS 
detected by DNA sequence analysis in three of the ST30 isolates (data not shown) 
could not be detected by HRM. Several factors have been shown to affect both the 
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sensitivity and specificity of HRM. Most notable are the amplicon length, GC content 
and class of mutation i.e. specific base change (Reed and Wittwer, 2004, Liew et al., 
2004, Graham et al., 2005, Palais et al., 2005, Krypuy et al., 2006). T/A mutations 
which belong to the previously described class 4 SNPs, are generally known as one of 
the more difficult SNP classes to detect, with a Tm shift of <0.1°C. While occurrence 
of this SNP has been shown to be readily detected in an amplicon of <50 bp (Liew et 
al., 2004), generally, small variations in Tm are less easily detected with increasing 
amplicon lengths. The relatively large size of the lukS amplicon (272 bp) may 
therefore explain the failure to detect the additional T/A mutation in the ST30 isolates. 
This effect of amplicon length on the sensitivity of HRM in detection of mutations is 
applicable across all SNP classes. Hence, amplicon lengths of less than 300 bp are 
currently recommended to ensure highest sensitivities (Krypuy et al., 2006, Reed and 
Wittwer, 2004). 
 
A further variable which could influence discriminatory power of HRM – mutation 
position within the amplicon – was also investigated using the lukS locus. One 
previous study carried out in 2004 had investigated the effect of mutation position on 
HRM sensitivity (Reed and Wittwer, 2004). However, the approach in this Reed and 
Wittwer study involved altering the mutation position by changing primer binding 
sites to create different amplicons of similar length. This process would however 
invariably create products differing in GC content (however slight) which could 
influence HRM profiles. The present study analysed lukS sequences which were 
identical in length and GC content but differed singly in the mutation position. The 
results showed that the position of the mutation did indeed affect discriminatory 
power of HRM for the lukS locus (Section 4.3.9). While the sequences tested, 
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theoretically have the same basic melt temperatures (Tm), due to their identical base 
composition and hence GC content, based on the nearest neighbour model (von Ahsen 
et al., 1999, Peyret et al., 1999) the Tm might differ. This model theorises that the melt 
behaviour of a DNA amplicon is dependent not just on its length and GC content but 
also on arrangement. The identity and orientation of neighbouring base pairs could 
affect the thermal stability of a given base pair and the nearest neighbour model has 
been found to give a more accurate Tm prediction (SantaLucia, 1998, SantaLucia et 
al., 1996, von Ahsen et al., 1999). 
 
In the present study, preliminary results based on mutations in the lukSF-PV locus 
have established HRM as a potentially useful technique in the rapid identification and 
genotyping of PVL-positive S. aureus isolates. Results however showed that the level 
of discrimination provided using this locus, was limited. Only three genotypes were 
represented within the initial test population as opposed to the six STs defined by 
MLST. As this factor could have a significant negative impact on the value of this 
technique, this study then went further to explore the possibility of increasing the 
discriminatory power by incorporating a second locus into the assay. 
 
The spa gene with its highly variable nature and current successful application in the 
typing of S. aureus isolates seemed a logical choice as the second locus to improve the 
discrimination of this present study. Most published studies though, have only used 
HRM to detect slight variants such as SNPs, with a few studies analysing short 
insertions or deletions in a product of specific length (Ciammaruconi et al., 2009, 
Parant et al., 2009). Applying HRM to the spa locus would however involve the 
differentiation of products of variable lengths, due to the nature of the spa gene. This 
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application of HRM to length polymorphisms has not been widely employed (Parant 
et al., 2009, Chan et al., 2009, Stephens et al., 2008). 
 
One previous study (Stephens et al., 2008) had explored the use of HRM in detecting 
different spa types using the Corbett Rotor-Gene 6000 HRM platform, but no further 
reports of the potential application of this method on other HRM platforms have been 
published. In the present study using HRM analysis at the spa locus on a Roche 
LC480, an initial hurdle was encountered right at the start of data analysis. Although 
temperature shift of the data is often important to eliminate slight temperature 
differences between samples, with respect to the spa gene, the use of this function 
only served to complicate result interpretation. Such a phenomenon was neither 
reported by Stephens et al. (2008) or in a second similar study involving the detection 
of variation in a clustered, regularly interspaced short-palindromic-repeat (CRISPR) 
(Price et al., 2007). CRISPR is structurally similar to the spa gene in that it is 
composed of variable numbers of repeats. Both of these published studies made use of 
the Corbett Rotor-Gene 6000. This differs from the Roche LC480 used in the present 
study in that it lacks the temperature shift function. These variations therefore possibly 
represent differences in the HRM platform. 
 
That the choice of HRM platform in use has an effect on result outcome has been 
previously observed (De Leeneer et al., 2008). As would be expected considering the 
variations in make and design, the various HRM platforms differ in dye chemistry, 
software used, mode of data acquisition, sample vessel (capillaries verse plates) and 
mode of heat distribution. These differences in turn potentially impact on result 
output. This was highlighted by the ability of HRM to distinguish between two highly 
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similar SNPs (c.3113A>G and c.3119G>A) in a 378 bp BRCA1 gene fragment in a 
2009 study (van der Stoep et al., 2009). These findings were in contrast to a 2008 
study in which these two SNPs were classed in the same group (De Leeneer et al., 
2008). These studies simply differed in the HRM platform used. While van der Stoep 
et al. (2009) used a 96-well LightScanner (Idaho Technology), De Leeneer et al. 
(2008) made use of LightCycler 480 (Roche). Furthermore, De Leeneer and 
colleagues comparing the use of two different HRM platforms in screening for BRCA1 
and BRCA2 mutations reported a higher degree of specificity and sensitivity using the 
96-well LightScanner as opposed to the Roche LC480 (De Leeneer et al., 2008). 
 
One of the major factors impacting on scanning sensitivity, specificity and accuracy of 
genotyping, is the degree of temperature uniformity exhibited by these instruments. 
Two previous studies (Herrmann et al., 2006, Herrmann et al., 2007) had set out to 
compare the use of HRM for mutation scanning and genotyping on the six different 
HRM platforms then available (Figure 4.26). These studies noted a wider ‗across 
plate‘ temperature variation in instruments using a heat block system as opposed to air 
based systems.  
219 
 
 
 
Figure 4.26: Illustration of across plate temperature variation 
observed in the different HRM platforms  
Reproduced from: Herrmann et al. (2007). Panel C on the figure shows the dynamic 
melt profile of the different HRM instruments. The study was carried out using 
variants of a 110 bp fragment of the β-globin gene.  
220 
 
 
The Roche LC480 utilized in this present study is a heat block system and might be 
expected to exhibit well to well temperature variation across the plate. This problem 
was clearly highlighted in the present study with the position dependent variation in 
amplification efficiency (Figure 4.8). This phenomenon impacted negatively on 
interpretation of the spa HRM data (Figure 4.9), by assigning identical aliquots 
analysed at varying well positions as different. This finding thereby created a need to 
take account of sample position in interpretation of the spa HRM data, hence limiting 
the use of this technique at the spa locus. 
 
As there was no indication that well to well temperature variation negatively impacted 
on interpretation of the lukSF-PV HRM data, the spa data highlights the importance of 
choosing the appropriate locus for analysis by a particular typing system. The lukSF-
PV locus potentially has only a few variants. In the present study, these could 
therefore be identified using strains of known genotypes as internal standards. In 
contrast, over 12,000 spa types currently exist (http://spa.ridom.de/spatypes.shtml, 
assessed 2
nd
 August 2013), making the use of internal standards unrealistic, creating a 
need for strain to strain comparison and thus enabling the well to well variation to 
have a negative impact on typing outcome. 
 
However, variation across the heating block may not be the only factor responsible for 
the issues raised in spa HRM data interpretation. The study by Price and colleagues 
using the Corbett Rotor-Gene 6000 identified an unexpected finding in relation to the 
dye used in the assay. Surprisingly, better results were obtained using the non-
saturating SYBR green I dye as opposed to the saturating SYTO9 dye. The SYTO9 
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dye resulted in less reproducible results which resulted in several duplicates being 
classed as different (Price et al., 2007). 
 
Overall the results presented in this chapter highlight the potential of HRM as a rapid 
typing alternative to the sequence based techniques currently in use. This potential 
was however limited by the limited discrimination using the lukSF-PV locus and the 
subjectivity needed for the interpretation of data for the spa locus. While HRM 
analysis of both loci characterised in the present study allowed detection of 
differences between various genotypes, overall, the poor predictive ability raises 
queries on its suitability as a typing tool based on the lukSF-PV and spa loci. The 
arising issues, rather than being only a function of the technique itself, appear to be a 
sum of the technique plus the HRM platform in use as well as the reagents. This 
present study therefore provides an indication of the potential value of HRM as a rapid 
diagnostic tool but also warns of possible hurdles in fulfilling this potential and the 
importance of selecting appropriate loci for analysis. 
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Chapter Five 
 
5 Development and Validation of an Enzyme-Linked 
ImmunoSorbent Assay for the detection and quantification of PVL 
and HLA toxins 
 
 Introduction 5.1
Currently, diagnosis of infections caused by PVL-positive strains of S. aureus, as 
documented in guidelines provided by the HPA (HPA, 2008), is based on clinical 
suspicion (recurrent boils, abscesses, necrotising skin and soft tissue infection, 
community-acquired necrotising pneumonia) and an antibiotic profile of 
gentamicin/trimethoprim resistance previously associated locally with the presence of 
lukSF-PV (Boakes et al., 2011b). Actual confirmation that these cases are caused by 
PVL-positive S. aureus however, is usually dependent on toxin gene profiling carried 
out by the HPA Staphylococcus Reference Unit (SRU). These tests are carried out 
daily and expected to be completed within a working day. They however only provide 
information regarding the presence or absence of the encoding genes, rather than the 
level of toxin gene expression. Information on toxin gene expression could act as a 
pointer to potential severity and prognosis of disease, enabling a more informed 
treatment strategy, thereby impacting on patient care. 
 
Presently, laboratory identification of S. aureus involves a range of methods. 
Following culture, isolates may be identified as S. aureus using various phenotypic 
methods such as the production of staphylococcal protein A and heat-stable nuclease. 
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Tube and/or slide coagulase tests then commonly serve as confirmatory tests (Fonsale 
et al., 2004, Brown et al., 2005). In addition, rapid commercial biochemical test 
systems have been developed which detect both clumping factor and staphylococcal 
protein A. Some tests additionally detect S. aureus group specific cell surface antigens 
(bioMerieux Slidex Staph Plus and Murex Diagnostics Ltd Staphaurex Plus) or the  
S. aureus capsular polysaccharide (Sanofi Diagnostics Pastorex Staph-Plus) (van 
Griethuysen et al., 2001, Smole et al., 1998).  
 
More expensive molecular test systems for the identification of S. aureus also exist. 
These have commonly been designed to target species-specific genes, some of which 
include genes encoding the nuclease, coagulase and protein A, as well as femA, femB 
and 16S rRNA (Brown et al., 2005, Brakstad et al., 1992, Martineau et al., 1998, 
Schmitz et al., 1997, Vannuffel et al., 1995, Towner et al., 1998). Following this, 
meticillin resistance may then be detected either by phenotypic assays using 
chromogenic agar media and disc diffusion methods (Andrews, 2009, Perry et al., 
2004), or with rapid molecular identification methods such as the Cephid GenXpert 
(http://www.cepheid.com/systems-and-software/genexpert-system) and BD-GenoOhm 
systems (http://bd.com/geneohm/english/products/idi_mrsa.asp). These methods 
detect the presence of a SCCmec element integrated into the S. aureus genome at the 
3′ end of the orfX gene (Brown et al., 2005, Malhotra-Kumar et al., 2008, Nathwani et 
al., 2008). 
 
Adding a high resolution melt based rapid method (as described in the preceding 
chapter) as an adjunct to this process, may well improve speed of diagnosis of 
infection with PVL-positive S. aureus by allowing rapid detection of the PVL 
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encoding genes. Like other molecular techniques however, this method would be 
limited by a general lack of RT-PCR facilities in diagnostic settings and hence would 
be more suited for use in research or reference laboratories. In addition, this method 
has the same limitation as the PCR technique in that it simply involves detection of 
the encoding genes without providing any information regarding the actual expression 
of the gene. Therefore, a method which both confirms PVL production and gives 
some indication of the amount of toxin produced by different S. aureus isolates could 
potentially be useful not just clinically but also as a research tool. 
 
By 2009, when the present work was initiated, a few studies had already attempted to 
quantify PVL production (Badiou et al., 2008, Hamilton et al., 2007, Tseng et al., 
2009, Oishi et al., 2008). The majority of these studies (3/4), described enzyme-linked 
immunosorbent assays (ELISAs) for PVL detection and quantification using a 
polyclonal antibody specific to either the LukF (Hamilton et al., 2007, Tseng et al., 
2009) or LukS (Badiou et al., 2008) PVL subunits. These ELISA protocols had 
however been designed as a research tool in quantifying PVL toxin production in vitro 
as part of a larger study, rather than for use specifically as a diagnostic tool in a 
clinical setting. 
 
 Enzyme-Linked Immunosorbent Assay (ELISA) 5.1.1
Immunoassays which depend on the immunological reactions between an antigen and 
its specific antibody have been widely applied as a diagnostic tool in the clinical 
microbiology laboratory (Peruski and Peruski, 2003, Atchison et al., 2009, Tuke et al., 
2008, Planche et al., 2008, Diggle and Clarke, 2006, Thorburn et al., 2004, Fry et al., 
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2009, Andre et al., 2008, Trotter et al., 2010, Smith et al., 2009). These tests have 
been used in the diagnosis of infections caused by several bacteria and viruses, 
examples of which include: rotavirus, hepatitis C virus, respiratory syncytial virus, 
Clostridium difficile, Neisseria meningitidis, Streptococcus pneumoniae and 
Bordetella pertussis. The predominant immunoassay system in use is the enzyme-
linked immunosorbent assay (ELISA). 
 
ELISA, which was first reported in the early 1970s (Engvall and Perlmann, 1971, 
Engvall et al., 1971, Engvall and Perlmann, 1972), differs from other immunoassays 
in two key areas. These include the adsorption of one immunological binding 
component to a solid phase support and the presence of an enzyme-labelled 
component. Several variations of the ELISA process exist. The basic principle of this 
technique may however be illustrated using the simplest ELISA protocol, the direct 
ELISA. In direct ELISA (Figure 5.1), the test solution is first incubated with the solid 
phase support to allow antigen binding, followed by washing to remove unbound 
components. This is then followed by the addition of a conjugated enzyme-labelled 
antibody specific for the target antigen, and a second wash to again remove unbound 
components. Binding of the conjugated enzyme-labelled antibody (Ab′) takes place 
only if the test antigen (Ag) is bound to the solid phase, resulting in an Ag-Ab′ 
complex. In the absence of the test Ag, this enzyme-labelled antibody is removed with 
the second wash. The final step in the ELISA protocol is the addition of the enzyme-
substrate. If the assay is positive (i.e. when the test Ag is present), this substrate is 
cleaved to produce a measurable colour change, proportionate to the amount of 
antigen bound to the solid phase support. 
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Figure 5.1: Illustration of the direct ELISA process. 
 
In direct ELISA, the presence of the test antigen bound to the solid phase is detected via specific antigen-specific antibody 
conjugated to an enzyme (Ab′). The enzyme cleaves a specific substrate to produce a detectable coloured reaction. 
Ag ( ); (Ab′)-Enzyme conjugate (       ); Coloured product (    ) 
Ag: Antigen; Ab: Antibody 
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Several different solid phases such as beads (Stiffler-Rosenberg and Fey, 1978), tubes 
and plates (Voller et al., 1976) have been employed in ELISA. While the polystyrene 
tube was the predominant solid phase system used in initial studies (Engvall and 
Perlmann, 1971, Engvall et al., 1971, Engvall and Perlmann, 1972), at present, the 
polystyrene microtitre well plate is the more common solid phase format now in use. 
This format was first reported in 1974 (Voller et al., 1974) and has the advantage of 
being cheap and requiring only small volumes of reagents, hence reducing costs. 
 
At present, there are four main variants of the ELISA technique. These four variants, 
the Direct, Indirect, Sandwich and Competition assays, all vary in complexity. Unlike 
the sandwich ELISA system (Figure 5.2 B) in which a specific primary antibody is 
the component bound to the solid surface, both direct and indirect ELISA first involve 
the binding of antigen in a test sample to the solid phase. The indirect ELISA (Figure 
5.2 A) then further differs from the direct technique, by involving the sequential use of 
two antibodies (one unlabelled ―primary‖ antibody and the second enzyme-labelled). 
The primary antibody recognises the test antigen. The second enzyme-labelled 
antibody specifically detects IgG from the animal species in which the primary 
antibody was produced (for example anti-rabbit IgG). Hence, this provides a greater 
degree of flexibility in the ELISA design. Indirect ELISA is therefore more commonly 
used in diagnosis (Crowther, 2000). Aspects of these three techniques are combined in 
the fourth variant of ELISA – competitive ELISA. This technique is so named because 
it involves competing the specific antigen present in a test sample against a labelled 
reference antigen of known concentration to produce a signal inversely proportional to 
the level of competing antigen present in the test sample (Anon, 1976, Voller et al., 
1976). 
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Figure 5.2: Representations of Indirect (A) and Sandwich (B) ELISA processes 
In indirect ELISA (A), the test antigen (Ag) bound to a solid phase is detected via a primary antibody (Ab) which is further 
detected via a secondary enzyme-labelled Ab (Ab′). The enzyme conjugated to the secondary Ab cleaves a specific substrate to 
produce a detectable coloured reaction. In Sandwich ELISA (B), the test Ag is detected via a primary capture Ab bound to a solid 
phase and a secondary enzyme-labelled detection Ab. This enzyme conjugated to the secondary Ab cleaves a specific substrate to 
produce a detectable coloured reaction. 
 
Ag ( ); Ab (       ); Ab-Enzyme conjugate (        ); Coloured product (    ) 
 
 
A B 
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Aims 
The first aim of this chapter was to develop and validate an ELISA protocol which 
could possibly be applied in diagnosis. At the onset of the present study, no such 
standard system was commercially available for the detection and quantification of the 
PVL toxin in the clinical microbiology laboratory. In addition to this, a second aim in 
setting up this system was to apply it locally as a research tool to quantify toxin 
production in our clinical collection of PVL-positive isolates. A previous study 
(Sloan, 2010) had noted a wide variation in PVL toxin production among this group of 
isolates using Western blot analysis. In addition, it appeared in these initial studies, 
that strains producing high levels of PVL also produced high levels of HLA. 
Therefore the present study also aimed to further explore this observation by the 
development of a second ELISA to detect HLA so that production of both toxins by 
these strains could be quantified and compared. 
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 Materials and Methods 5.2
 Pre-protein expression and purification steps 5.2.1
 Background 5.2.1.1
The first stage in the ELISA development involved production of recombinant LukF 
and S. aureus alpha toxin (HLA) proteins using the widely employed pET expression 
system (Sorensen and Mortensen, 2005) first described in the mid-1980s. This system 
makes use of a powerful T7 promoter carried on the pET vector and not found 
naturally in bacteria. High level expression of target genes from the T7 promoter takes 
place in the presence of the bacteriophage T7 RNA polymerase which is integrated in 
the genome of an E. coli host (Studier and Moffatt, 1986). 
 
pET-21d is an engineered plasmid expression vector which contains a T7/lac hybrid 
promoter. This hybrid contains the molecular switch of the lac operon. Therefore, in 
the absence of an inducer, the T7/lac hybrid promoter is ‗switched off‘ due to the 
presence of the constitutively expressed lactose repressor protein (LacI). This 
repressor protein shares the same binding site as the polymerase, hence binding of 
LacI prevents transcription (Wilson et al., 2007). Therefore for transcription to take 
place, an inducer must be present. Isopropyl-β-D-thiogalactopyranoside (IPTG) is a 
commonly used inducer. This binds the LacI protein, reducing its affinity for the 
operator site and enabling polymerase binding. 
 
The T7 promoter is however not recognised by E. coli RNA polymerase. Therefore, a 
compatible expression host is also needed for transcription to take place. BL21/DE3 is 
231 
 
an engineered E. coli strain lysogenized by a DE3 phage fragment. The DE3 phage 
encodes the T7 RNA polymerase, making E. coli BL21/DE3 a suitable host for 
expression from pET-21d recombinant plasmids. Similar to the T7/lac promoter, these 
genes are under the control of an IPTG inducible lacUV5 promoter. 
 
Other salient features of the pET-21d expression vector include the presence of a gene 
encoding ampicillin resistance (allowing selection for plasmid uptake and 
maintenance in E. coli) and a sequence encoding a hexa-histidine tag (allowing rapid 
purification of tagged protein). Furthermore, E. coli BL21/DE3 lacks genes encoding 
ompT and lon proteases in BL21/DE3 (to ensure the production of intact recombinant 
proteins) (Baneyx, 1999). 
 
 Construction of pET-21d(+)-hlaH35L plasmid expression construct 5.2.1.2
pGEMT containing the hla-H35L gene (kindly provided by Dr Alan Cockayne) was 
first used as the template in a PCR designed to incorporate the NcoI and XhoI 
restriction sites into the gene fragment. Amplification was carried out with a forward 
5′-ATAATCCATGGCAGATTCTGATATTAATATTAAAAC-3′ and reverse 5′-
CGATCTCGAGATTTGTCATTTCTTCTTTTTCCCA-3′ primer pair containing the 
NcoI and XhoI restriction sites (underlined) respectively. The reverse primer was 
designed to allow incorporation of a C′ terminal hexa-histidine tag on the expressed 
protein. 
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The hla-H35L gene used in the present study contains a mutation which causes a loss 
of haemolytic activity, resulting in reduced lethality to mice thereby making it useful 
in antibody generation (Menzies and Kernodle, 1994). 
 
Following PCR amplification, the resulting fragment was A-tailed (2.11.1) and ligated 
(2.11.2) into pGEMT before transformation into E. coli Top10 and selection of 
ampicillin – resistant transformants. A plasmid (designated pKO1) was isolated from 
one transformant and the DNA sequence of the hla-H35L insert confirmed using 
M13F and M13R primers. (M13F: 5′-GTAAAACGACGGCCAGT-3′ and M13R: 5′-
GGAAACAGCTATGACCATG-3′) 
 
Following restriction enzyme digestion of both pKO1 and pET-21d(+) using NcoI and 
XhoI (2.11.3), and gel purification of the vector and insert fragments, the hla-H35L 
gene was ligated into pET-21d(+) (Novagen) (Figure 5.3). Ligation mixtures were 
electroporated into E. coli Top10 and ampicillin – resistant transformants selected. A 
plasmid (designated pKO2) was isolated from one transformant, sequenced and the 
insertion site of the hla-H35L insert confirmed using the T7 promoter primer  
(5′-TAATACGACTCACTATAGGG-3′). 
 
 pET-21d(+)-lukF expression construct 5.2.1.3
A pET-21d(+) construct (pKO3) containing the complete lukF gene (Okolie, 2009) 
was kindly provided by Dr. Charles Okolie. LukF expressed from this construct has a 
C′ terminal hexa-histidine tag. 
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Figure 5.3: Map of the pET-21d(+) plasmid expression vector. 
Relevant features of the pET-21d(+) plasmid (Novagen) include: 1. An inducible T7/lac 
hybrid promoter (circled red). Transcription from this promoter in a compatible host 
takes place in the presence of an inducer (IPTG). The inducer binds the LacI repressor 
protein enabling polymerase binding while the compatible host (e.g. E. coli BL21/DE3) 
carries the genes encoding the polymerase specific for the T7 promoter (T7 RNA 
polymerase). The promoter region also includes the DNA sequence encoding for a C′ 
terminal hexa-histidine tag. 2. Multi-cloning sites (circled blue) that allow the in-frame 
cloning of a gene or gene fragment downstream of the T7/lac promoter. 3. Two labelled 
open reading frames (ORF1 and ORF2). These contain the gene which confers 
ampicillin resistance (circled black – ORF 1) and the lacI gene (circled yellow – ORF 
2) respectively. 
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 Protein expression 5.2.2
The next step in this study was the expression of recombinant LukF and HLA-H35L 
proteins. For protein expression, both pET-21d constructs (pKO2 and pKO3) were 
first transformed separately into E. coli BL21/DE3 cells as described in 2.11.5. 
Transformants (BL21/DE3pKO2 and BL21/DE3pKO3) were subsequently selected 
on LB agar containing 100 µg/ml of ampicillin. 
 
Single transformant colonies of BL21/DE3pKO2 and BL21/DE3pKO3 were 
inoculated into LB broth supplemented with 100 µg/ml ampicillin and grown with 
shaking overnight at 37°C, in a G25 shaker incubator (New Brunswick Scientific Co 
Inc. Edison, New Jersey USA). Overnight cultures were then diluted 1:100 into fresh 
LB broth supplemented with 100 µg/ml ampicillin and grown with shaking at 200 rpm 
at 37°C until an OD600nm of 0.4 was achieved. 
 
Expression of both the HLA-H35L and LukF recombinant proteins was then induced 
by the addition of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and growth 
continued with shaking at 37°C for 2 h. Following this, cells were harvested by 
centrifugation at 9,000 rpm for 10 min at 4°C (Allegra X-22R, Beckman Coulter). 
 
An aliquot of the harvested cells was subsequently analysed in order to confirm the 
presence, relative amount and solubility of the expressed proteins. To do this, cells 
resuspended in PBS were disrupted by sonication on ice (2.12.1), fractionated (2.12.2) 
by centrifuging at 13,000 rpm for 10 min, and the soluble and insoluble fractions run 
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on an 11.5% SDS-PAGE gel and proteins visualised using Coomassie blue stain 
(2.12.4). 
 
 Protein Purification 5.2.3
Following a large scale expression of proteins using 500 ml cultures under optimised 
conditions, the expressed proteins were initially purified using a Novagen His Bind 
Resin
®
 protein purification kit according to the manufacturer‘s instructions. In this 
process, purification depends on the ability of His-tagged proteins to bind nickel ions 
in the resin. Unbound proteins are then removed in a subsequent wash and the 
recombinant His-tagged proteins eluted following displacement in buffer containing a 
high concentration of imidazole. 
 
Purified proteins were subsequently dialysed using a Spectra/Por 1 dialysis tubing  
(6 – 8000 Da MWCO) into PBS to reduce the imidazole concentration, fractionated 
and the final purified protein stored in aliquots at -80°C. 
 
 Protein Quantification 5.2.4
As known concentrations of protein are required for ELISA development, the proteins 
were quantified using the Pierce® BCA protein assay kit according to manufacturer‘s 
instructions. In brief, 0.1 ml of test sample was added to 2 ml of BCA working 
reagent. Protein standards containing known concentrations (0 µg/ml – 2000 µg/ml) of 
bovine serum albumin (BSA) were tested simultaneously for the preparation of a 
standard curve. Following 30 min incubation at 37°C, samples were cooled to room 
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temperature and absorbance readings determined at 562 nm. Protein concentrations of 
unknown samples were then determined from the standard curve. 
 
 Protein Biotinylation 5.2.5
As competitive ELISA depends on the competition between a labelled and unlabelled 
version of the same protein, samples of both the HLA-H35L and LukF antigens used 
in the present study were biotinylated using EZ-Link® NHS-LC-Biotin (Thermo 
Scientific, Surrey UK) as a first step in ELISA development. This process was carried 
out in a glass bijoux according to manufacturer‘s instructions and involved incubating 
25 µl of a freshly prepared 2 mg/ml biotin solution (dissolved in DMF) with 1 mg of 
protein (in PBS) at 4°C for 1 h. Following this, unbound excess biotin was removed 
by overnight dialysis into PBS using a Spectra/Por 1 dialysis tubing (6 – 8000 Da 
MWCO). The biotinylated proteins were stored in aliquots at -20°C. 
 
 ELISA to evaluate protein biotinylation 5.2.5.1
In order to evaluate the extent of protein biotinylation and to establish appropriate 
working concentrations, an ELISA was set up as illustrated in Figure 5.4. Mouse 
monoclonal antibodies specific for either HLA-H35L or LukF used in the assays were 
supplied by Prof. Lyndy Durrant, Oncology Unit, Nottingham City Hospital Campus, 
University of Nottingham. 
 
A 96-well Maxisorp microtiter plate (Nunc, Roskilde, Denmark) was coated overnight 
at 4°C with 50 µl per well of appropriate antibody against each protein (5 µg/ml in 
PBS). Exposed well surfaces were subsequently blocked by the addition of 100 µl of 
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3% w/v BSA in PBS for 1 h on ice. The plates were then washed three times using 
PBS containing 0.1% v/v Tween-20 (PBST). The next step involved the addition to 
triplicate wells of 50 µl of varying concentrations of biotinylated protein (10, 3, 1, 0.3, 
0.1, 0.03, 0 µg/ml) and incubation for 1 h on ice. The plates were then washed three 
times with PBST. 50 µl of 1 µg/ml Pierce® high sensitivity streptavidin-horseradish 
peroxidase (HRP) conjugate in PBS was added to each well and the plates were then 
incubated on ice for 1 h. The plates were then washed six times with PBST before 
addition of 150 µl/well of ready to use 2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid) [ABTS] (Thermo Scientific, Surrey, UK) and incubation for 45 min at 
room temperature. The absorbance of each well was then read at 405 nm on a Gen5 
microplate reader (Biotek, Bedfordshire, UK). 
 
 Competitive ELISA 5.2.6
Subsequent to the successful labelling of the HLA-H35L and LukF proteins, a 
competitive ELISA was set up as previously described (Kurstak, 1985). The protocol 
for this is as described in Section 5.2.5.1, with one additional step (the competition 
step proper). This involved addition of 25 µl of various concentrations of competing 
non-biotinylated test protein, test sample or buffer control to appropriate microtitre 
plate wells and incubation for 1 h on ice prior to the addition of biotinylated protein 
(25 µl) with no wash in between these additions (Figure 5.5). 
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Figure 5.4: Flowchart depicting the two major ELISA protocols used 
in the present study.  
The flowchart shows the sequential addition of the ELISA components separated by an 
incubation and wash step. The competitive ELISA protocol differs from the 
biotinylation testing ELISA protocol by incorporating an extra step involving the 
addition of unlabelled protein, test sample or buffer control without any additional wash 
step (as indicated by X), prior to addition of biotinylated protein. 
 
ABTS: 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
 
Monoclonal Antibody 
Unlabelled Protein or 
Test Sample or buffer 
control 
Biotinylated Protein 
Streptavidin-HRP 
ABTS 
Biotinylation testing Competitive ELISA 
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 Results 5.3
 Confirmation of hla-H35L sequence prior to protein expression 5.3.1
Before cloning of the mutated hla-H35L gene into the pET-21d(+) plasmid expression 
vector, sequencing of the hla-H35L gene in pKO1 and subsequent comparison against 
the S. aureus Newman hla gene (NWMN_1073, Pubmed accession number 
AP009351.1) confirmed the presence of the H35L protein mutation and the successful 
insertion of the restriction sites as indicated below (Figure 5.5). A second C to T SNP 
at nucleotide 453 was however found in the mutant hla gene but this mutation was 
silent, not resulting in a second amino acid change (Figure 5.6). 
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HLA_NWMN  ---------------------------GCAGATTCTGATATTAATATTAAAACCGGTACT 33 
HLA-H35L  GCCATGGCCGCGGGATTATAATCCATGGCAGATTCTGATATTAATATTAAAACCGGTACT 60 
                                     ********************************* 
 
HLA_NWMN  ACAGATATTGGAAGCAATACTACAGTAAAAACAGGTGATTTAGTCACTTATGATAAAGAA 93 
HLA-H35L  ACAGATATTGGAAGCAATACTACAGTAAAAACAGGTGATTTAGTCACTTATGATAAAGAA 120 
          ************************************************************ 
 
HLA_NWMN  AATGGCATGCACAAAAAAGTATTTTATAGTTTTATCGATGATAAAAATCATAATAAAAAA 153 
HLA-H35L  AATGGCATGCTAAAAAAAGTATTTTATAGTTTTATCGATGATAAAAATCATAATAAAAAA 180 
          **********  ************************************************ 
 
HLA_NWMN  CTGCTAGTTATTAGAACGAAAGGTACCATTGCTGGTCAATATAGAGTTTATAGCGAAGAA 213 
HLA-H35L  CTGCTAGTTATTAGAACGAAAGGTACCATTGCTGGTCAATATAGAGTTTATAGCGAAGAA 240 
          ************************************************************ 
 
HLA_NWMN  GGTGCTAACAAAAGTGGTTTAGCCTGGCCTTCAGCCTTTAAGGTACAGTTGCAACTACCT 273 
HLA-H35L  GGTGCTAACAAAAGTGGTTTAGCCTGGCCTTCAGCCTTTAAGGTACAGTTGCAACTACCT 300 
          ************************************************************ 
 
HLA_NWMN  GATAATGAAGTAGCTCAAATATCTGATTACTATCCAAGAAATTCGATTGATACAAAAGAG 333 
HLA-H35L  GATAATGAAGTAGCTCAAATATCTGATTACTATCCAAGAAATTCGATTGATACAAAAGAG 360 
          ************************************************************ 
 
HLA_NWMN  TATATGAGTACTTTAACTTATGGATTCAACGGTAATGTTACTGGTGATGATACAGGAAAA 393 
HLA-H35L  TATATGAGTACTTTAACTTATGGATTCAACGGTAATGTTACTGGTGATGATACAGGAAAA 420 
          ************************************************************ 
 
HLA_NWMN  ATTGGCGGCCTTATTGGTGCAAATGTTTCGATTGGTCATACACTGAAATATGTTCAACCT 453 
HLA-H35L  ATTGGTGGCCTTATTGGTGCAAATGTTTCGATTGGTCATACACTGAAATATGTTCAACCT 480 
          ***** ****************************************************** 
 
HLA_NWMN  GATTTCAAAACAATTTTAGAGAGCCCAACTGATAAAAAAGTAGGCTGGAAAGTGATATTT 513 
HLA-H35L  GATTTCAAAACAATTTTAGAGAGCCCAACTGATAAAAAAGTAGGCTGGAAAGTGATATTT 540 
          ************************************************************ 
 
HLA_NWMN  AACAATATGGTGAATCAAAATTGGGGACCATATGATAGAGATTCTTGGAACCCGGTATAT 573 
HLA-H35L  AACAATATGGTGAATCAAAATTGGGGACCATATGATAGAGATTCTTGGAACCCGGTATAT 600 
          ************************************************************ 
 
HLA_NWMN  GGCAATCAACTTTTCATGAAAACTAGAAATGGCTCTATGAAAGCAGCAGATAACTTCCTT 633 
HLA-H35L  GGCAATCAACTTTTCATGAAAACTAGAAATGGCTCTATGAAAGCAGCAGATAACTTCCTT 660 
          ************************************************************ 
 
HLA_NWMN  GATCCTAACAAAGCAAGTTCTCTATTATCTTCAGGGTTTTCACCAGACTTCGCTACAGTT 693 
HLA-H35L  GATCCTAACAAAGCAAGTTCTCTATTATCTTCAGGGTTTTCACCAGACTTCGCTACAGTT 720 
          ************************************************************ 
 
HLA_NWMN  ATTACTATGGATAGAAAAGCATCCAAACAACAAACAAATATAGATGTAATATACGAACGA 753 
HLA-H35L  ATTACTATGGATAGAAAAGCATCCAAACAACAAACAAATATAGATGTAATATACGAACGA 780 
          ************************************************************ 
 
HLA_NWMN  GTTCGTGATGACTACCAATTGCACTGGACTTCAACAAATTGGAAAGGTACCAATACTAAA 813 
HLA-H35L  GTTCGTGATGACTACCAATTGCACTGGACTTCAACAAATTGGAAAGGTACCAATACTAAA 840 
          ************************************************************ 
 
HLA_NWMN  GATAAATGGATAGATCGTTCTTCAGAAAGATATAAAATCGATTGGGAAAAAGAAGAAATG 873 
HLA-H35L  GATAAATGGATAGATCGTTCTTCAGAAAGATATAAAATCGATTGGGAAAAAGAAGAAATG 900 
          ************************************************************ 
 
HLA_NWMN  ACAAAT------------------------------------------------------ 879 
HLA-H35L  ACAAATCTCGAGATCGAATCACTAGTGCGGCCGCCTGCAGGTCGACCATATGGGAGAGCT 960 
          ******                                                       
Figure 5.5: DNA sequence alignment of hla-H35L in pKO1 and the S. aureus 
Newman hla  
The DNA sequence alignment shows the position of the H35L mutation (highlighted in red) and a 
second silent SNP (highlighted in blue). The NcoI and XhoI restriction sites are highlighted in yellow 
 
NcoI site 
XhoI site 
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HLA-H35L        ADSDINIKTGTTDIGSNTTVKTGDLVTYDKENGMETLKKVFYSFIDDKNHNKKLLVIRTK 60 
HLA_NWMN        ADSDINIKTGTTDIGSNTTVKTGDLVTYDKENGMETHKKVFYSFIDDKNHNKKLLVIRTK 60 
                ************************************ *********************** 
 
HLA-H35L        GTIAGQYRVYSEEGANKSGLAWPSAFKVQLQLPDNEVAQISDYYPRNSIDTKEYMETSTL 120 
HLA_NWMN        GTIAGQYRVYSEEGANKSGLAWPSAFKVQLQLPDNEVAQISDYYPRNSIDTKEYMETSTL 120 
                ************************************************************ 
 
HLA-H35L        TYGFNGNVTGDDTGKIGGLIGANVSIGHTLKYVQPDFKTILESPTDKKVGWKVIFNNMET 180 
HLA_NWMN        TYGFNGNVTGDDTGKIGGLIGANVSIGHTLKYVQPDFKTILESPTDKKVGWKVIFNNMET 180 
                ************************************************************ 
 
HLA-H35L        VNQNWGPYDRDSWNPVYGNQLFMETKTRNGSMETKAADNFLDPNKASSLLSSGFSPDFAT 240 
HLA_NWMN        VNQNWGPYDRDSWNPVYGNQLFMETKTRNGSMETKAADNFLDPNKASSLLSSGFSPDFAT 240 
                ************************************************************ 
 
HLA-H35L        VITMETDRKASKQQTNIDVIYERVRDDYQLHWTSTNWKGTNTKDKWIDRSSERYKIDWEK 300 
HLA_NWMN        VITMETDRKASKQQTNIDVIYERVRDDYQLHWTSTNWKGTNTKDKWIDRSSERYKIDWEK 300 
                ************************************************************ 
 
HLA-H35L        EEMETTN 307 
HLA_NWMN        EEMETTN 307 
                ******* 
Figure 5.6: Protein sequence alignment of the HLA_NWMN and  
HLA-H35L protein sequences. 
The protein sequence alignment shows the predicted single amino acid difference (highlighted 
in red) between the HLA-H35L protein sequence obtained from the gene sequence described 
in Figure 5.5 and the S. aureus Newman hla gene (NWMN_1073, Pubmed accession number 
AP009351.1). Both proteins are ≈33.2 kDa 
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 Pilot studies to confirm HLA-H35L and LukF protein expression 5.3.2
SDS-PAGE analysis was used to confirm the expression of the ≈33.2 kDa 
recombinant HLA-H35L protein containing a C-terminal hexa-histidine tag in 
BL21/DE3pKO2 following a 2 h induction with 1 mM IPTG (Figure 5.7, Lane 2). 
Analysis of cell fractions prepared as described in Section 2.12.4 showed that despite 
the presence of some HLA-H35L in the insoluble fraction (Lane 4), the amount of 
protein in the soluble, cytoplasmic fraction (Lane 3) was considered sufficient to 
attempt purification using Ni affinity chromatography. 
 
For the ≈34 kDa recombinant LukF protein on the other hand, although protein 
expression at 37°C was quite efficient (Figure 5.8, Lane 1), most of the protein was 
insoluble (Lane 3). In this case, it was therefore necessary to optimise the protein 
expression process for soluble protein production. Growth temperature has previously 
been reported to affect protein solubility (Klein and Dhurjati, 1995). Expression of the 
recombinant LukF protein was therefore carried out at both 30°C and 37°C to 
ascertain if this improved the production of soluble forms of the protein. This process 
showed that while the yield of protein following induction at 30°C (Lane 5) was 
slightly less than the total amount of protein produced at 37°C, induction at 30°C 
resulted in more LukF protein present in the soluble fraction (Lane 6) as opposed to 
the insoluble fraction. Consequently induction at 30°C was used for all further 
expression experiments with LukF. 
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Figure 5.7: SDS-PAGE analysis of recombinant HLA-H35L protein 
expression at 37°C in E. coli BL21/DE3pKO2. 
The expression of recombinant HLA-H35L from E. coli BL21/DE3pKO2 cells 
following induction with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 37°C 
was carried out as described in Section 5.2.2. The separation and visualisation of the 
protein fractions were carried out as described in Section 2.12. 
 
Lane A: Protein molecular weight standards; Lane 1: Total proteins of uninduced E. 
coli BL21/DE3pKO2 cells; Lane 2: Total proteins of IPTG induced BL21/DE3pKO2 
cells; Lane 3: Soluble fraction of IPTG induced BL21/DE3pKO2 cells; Lane 4: 
Insoluble fraction of IPTG induced BL21/DE3pKO2 cells. 
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Figure 5.8: SDS-PAGE analysis of recombinant LukF protein 
expression at 30°C or 37°C in E. coli BL21/DE3pKO3. 
The expression of recombinant LukF protein from E. coli BL21/DE3pKO3 cells 
following induction with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was 
carried out at both 30°C and 37°C as described in Section 5.2.2. The separation and 
visualisation of the protein fractions were carried out as described in Section 2.12. 
 
Lane A: Protein molecular weight standards; Lane 1: Total proteins of IPTG induced 
BL21/DE3pKO3 cells grown at 37°C; Lane 2: Soluble fraction of IPTG induced 
BL21/DE3pKO3 cells grown at 37°C; Lane 3: Insoluble fraction of IPTG induced 
BL21/DE3pKO3 cells grown at 37°C; Lane 4: Total proteins of uninduced 
BL21/DE3pKO3 cells; Lane 5: Total proteins of IPTG induced BL21/DE3pKO3 cells 
grown at 30°C; Lane 6: Soluble fraction of IPTG induced BL21/DE3pKO3 cells 
grown at 30°C; Lane 7: Insoluble fraction of IPTG induced BL21/DE3pKO3 cells 
grown at 30°C. 
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 Affinity Protein Purification 5.3.3
Purification using the Novagen His Bind Resin
®
 kit, from soluble fractions prepared 
from 500 ml IPTG-induced cultures was more successful for the LukF protein than the 
HLA-H35L protein (Figure 5.9). For both of these proteins monitoring of the 
purification process using SDS-PAGE revealed efficient selective binding of the His 
tagged protein. This was indicated by the absence of an appropriate sized protein in 
the column run through compared to the starting sample (Figure 5.9; Lanes 1 and 2). 
Neither protein was eluted from the column in the wash buffer (Lane 3). 
 
However, following protein elution by displacement with 25 mM imidazole, while the 
process for the LukF protein produced a high yield (1800 µg/ml) with a low level of 
contaminating protein, the level of contaminating protein after the HLA-H35L 
purification process was deemed unacceptable (Lanes 4 – 9). This suggested that 
further modification of the purification process was required for the HLA-H35L 
protein. 
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Figure 5.9: SDS-PAGE analysis of recombinant LukF (top panel) and 
HLA-H35L (bottom panel) expressed in E. coli BL21/DE3 and purified 
using the Novagen His Bind Resin. 
The expression of both recombinant HLA-H35L and LukF proteins from E. coli 
BL21/DE3 cells following induction with 1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG) was carried out as described in Section 5.2.2 and expressed recombinant 
proteins purified using the Novagen His Bind Resin as described in Section 5.2.3. The 
separation and visualisation of the protein fractions were carried out as described in 
Section 2.12. 
 
Lane A: Protein molecular weight standards; Lane 1: Resuspended IPTG induced cell 
pellets (Starting Material); Lane 2: Initial binding buffer run through (purification flow 
through following initial binding); Lane 3: Wash buffer run through; Lanes 4 – 9: 
Sequential fractions collected during protein elution. 
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 Modification of HLA-H35L purification procedure 5.3.4
As protein elution using the Novagen His Bind Resin
®
 protein purification kit proved 
rather unsatisfactory for the HLA-H35L protein due to the presence of many 
contaminating proteins (Figure 5.9), a different purification system was explored. The 
HLA-H35L protein was therefore purified using His Trap affinity columns on the 
BioRad
®
 Biologic LP affinity chromatographic system. To achieve this, after 
induction with IPTG, BL21/DE3pKO2 cell pellets were resuspended in NiC buffer  
(20 mM imidazole, 50 mM NaCl, 10% v/v glycerol), lysed by sonication (2.12.1), and 
cell debris removed by both centrifugation at 13,000 rpm for 30 min at 4°C and 
filtration using a 0.2 µm filter (Sartorius Biotech, Germany). The resulting cell-free 
supernatant was then applied to the column charged with 50 mM NiSO4 at a flow rate 
of 1 ml/min. After washing the column with buffer A (50 mM NaCl in PBS) to 
remove unbound proteins, the His-Tagged protein was eluted from the column using a 
linear gradient of imidazole (50  400 mM) in buffer A and the eluted fractions were 
collected and examined using SDS-PAGE. 
 
This approach resulted in a more efficient purification of the HLA-H35L protein 
(Figure 5.10, Lanes 9 – 17), with protein elution occurring over a wide range of 
imidazole concentrations and resulting in a relatively pure product. 
 
Dialysis of the pooled protein fractions (10 – 17) against PBS overnight to remove 
imidazole resulted in precipitation of approximately 55% of the HLA-H35L protein 
leaving about 45% of protein in solution (Figure 5.11, Lane 3). This protein had an 
apparent molecular mass in agreement with the expected value of approximately  
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33.2 kDa. The lack of haemolytic activity of the soluble purified mutated HLA-H35L 
protein was confirmed by assessing haemolysis on horse blood agar with an equal 
concentration of purified S. aureus alpha toxin (Sigma-Aldrich, Dorset UK) as a 
positive control (Appendix 4). The purified, soluble protein (190 µg/ml) was stored in 
aliquots at -80°C.  
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Figure 5.10: SDS-PAGE analysis of recombinant HLA-H35L expressed in E. coli 
BL21/DE3 and purified using the BioRad
®
 Biologic LP affinity chromatographic system 
The expression of recombinant HLA-H35L protein from E. coli BL21/DE3pKO2 cells following induction 
with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was carried out as described in Section 5.2.2 and 
expressed recombinant proteins purified using the BioRad
®
 Biologic LP affinity chromatographic system as 
described in Section 5.3.4. The separation and visualisation of the protein fractions were carried out as 
described in Section 2.12. 
 
Lane A: Protein molecular weight standards; Lane 1: Soluble fraction of IPTG induced BL21/DE3pKO2 cell 
pellet resuspended and lysed in NiC buffer (Starting Material); Lane 2: Initial binding buffer run through; 
Lanes 3 – 17: Sequential fractions collected during protein elution. 
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Figure 5.11: SDS-PAGE analysis of purified and dialysed recombinant 
HLA-H35L. 
The expression of recombinant HLA-H35L protein from E. coli BL21/DE3 cells 
following induction with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was 
carried out as described in Section 5.2.2 and expressed recombinant proteins purified 
using the BioRad
®
 Biologic LP affinity chromatographic system as described in 
Section 5.3.4. The separation and visualisation of the protein fractions were carried out 
as described in Section 2.12. The dialysis of the purified protein was carried out as 
described in Section 5.2.3. 
 
Lane A: Protein molecular weight standards; Lane 1: Pooled, eluted purified  
HLA-H35L recombinant protein prior to dialysis; Lane 2: Soluble fraction of  
HLA-H35L recombinant protein after dialysis against PBS; Lane 3: Insoluble fraction 
of HLA-H35L recombinant protein after dialysis against PBS. 
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 Use of purified recombinant LukF and HLA-H35L proteins in competitive 5.3.5
ELISA development 
 Protein Biotinylation 5.3.5.1
Protein biotinylation is a necessary step in the development of a competitive ELISA. 
An assessment of the biotinylation process (Section 5.2.5) which was carried out as 
described in Section 5.2.5.1 indicated a successful biotinylation of both purified 
recombinant LukF and HLA-H35L proteins (Figure 5.12). In this process, addition of 
50 µl of increasing amounts of biotinylated proteins (10, 3, 1, 0.3, 0.1, 0.03, 0 µg/ml) 
to the microtitre wells coated with the relevant monoclonal antibodies, resulted in 
concurrent increase in OD readings (Figure 5.12) following addition of streptavidin-
HRP conjugate and the HRP substrate, ABTS. 
 
Results of the biotinylated HLA-H35L protein assay however, appeared to indicate a 
less efficient biotinylation process (Figure 5.12 A). Results of the biotinylated LukF 
assay generated OD405nm values ranging from 0.62 to 2.98 and resulting in a maximum 
4.8 fold difference between lowest and highest concentrations tested. In contrast, the 
HLA-H35L assay resulted in values which ranged only from 0.46 to 0.83 (maximum 
fold difference of 1.8). In addition, use of the higher concentrations of biotinylated 
HLA-H35L (10 µg/ml and 3 µg/ml) appeared to have a saturation/inhibition effect. 
These resulted in slightly lower OD405nm values (0.803 and 0.763 respectively) than 
those obtained with addition of 1 µg/ml protein (0.828) (Figure 5.12 A). 
 
Due to the less efficient biotinylation achieved using the HLA-H35L protein, a second 
biotinylation was carried out on both LukF and HLA-H35L in an attempt to improve 
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efficiency and to investigate reproducibility of the reaction. This was done using the 
same process as described in Section 5.2.5 but using 75 µl of 4 mg/ml EZ-Link® 
NHS-LC-Biotin per 1 mg of protein. When used in ELISAs, proteins from the second 
biotinylation provided a higher level of discrimination resulting in OD values ranging 
from 0.62 to 2.98 and 0.07 to 1.35 with concurrent maximum fold differences of 4.81 
and 19.29, for the HLA-H35L (Figure 5.12 C) and LukF proteins (Figure 5.12 D) 
respectively. 
 
Based on these results for both assays, a working concentration of 3 µg/ml 
biotinylated protein was subsequently selected for use in further competition assays. 
This concentration generated fold differences of 4.1 and 7.4 for OD values in the 
presence and absence of HLA-H35L and LukF proteins respectively. These 
differences were considered to be sufficient to be able to assess competitive inhibition 
using test samples. 
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Figure 5.12: Determination of the biotinylation efficiency of the recombinant HLA-H35L and LukF proteins 
obtained in two separate biotinylation reactions. 
The ELISA protocol used to assess the efficiency of the biotinylation process was carried out as described Section 5.2.5.1. The 1
st
 biotinylation 
reactions (A and B) were carried out using 25 µl 2 mg/ml of EZ-Link® NHS-LC-Biotin. The 2
nd
 biotinylation reactions (C and D) were carried 
out using 75 µl 4 mg/ml of EZ-Link® NHS-LC-Biotin. The optical density readings reflect the colour change produced from the breakdown of 
ABTS bound to streptavidin-HRP conjugate which allows the detection and quantification of biotinylated protein present in the assay. 
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 Competitive ELISA exploring competitive ability of biotinylated proteins 5.3.6
Following the assessment of protein biotinylation, an initial competitive ELISA was 
carried out using known concentrations of unlabelled HLA-H35L and LukF in PBS as 
described in Section 5.2.6.1. These initial ELISA tests were designed to explore the 
ability of unlabelled protein to inhibit binding of biotinylated protein using standard 
protein concentrations of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003 and 0 µg/ml. 
Both batches of biotinylated HLA-H35L and LukF (Section 5.3.5.1), were used in 
these assays which clearly demonstrated the competitive abilities of the unlabelled 
proteins. However, comparing results using both sets of biotinylated proteins 
highlighted the effect of poor biotinylation on experimental outcomes. Batch 1 
biotinylated proteins (Figure 5.13 A and B) provided a low level of discrimination 
between the lowest and highest concentrations of non-biotinylated protein tested. This 
was as indicated by maximum OD differences of 0.33 and 0.55 for HLA-H35L and 
LukF respectively as opposed to the 11.1 and 4.5 fold OD differences noted with the 
batch 2 biotinylated proteins (Figure 5.13 C and D). 
 
The degree of competition shown in Figure 5.13 C and D, was also expressed 
quantitatively as percentage inhibition (Figure 5.13 E and F) calculated using the 
formula [1 — (B/B0)] × 100. 
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Quantitative representation of level of competition 
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Figure 5.13: Pilot competitive ELISA results comparing the ability of two batches of 
biotinylated HLA-H35L and LukF to inhibit binding of unlabelled proteins. 
The competitive ELISA protocol used to explore the ability of unlabelled protein to inhibit binding 
of biotinylated protein was carried out as described in Section 5.2.6. The charts show variations in 
OD readings obtained after addition of varying concentrations of unlabelled proteins to assay wells, 
in the presence of a fixed amount of biotinylated HLA-H35L or LukF 
 
Panels A and B show the results from competitive assays using batch 1 HLA-H35L and LukF 
proteins respectively. 
Panels C and D show the results from competitive assays using batch 2 HLA-H35L and LukF 
proteins respectively. 
Panels E and F show results from C and D respectively, expressed as percent (%) inhibition by the 
different concentrations of competing protein relative to uncompeted control. 
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 Pilot studies using spiked culture media in competitive ELISA 5.3.7
Three culture media (BHI, LB and CYGP) were spiked with known concentrations of 
unlabelled LukF or HLA-H35L and used in the competition ELISA. Lower OD values 
were observed in the presence of BHI and LB culture media spiked with protein as 
opposed to assays using culture media alone (Figure 5.14 A and B) clearly indicating 
inhibition of biotinylated protein binding. 
 
The data generated using CYGP medium however, identified a potential problem with 
the interpretation of the ELISA results. CYGP is the medium of choice for S. aureus 
protein studies (Novick, 1991). For the HLA-H35L assay, addition of CYGP medium 
alone competed with binding of the biotinylated protein (Figure 5.14 A). In the case 
of the LukF assay, the CYGP medium alone did not appear to cause interference. 
Addition of unlabelled LukF however failed to result in any inhibition (Figure 5.14 
B). Rather, higher OD values of 1.73 and 1.59 were obtained with 1 µg/ml and  
10 µg/ml of LukF protein added respectively as opposed to an OD value of 1.36 
obtained with addition of CYGP alone. 
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Figure 5.14: Results of competitive ELISA using various culture media (BHI, LB and CYGP) spiked with HLA-
H35L or LukF 
Charts show OD values generated following a competitive ELISA carried out as described in Section 5.2.7 using three different culture media 
(BHI, LB and CYGP) spiked with the indicated protein concentrations.  
 
HLA-H35L or LukF diluted in PBS or PBS alone served as the controls 
 
LB: Luria Bertani broth; BHI: Brain heart infusion broth; CYGP: Casamino acids-yeast extract-glycerophosphate broth; PBS: Phosphate 
buffered saline. 
0
0.5
1
1.5
2
2.5
3
O
D
4
0
5
n
m
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
O
D
4
0
5
n
m
 
258 
 
Based on analysis of the components of the various media, this phenomenon was 
suspected to be due to the β-glycerophosphate component of the CYGP medium. 
Therefore, a competitive ELISA was carried out to explore this using dilutions of 
CYGP (1:10 and 1:100 in PBS), with and without the β-glycerophosphate 
component. All dilutions were spiked with identical amounts of unlabelled 
protein (10 µg/ml). Data shown in Figure 5.15 A and B show that removal of the 
β-glycerophosphate component or dilution of the CYGP broth in PBS prior 
addition of unlabelled protein and use in the ELISA, resulted in clear inhibition of 
binding of the biotinylated proteins. 
 
For the HLA-H35L competitive ELISA, in contrast to an OD value of 0.36 
obtained following addition of CYGP medium alone (i.e. without protein), 
addition of CYGP minus β-glycerophosphate (CYGP-) alone (i.e. without 
protein), resulted in an OD value of 1.88. This was similar to the OD value of 
1.82 obtained with addition of the PBS control. In addition, diluting the complete 
CYGP medium in PBS prior to spiking with 10 µg/ml of protein produced 
identical optical density readings of 0.23 and 0.23 for the 1:10 and 1:100 dilutions 
respectively as opposed to an optical density of 0.57 obtained when undiluted 
CYGP was spiked with the same amount of protein. 
 
For the LukF competitive ELISA, addition of CYGP medium alone (i.e. without 
protein) also showed some inhibition of biotinylated protein binding resulting in 
an OD value of 1.02 which was lower than obtained with the PBS control (1.36). 
Unexpectedly however, no additional competition was observed on addition of 
unlabelled protein. Addition of CYGP containing 10 µg/ml of LukF actually 
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resulted in an increased OD value of 1.68. These anomalies were resolved by 
either leaving the β-glycerophosphate component out of the medium or by 
dilution of the CYGP broth (Figure 5.15 B). These assays gave OD values 
similar to those obtained using the PBS control spiked with 10 µg/ml of the 
protein. 
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Figure 5.15: Effects of β-glycerophosphate and CYGP dilution on competitive ELISA results. 
Charts comparing OD values generated following competitive ELISA carried out as described in Section 5.2.6 using various dilutions of CYGP 
with and without β-glycerophosphate, spiked with 10 µg/ml HLA-H35L or LukF. 
 
HLA-H35L or LukF diluted in PBS or PBS alone served as the controls 
 
CYGP: Casamino acids-yeast extract-glycerophosphate broth; PBS: Phosphate buffered saline. 
CYGP-: CYGP broth without β-glycerophosphate. 
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To determine if other S. aureus proteins present in culture supernatants could interfere 
with the performance of the LukF competitive ELISA, supernatants from three known 
PVL-negative isolates (TS3, TS4, TS10) were tested in the assay. Three dilutions of 
filter sterilised supernatants of overnight CYGP broth cultures (1:2, 1:5 and 1:10 in 
PBS) were tested. In comparison with the positive and negative controls, the data 
presented in Figure 5.16 confirm that other proteins present in these culture 
supernatants did not interfere with the performance of the LukF assay. All three 
dilutions of the PVL-negative test isolates resulted in OD values ranging from 1.15 – 
1.24. These values were similar to the OD value of 1.35 obtained in the no competitor 
control. 
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Figure 5.16: Specificity testing of LukF ELISA using CYGP culture 
supernatants of PVL-negative S. aureus isolates 
 
Charts show OD values generated following competitive ELISA carried out as described in 
Section 5.2.6 using CYGP culture supernatants of PVL-negative S. aureus isolates. 
 
PBS alone or PBS containing the indicated LukF concentrations served as the controls. 
 
Test isolates represent a random selection of PCR confirmed PVL-negative isolates in our 
collection of strains obtained from the NUH trust between 2008 and 2009 
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 Validation of ELISA 5.3.8
 Generation of Standard Inhibition Curves for protein quantification using 5.3.8.1
the competitive ELISAs 
In order to obtain quantitative data of concentrations of HLA or LukF in culture 
supernatants using the competitive ELISAs, it was first necessary to generate standard 
inhibition/competition curves using recombinant HLA-H35L or LukF. The non-linear 
competition curves (Figure 5.17) were obtained by creating a plot of normalised 
signal (B/B0) against standard protein concentration using the GraphPad Prism 5.04 
software. B values represent the mean absorbance in the presence of test protein while 
B0 is the mean absorbance of control biotinylated protein only wells (i.e. wells with no 
competing protein). Competition curve data was obtained from four independent 
experiments carried out in triplicate. OD values were obtained from competitive 
ELISAs as described in Section 5.2.6, using known concentrations (100, 30, 10, 3, 1, 
0.3, 0.1, 0.03, 0.01, 0.003, 0 µg/ml) of either recombinant HLA-H35L or LukF 
proteins. 
 
The HLA-H35L and LukF standard inhibition curves produced different dynamic 
ranges. LukF had a range of 0.04 – 0.54 µg/ml while HLA-H35L had a range of 0.01 
– 0.14 µg/ml. The limit of detection (LOD) was 0.007 µg/ml and 0.004 µg/ml for the 
LukF and HLA-H35L assays, respectively. Dynamic range which was calculated 
using the ‗log(Agonist) vs. response -- Find ECanything‘ function of the Graph Prism 
5.04 software, is defined as the protein concentration providing 20 – 80% inhibition 
(IC 20 – IC 80 values) of the maximum signal. These values refer to the range of 
antigen concentrations in a specific assay at which accurate quantification is possible. 
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This is highlighted in Table 5.1 which shows the relationship between interpolated 
protein concentration based on normalised signal values, actual starting protein 
concentrations and recovery rate which was determined as previously described 
(Djoba Siawaya et al., 2008). For the LukF assay, higher concordant values were 
obtained for protein concentrations close to the dynamic range (0.1 – 1.0 µg/ml). 
Recoveries of the spiked LukF sample concentrations ranged from 70% to 120% 
within this range, in contrast concentrations outside this range resulted in recoveries 
ranging from 0% to 173% of the starting concentration. In the case of the HLA-H35L 
assay, this concordance was noted with concentrations ranging from 0.01 – 0.1 µg/ml. 
These concentrations yielded recoveries ranging from 67% to 119% while 
concentrations outside this range yielded 18% to 119% recoveries. Acceptable 
recovery ranges have been reported as 80% to 120% (Evan L.Chiswick, 2012, Giraudi 
et al., 1999) and 70% to 130% (Djoba Siawaya et al., 2008, Zhu-Shimoni et al., 2009). 
 
The LOD is the lowest concentration of protein that can be reliably detected and was 
defined as the protein concentration providing a 10% inhibition (IC 10) of the 
maximum signal (Campas et al., 2007). 
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LukF Inhibition Calibration Curve
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Figure 5.17: Standard inhibition calibration curves for HLA-H35L and LukF proteins generated using GraphPad 
Prism. 
The data used to create the calibration curves were generated from four individual assays carried out in triplicates as described in Section 
5.3.8.1. The standard calibration curves were obtained by plotting normalised signal (B/B0) against protein concentration. 
 
Vertical bars indicate the ±SD 
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Table 5.1: Correlation between actual and interpolated protein 
concentrations 
Actual Starting Protein 
Concentration (µg/ml)
*
 
Interpolated Protein Concentration (µg/ml)
**
 
 LukF  HLA-H35L 
100 115 [115%]  ND
***
 
30 17.6 [59%]  ND 
10 14.3 [143%]  ND 
3 5.2 [173%]  0.55 [18%] 
1 1.2 [120%]  0.35 [35%] 
0.3 0.30 [100%]  0.20 [66%] 
0.1 0.07 [70%]  0.12 [119%] 
0.03 0.04 [133%]  0.035 [114%] 
0.01 0.014 [140%]  0.0075 [67%] 
0.003 0.0025 [82%]  0.004 [105%] 
0.001 0.00005 [0%]  0.0005 [-70%] 
0 0.00005   0.00085 
 
The data presented in this table was generated as described in Section 5.3.8.1. The figures in 
bracket show the agreement between interpolated and actual protein concentrations. These 
values were calculated using the following formula: 
 
Interpolated Concentration – Interpolated Concentration for 0 µg/ml competing protein × 100% 
Actual Starting Concentration 
 
*
Actual starting protein concentration indicates known protein concentrations employed in the 
competitive ELISAs used to create the standard inhibition curve (Section 5.3.8.1) 
 
**
Interpolated protein concentration indicates the corresponding protein concentration for each 
standard determined from the standard inhibition curves. 
 
***
ND (Not Determined) indicates an inability to ascertain protein concentrations from the 
standard inhibition curves. 
 
Concentrations around the dynamic range (shaded yellow) for both proteins resulted in a better 
agreement between the actual and interpolated protein concentration. 
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 Application of Competitive ELISA to a panel of S. aureus isolates. 5.3.8.2
The developed competitive ELISAs were subsequently used to detect and quantify 
both PVL and HLA levels in overnight CYGP broth cultures of all the PVL-positive 
S. aureus isolates in our collection (Table 2.1 and Table 2.2). Two known PVL-
negative isolates (RSS043 and RSS063) were also included in the analysis. Due to the 
number of test isolates (40), the assays were carried out in two batches (Set 1 and Set 
2). 
 
These assays revealed a wide variation in concentrations of LukF and HLA detected 
(Table 5.2). The concentrations ranged from 0.01 – 7.91 µg/ml for the LukF protein 
and 0.03 – 8.52 µg/ml for the HLA protein (Raw data is presented in Appendix 5). No 
LukF protein was however detected in 7.9% (3/38) of the PVL-positive test isolates or 
in the two PVL-negative isolates. This finding of a lack of detection of the LukF 
protein in PCR confirmed PVL-positive test isolates was in contrast to previous 
studies which reported a 100% detection of PVL protein expression in all strains 
harbouring the encoding genes (Loughman et al., 2009, Hamilton et al., 2007, Said-
Salim et al., 2005, Badiou et al., 2010). 
 
Based on a previous report of a possible positive correlation between the expression 
levels of LukF and HLA (Sloan, 2010) which could potentially have some 
significance with relation to variation in strain pathogenicity, the concentrations of the 
two proteins produced were compared for each isolates. Similar concentrations of both 
proteins (defined as concentrations differing by approximately 2 fold or less) were 
268 
 
produced by 28.9% (11/38) of isolates (Table 5.3) with concentrations of both LukF 
and HLA protein detected in TS24 as high as 7.91 µg/ml and 5.06 µg/ml respectively 
as compared to the lowest detectable protein concentration of 0.01 µg/ml (LukF, TS7). 
This phenomenon was however not universal among the isolates. For example the 
concentration of LukF protein detected for TS14 (1.11 µg/ml) was 22 fold more than 
that of HLA (0.05 µg/ml).  
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Table 5.2: Detection and Quantification of LukF and HLA proteins using the newly developed ELISA platforms 
Conc (µg/ml) Not Detected 0 – 0.09  0.1 – 0.99  1.0 – 4.9  5.0 – 10.0  
SET 1      
LukF  (0.01 – 0.08) 
TS7, TS12, TS15, TS5, TS13 
TS21, TS8, TS25, TS16 
(ST 30, 30, 30, 772, 22, 88, 772, 
1, 30)  
(0.15 – 0.97) 
TS9, TS1, TS2, TS6, TS19 
(ST22, 1518, 772, 22, 22) 
(1.27 – 4.34) 
TS23, TS20, TS18, TS14, 
TS17 
(ST22, 22, 22, 22, 22) 
7.91 
TS24 
(ST22) 
HLA  (0.05 – 0.07) 
TS14, TS12, TS7 
(ST22, 30, 30) 
(0.10 – 0.64) 
TS8, TS2, TS1, TS25, TS20, 
TS21, TS5, TS18, TS15, TS13 
(ST772, 772, 1518, 1, 22, 88, 
772, 22, 30, 22) 
(1.33 – 4.62) 
TS6, TS9, TS19, TS17, 
TS23 
(ST22, 22, 22, 22) 
5.06 
TS24 
(ST22) 
SET 2       
LukF  
TS29, TS30, 
NRS229, RSS043, 
RSS063 
(ST8, 8, 1, 22, 22) 
(0.04 – 0.10) 
RSS289, NRS192, NRS248, 
NRS194, NRS162, NRS255, 
NRS123, RSS290, TS28, 
(ST30, 1, 1, 1, 30, 80, 1, 30, 88) 
(0.11 – 0.66) 
TS27, TS26, NRS158, NRS227, 
NRS157 
(ST8, 1, 8, 25, 22) 
(1.58) 
NRS185 
(ST121) 
  
HLA  
TS29, TS30, 
NRS123, NRS162, 
NRS185, RSS289, 
RSS290 (ST8, 8, 1, 
30, 121, 30, 30) 
(0.03) 
TS26 (ST8)  
(0.11 – 0.87) 
NRS194, NRS248, TS28, 
NRS157, NRS229, NRS192, 
TS27, RSS063, NRS255, 
NRS158 (ST1, 1, 88, 22, 1, 1, 8, 
22, 80) 
 (6.70 – 8.52) 
RSS043, NRS227 
(ST22, 25) 
The competitive ELISA protocols were carried out in two batches (Set 1 and Set 2), as described in Section 5.2.6. Isolates producing toxins in 
each range of concentrations are as indicated with the actual lowest and highest concentrations detected within each range shown above the 
isolate identity. The concentration values for each range were arbitrarily decided. 
The sequence type of each isolate is indicated below the isolate identity. 
  
 
Table 5.3: Comparison of LukF and HLA protein production for 
selected isolates 
S/No Isolate ID LukF Concentration (µg/ml) HLA Concentration (µg/ml) 
1.  TS1 0.27 0.12 
2.  TS8 0.07 0.10 
3.  TS16 0.08 0.10 
4.  TS17 4.34 4.48 
5.  TS19 0.97 2.07 
6.  TS24 7.91 5.06 
7.  TS25 0.08 0.16 
8.  TS28 0.10 0.21 
9.  TS29 ND ND 
10.  TS30 ND ND 
11.  NRS194 0.05 0.11 
 
Protein concentrations were defined as similar if they had an approximate difference 
of 2 fold or less 
 
ND: Not Detected i.e. below level of detection of the assay 
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 Discussion 5.4
 ELISA protocol 5.4.1
Currently, confirmation of S. aureus isolates as PVL-positive is carried out by the 
HPA SRU, based on the presence of the genes encoding the PVL toxin. This does not 
however provide any information regarding levels of toxin gene expression. The 
present study set out to describe an ELISA capable of detecting and quantifying PVL 
toxin production, with the potential for use as a diagnostic and research tool. At the 
start of the present study, no PVL-ELISA protocol had been specifically described 
designed for use as a diagnostic tool. Two publications had however made mention of 
PVL ELISA (Hamilton et al., 2007, Tseng et al., 2009). In these studies, ELISA had 
been used as a research tool in quantifying PVL toxin production in vitro, as part of a 
larger study. The ELISA protocol described in the present study differs from these 
other studies in several respects. 
 
The first variation was in design. The ELISA protocols used in all three studies had a 
similar number of steps but differed in specific format. A competitive ELISA protocol 
comprised of 5 steps was used in the present study. In contrast, Hamilton et al. (2007) 
used a 6 step sandwich ELISA protocol. This protocol additionally required a 5-fold 
sample concentration prior to the start of the assay and each ELISA step involved a  
2 h incubation. Comparatively therefore, the ELISA described in this present study 
was simpler and quicker in its execution. No sample concentration was required, and 
incubation times for each step ranged from 0.5 h to 1 h. In addition, in the present 
study, a lower threshold detection level of 7 ng/ml was obtained in comparison to a 
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threshold detection limit of 36 ng/ml reported by Hamilton et al. (2007). On the other 
hand, the ELISA protocol described by Tseng et al. (2009), which involved the use of 
a 4 step indirect ELISA protocol, showed a better threshold detection limit (2 ng/ml) 
than noted in the present study. 
 
One other significant difference between the ELISA protocol described in the present 
study and the earlier reported PVL-ELISA protocols was the type of primary antibody 
employed. Unlike both the Hamilton and Tseng studies which made use of a 
polyclonal primary capture antibody, a monoclonal primary capture antibody was 
used in the present study. Polyclonal antibodies are generated by immunisation of 
experimental animals with the appropriate antigen. The resulting antiserum, contains a 
mixture of specific antibodies which are derived from different B lymphocyte clones 
which recognise a range of epitopes present on the antigen (Nelson et al., 2000). 
These antibodies offer the advantages of being relatively cheap and easy to generate 
and high titre sera can be obtained. Two significant drawbacks are however associated 
with these antibodies. The polyclonal nature of the antibodies present results in a 
higher potential for cross-reactivity with other antigens present in test samples, and 
this could reduce assay specificity. Secondly, as no mechanism exists to ensure that 
the antibodies produced during each round of  immunization and in different animals 
are against identical epitopes (Hjelm et al., 2012), the use of polyclonal antibodies is 
affected by potential batch to batch variations. 
 
In contrast, monoclonal antibodies are by definition antibodies produced by a single B 
lymphocyte clone against a specific epitope. These antibodies are classically 
generated using the hybridoma technology developed in the 1970s (Kim et al., 2012, 
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Kohler and Milstein, 1975). This method involves the fusion of splenocytes from 
immunized animals with immortal mouse myeloma cell lines capable of producing 
antibodies. Following this, hybrid cells are selected and screened for a specific 
antibody producing clone. These cells can then be grown and the monoclonal antibody 
harvested from the supernatant. Thus, although initially more technically demanding 
to produce, use of monoclonal antibodies reduces the risk of cross-reaction, eliminates 
the possibility of batch to batch variation and ultimately reduces use of experimental 
animals. 
 
A third PVL-ELISA protocol has also been described. This protocol which was briefly 
summarised in 2008 (Badiou et al., 2008), was only recently fully described and 
further evaluated for the detection of the PVL toxin in clinical samples (Badiou et al., 
2010). This system is however not yet commercially available. Unlike previous PVL-
ELISA protocols, this 4 step sandwich ELISA detects the LukS rather than LukF 
protein and also uses a monoclonal antibody. It has incubation times for each step in 
the protocol ranging from 0.5 h to 1.5 h and a 5 ng/ml detection limit. 
 
The competitive ELISA protocol used specifically in the present study involved the 
use of a biotinylated protein/antigen detected via a streptavidin-HRP conjugate. This 
assay could thus be further described as ‗a biotin-avidin (BA) ELISA‘. This labelled 
avidin-biotin (LAB) technique which was first described in 1979 (Guesdon et al., 
1979), takes advantage of the very strong almost irreversible high affinity binding 
(Gyorgy and Rose, 1941, Green, 1963, Melamed and Green, 1963, Chen et al., 2012) 
found to occur between the 244.31 Da molecular weight biotin molecule and the  
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≈67 kDa egg protein avidin. The very small size of biotin enables the labelling of 
either antibodies or antigen without any effect on activity of these molecules. The very 
highly specific avidin-biotin affinity additionally ensures binding to only target 
molecules, thus reducing non-specific binding and improving specificity (Diamandis 
and Christopoulos, 1991). 
 
The use of streptavidin rather than avidin is a more recent variation of the avidin-
biotin interaction. Streptavidin has similar binding characteristics for biotin as avidin 
(Chaiet and Wolf, 1964, Tausig and Wolf, 1964) and is produced by Streptomycetes 
avidinii. This protein however differs in amino acid sequence from avidin. Unlike 
avidin, streptavidin has no carbohydrate content resulting in lower non-specific 
binding when compared with avidin (Diamandis and Christopoulos, 1991, Kurstak, 
1985). 
 
Other advantages of the LAB technique include an increase in ELISA sensitivity when 
compared with a standard ELISA process involving the detection of an immune 
reaction simply using enzyme labelled antibodies or antigen. This increased sensitivity 
was demonstrated in a 1983 study designed to detect anti-hepatitis B surface antigen 
antibody in mice (Kendall et al., 1983). In this study, a nearly 100 fold difference was 
found between standard and biotin-avidin (BA) ELISAs. The standard ELISA was 
also 50 times more sensitive than a commercial radioimmunoassay (AUSAB) test 
while the BA ELISA was 4,134 times more sensitive than this standard. Similarly, 
other studies reported increased sensitivities of 8-fold (Wang et al., 2010) and 32-fold 
(Edwin, 1989) when compared with non- BA-ELISA systems. 
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 Recombinant protein production 5.4.2
The general need for large quantities of microbial proteins in both therapeutics and 
research naturally drove the science of recombinant gene cloning, protein expression 
and protein purification. Several different expression systems exist and these rely on a 
variety of promoter systems which differ in their level of expression (Terpe, 2006, 
Baneyx, 1999). Compared to other promoter systems such as the L-arabinose 
inducible PBAD promoter, the trc and tac promoter, the lambda phage promoter and the 
anhydrotetracycline-inducible promoter, the T7 phage promoter employed in the pET 
expression system is known for its very high levels of expression (Terpe, 2006). 
 
The suitability of the pET expression system in the cloning and expression of both 
LukF and HLA-H35L proteins was noted in the present study. Despite the widespread 
use of the pET system, it has been found unsuitable in some cases by failing to result 
in protein expression. This problem usually arises during the production of membrane 
proteins or proteins lethal to the cell (Baneyx, 1999). One such failure of the pET 
system was reported during the production of the adenylate cyclase enzyme where no 
protein was detected following cloning and expression of the enzyme genes (Reddy et 
al., 1989). This phenomenon was thought in part, to be due to issues of leaky T7 RNA 
polymerase expression. Leaky or uninduced expression has been associated with 
promoters derived from the lac operon (Giacalone et al., 2006, Grossman et al., 1998). 
Leaky expression occurs when the promoter is not tightly regulated and refers to the 
background expression of an inducible promoter in the absence of its inducer. This 
phenomenon could lead to plasmid instability with or without a loss of the plasmid, 
thus negatively impacting on the level of expression. Furthermore, leaky expression 
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may equally result in inconsistent levels of protein expression in some cases (Paul et 
al., 1997, Mertens et al., 1995, Spehr et al., 2000). 
 
Methods to either overcome or bypass this limitation have included the use of low 
levels of phage T7 lysozyme. Phage T7 lysozyme degrades the T7 RNA polymerase, 
thereby inhibiting its activity (Studier, 1991, Baneyx, 1999). In addition to such 
modifications to existing systems to create a tighter regulation and prevent leaky 
expression, the use of alternate promoter systems specifically designed to prevent 
leaky expression, has been reported. Examples of these include the bacteriophage 
lambda promoter (PL) (Elvin et al., 1990, Terpe, 2006) the L-rhamnose inducible 
promoter (Prha) (Haldimann et al., 1998), the L-arabinose inducible promoter (PBAD) 
(Guzman et al., 1995) and the hybrid lac and arabinose promoter (Plac/ara-1) (Lutz 
and Bujard, 1997) based systems. In this present study however, none of these issues 
were observed to pose a problem. This was reflected by a lack of background 
expression in the uninduced state (which could cause toxicity and hinder recovery of 
target protein), and the rapid induction of expression with high levels of protein 
produced within 2 h as depicted in Figure 5.7 and Figure 5.8. 
 
On the other hand however, the significant level of insolubility of the LukF protein 
following induction at 37°C (Figure 5.8), represented a different set of issues linked 
with the pET expression system. The problem of formation of insoluble inclusion 
bodies has long been associated with this system (Paul et al., 1997). This problem 
ironically is associated with the high level of protein expression achieved by the 
system (Baneyx, 1999). Inclusion body formation has been linked with 
overproduction of a protein. As higher growth rate is linked to increased temperatures, 
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insolubility has been shown to be enhanced when higher growth temperatures were 
used (Klein and Dhurjati, 1995). Conversely, protein induction at lower temperatures 
has been shown to result in increased protein solubility, though this is often associated 
with reduced levels of protein expression. This phenomenon, which has been reported 
for a variety of proteins (Chalmers et al., 1990, Weickert et al., 1997, Back et al., 
1994), was also observed in the present study (Figure 5.8). 
 
Protein purification in the present study was carried out using kits which rely on 
immobilised metal affinity chromatography (IMAC) (Porath et al., 1975) for the 
separation of target protein from all other proteins in solution. This method exploits 
the high affinity of specific amino acids (histidine and cysteine) for transition metal 
ions such as Zn
2+
, Cu
2+
, Ni
2+
 and Co
2+
 (Smith et al., 1988). A widely used application 
of this is the purification of a 6 × his-tag fused to a recombinant protein using nickel 
charged columns (Block et al., 2009) as used in the present study. His-tags are added 
as part of the cloning process. For example, the pET-21d(+) plasmid expression vector 
used in the present study for the cloning and expression of both proteins, is designed 
to incorporate a C′-terminal hexa-histidine tag onto the protein, thereby enabling ease 
of purification. The affinity of histidine for nickel is both specific and reversible 
(Cuatrecasas, 1970). Additionally, as this tag is uncharged at physiological pH and 
generally poorly immunogenic it has generally been found to have little effect on the 
properties of the tagged protein (Crowe et al., 1994, Bornhorst and Falke, 2011). 
 
While different commercial purification protocols rely broadly on the principles of 
IMAC, the specifics of the process may vary from one to another. In the present study, 
improved purification of the HLA-H35L protein was achieved with the BioRad
®
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Biologic LP affinity chromatographic system. The significant difference between this 
system and the Novagen His Bind Resin
®
 protein purification kit is in the use of a 
linear imidazole gradient for protein elution as opposed to the stepwise elution used 
by the Novagen kit. The stepwise elution process limits protein elution to a single high 
concentration of imidazole (250 mM) and works effectively for many proteins, as was 
observed with the LukF purification (Figure 5.9). Gradient elution however, takes 
into consideration the fact that all bound proteins do not necessarily have similar 
elution profiles, and enables contaminating proteins bound non-specifically to be 
washed out at lower imidazole concentrations. This highlights how slight variations of 
IMAC protocols may impact on the efficacy of purification of different proteins. 
 
 Summary 5.4.3
Overall, this chapter described the development of sensitive ELISA protocols for the 
detection and quantification of LukF and HLA proteins using monoclonal antibodies. 
These preliminary results generated following the development and validation of both 
immunoassays indicate the potential of the assays, both for clinical diagnosis and as 
research tools to detect and investigate the expression of these toxins. Further 
validation would however be essential before this potential can be achieved.  
 
One significant variation in the results generated in this chapter from those of 
previously published studies (Hamilton et al., 2007, Badiou et al., 2010, Loughman et 
al., 2009, Said-Salim et al., 2005), was the inability to detect any expressed LukF 
protein in three PCR confirmed PVL-positive strains. This potentially false negative 
finding could drastically alter the potential application of ELISA in clinical diagnosis 
of PVL-positive isolates. A comprehensive follow-up study would be needed to 
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quantitatively explore the effect of various previously reported parameters on toxin 
expression (Section 1.6.6) to explore the possibility of improving the potential utility 
of the assay. 
 
For the other isolates tested, the ELISA assays showed clear differences in expression 
levels of both LukF and HLA. In some cases, similar levels of both proteins were 
produced by individual isolates but for others, expression levels did not appear to be 
linked. These data suggest that factors controlling toxin expression vary between 
different isolates though the mechanisms involved are currently not defined and 
require additional study. 
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Chapter Six 
 
6 General Discussion 
 Overview 6.1
The ability of S. aureus to cause infection in a wide variety of tissues and the 
extensive array of virulence determinants it possesses has been well documented 
(Archer, 1998, Casey et al., 2007, Lowy, 1998). These characteristics, together with 
its penchant for development of antibiotic resistance have combined to make this 
species a significant cause for concern, with the hospital acquired strains proving 
increasingly problematic for over four decades. Up to 2001, the voluntary MRSA 
reporting scheme begun in England in the 1990s had showed a steady increase in the 
number of reported MRSA bacteraemia cases. Over this time period, the number of 
reported cases had risen to 5,000 per year. Data collected following the introduction of 
mandatory MRSA reporting in England in 2001 (Department-of-Health, 2001), 
confirmed the high prevalence of MRSA bacteraemia cases (Figure 6.1), with over 
7,000 cases per year reported by 2002. This therefore, led to a government 
intervention in 2003 to reduce the incidence of MRSA bacteraemia (HPA, 2004), and 
a target of a 50% reduction in MRSA bacteraemia cases by 2008 was set. Despite the 
possibility that the rise in number of cases was an anomaly due to increased awareness 
and surveillance, by 2008, the government target of a 50% reduction in MRSA 
bacteraemia cases was achieved (Figure 6.1 and Figure 6.2). Furthermore, as the data 
from the voluntary surveillance showed (Figure 6.2), this reduction was specific for 
bacteraemia caused by MRSA cases rather than MSSA bacteraemia cases in general. 
Numbers of bacteraemia cases caused by MSSA showed a slight increase over this 
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period. Notwithstanding the further steady decline in incidence of MRSA bacteraemia 
cases reported by the HPA (Johnson et al., 2012), the fight against S. aureus is not yet 
over, as once again the ‗modus operandus‘ of this ever versatile species appears to be 
changing. 
 
  
 
 
 
Figure 6.1: Incidence of reported MRSA bacteraemia in England (1993 – 2008)  
The figure represents data on the number of MRSA bacteraemia reports obtained initially via the voluntary MRSA surveillance 
scheme only (1993 – 2002), and then also from the with mandatory MRSA surveillance scheme (2002 – 2008). The figure 
shows a similar trend between voluntary and mandatory surveillance reports from 2002 and a steady post 2003 decline in 
reported cases. 
 
The figure is reproduced from Pearson et al. (2009).  
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Figure 6.2: Incidence of reported S. aureus bacteraemia in the UK (2002 – 2011). 
The graph shows data on the number of cases of bacteraemia caused by MSSA, MRSA and total S. aureus from the voluntary 
reporting scheme. This data shows consistency of reported numbers of MSSA bacteraemia over the reporting period. 
 
Source: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317135574852. 
  
 
The changing face of S. aureus was first observed in the 1990s with initial reports of 
MRSA causing infection in the community (Herold et al., 1998, Price et al., 1998, 
CDC, 1999, L'Heriteau et al., 1999, Gwynne-Jones and Stott, 1999, Berman et al., 
1993). These new ―CA-MRSA‖ strains were then subsequently disseminated 
worldwide. The epidemiology of infections caused by these S. aureus strains has since 
evolved further. CA-MRSA strains have now spread into healthcare facilities and have 
been reported as causing nosocomial infections (Saunders et al., 2007, David et al., 
2006, Patel et al., 2007, Valsesia et al., 2010). More recently, there has also been an 
increase in reports of specific MRSA clones colonising or infecting livestock. These 
livestock associated MRSA (LA-MRSA) isolates have also been reported in humans 
exposed to various animals (Garcia-Graells et al., 2012, Richter et al., 2012, Kock et 
al., 2012) and have even been isolated from healthcare facilities (Lozano et al., 2012, 
Kock et al., 2011). Together with the higher numbers of PVL-MSSA strains noted in 
the UK (Table 1.3) and continuing high incidence of MSSA bacteraemia despite the 
reduction in MRSA bacteraemia in recent years (Figure 6.2), these observations 
highlight the continuing evolution of the interaction between S. aureus and humans to 
facilitate the survival of this species in the human population. It is therefore important 
for the scientific community to keep up with these changes. 
 
This thesis aimed to increase understanding of the role of the PVL toxin in 
staphylococcal biology, with particular reference to PVL-MSSA isolates and to 
evaluate novel methods for typing and detection of toxin production by these isolates. 
  
 
A detailed characterisation of a collection of PVL-MSSA isolates was carried out as 
part of this research. Generally, this group of isolates appear to have been overlooked 
in favour of studies with MRSA isolates, with regards to focused epidemiological and 
typing studies. The gap in accurate epidemiological data for MSSA in general has 
increasingly been noted, causing the UK Health Protection Agency in January 2011 to 
introduce a mandatory surveillance system for MSSA bacteraemia cases (HPA, 
2011b, Wilson and Kiernan, 2012). 
 
Four different typing systems, in addition to virulence and resistance gene profiling, 
were employed in the characterisation of PVL-MSSA isolates in the present study. 
Over the years, the systems used in the characterisation and typing of S. aureus have 
evolved significantly and at present, PFGE, MLST and spa typing are the three most 
commonly used methods described in the literature. Increasingly, researchers do not 
apply only a single technique to the typing of S. aureus isolates. Rather, typing is 
starting to involve a combination of at least two of these techniques in a bid to 
improve discrimination (Shore et al., 2010, Ellington et al., 2010, Vindel et al., 2009) 
and capture both the long and short term evolutionary processes taking place within 
this group of isolates. One such study demonstrated a higher discriminatory power of 
99.98 when PFGE and spa were combined, compared with the discrimination of the 
individual techniques [PFGE (99.69); MLST (94.82); spa (97.31)] (Faria et al., 2008). 
 
PFGE was deemed the gold standard in S. aureus typing (Peacock et al., 2002a). 
However, PFGE is cumbersome and the difficulty of intra-laboratory comparisons 
mean that fewer studies now employ this technique as a typing tool. Rather, the 
sequence based MLST and spa typing systems employed in the present study are 
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increasingly becoming the techniques of choice, due to a comparable level of 
discrimination as PFGE. Applying these techniques to the subset of clinical PVL-
MSSA isolates in the present study provided a wealth of information. An even more 
diverse genetic background was noted among these strains than previously reported in 
PVL-MRSA isolates (Table 3.5 and Table 3.6), especially when compared with the 
general CA-MRSA population (Muttaiyah et al., 2010, Rasigade et al., 2010, Tong et 
al., 2010). Interestingly, despite the limited sample size, the test isolates in the present 
study, appeared to provide a snapshot of trends previously noted among PVL-positive 
strains in this locale (Ellington et al., 2009, Grundmann et al., 2010, Monecke et al., 
2007b, Otter et al., 2009. These PVL-MSSA isolates represented identical clones (as 
described by both MLST and spa typing) as those previously found in PVL-MRSA 
isolates, supporting the hypothesis that the latter strains had emerged from the former 
simply by the acquisition of the SCCmec element (Figure 3.1). As the number of test 
isolates in the present study was rather limited, further studies typing a larger subset of 
isolates would be essential to confirm the hypothesis. 
 
Based on MLST and spa typing schemes alone however, it would not be possible to 
prove that a specific set of PVL-MSSA strains in a locale gave rise to the PVL-MRSA 
strains circulating in the same population. Theoretically, a stronger evidence to 
support this hypothesis would be the isolation of both PVL-MSSA and PVL-MRSA 
strains which are more or less identical not just in terms of their MLST and spa types 
but also with respect to the variations in PVL encoding genes, type of PVL phage 
present, and virulence gene profile. Considering the association sometimes of 
resistance genes with the SCCmec element (Ito et al., 2001), it might also be expected 
that the evolving PVL-MRSA strains would be more resistant than their meticillin 
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susceptible counterparts. This is why the other two typing schemes employed in the 
present study (PVL sequence and PVL phage typing) were used to clearly demonstrate 
a possible evolutionary link between isolates in the present study and others as 
previously described (Ellington et al., 2009, Ellington et al., 2010). 
 
Subsequent to the present study, further research in other geographical locations 
would however need to be performed to determine if indeed these findings are 
widespread or are limited to the PVL strains found in the UK. Should this hypothesis 
be confirmed and found applicable to the various PVL-positive strains found 
worldwide, this could cause a shift in intervention policies leading to proactive as 
opposed to reactive measures. Rather than looking at ways to manage outbreaks of 
PVL-positive strains, future interventions could focus on ways to prevent spread of 
PVL phages within the S. aureus population or target those clones susceptible to 
infection by these phages. This may involve more directed research looking at PVL 
phages, their reservoirs and mode of evolution. This may be a more pressing issue 
than is currently appreciated as in the last year several reports have described different 
bacteriophages which carry the genes encoding the PVL toxin (Zhang et al., 2011, Le 
et al., 2012, Ito et al., 2012). One of these studies (Zhang et al., 2011) described two 
novel PVL phages in a single clone (ST59) with 99% identity between them. The 
genomes of these phages demonstrated a high degree of homology to previous PVL 
phages with respect to five genes located at the end of the prophage (int (integrase), 
hol (holin), ami (amidase), lukS-PV, and lukF-PV). They are however otherwise quite 
different from that of previously published PVL phages. These novel PVL phages 
exhibit a higher degree of homology to non-PVL group 3 Sfi21-like Siphoviridae 
phages (Zhang et al., 2011). This led the researchers to propose that novel PVL 
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phages may simply be generated by what they termed ‗illegitimate recombination‘ 
involving the uptake of the region containing the five genes mentioned above. 
 
One issue the present study did highlight was the need for more comprehensive typing 
of S. aureus isolates. Apart from the group of isolates in the present study which had 
novel spa or MLST types described for the first time, there was also another set of 
isolates from which conclusions could not be drawn simply because no comparable 
data existed for their PVL-MRSA counterparts, or in some cases, this data was 
incomplete. An analysis of the literature revealed that while the use of more than one 
typing scheme is becoming more common, quite a number of studies have still failed 
to appreciate the need for this approach, particularly the necessity of spa typing. In a 
sense, MLST and PFGE are two ends of the typing spectrum. MLST involves an 
analysis of 7 housekeeping genes thought to evolve slowly over time (Enright et al., 
2000). Hence the information it provides is more global, long term epidemiology. 
PFGE on the other hand involves an analysis of total DNA and has a discriminatory 
power such that a single genetic change could result in a change in banding pattern 
and hence data interpretation (Bannerman et al., 1995). On the typing spectrum then, 
the information provided by spa typing falls between these two methods as reflected 
in its discriminatory power being higher than that of MLST but lower than PFGE 
(Faria et al., 2008). 
 
The analysis of a collection of MSSA-PVL-positive isolates found in the UK as 
carried out in the present study, clearly demonstrates the value of spa typing. While 
one of the predominant clones represented among UK PVL-positive isolates is the 
same clone to which the notorious EMRSA-15 responsible for hospital outbreaks 
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belongs (Holmes et al., 2005, Ellington et al., 2009, Boakes et al., 2011b), their 
associated spa types differ. Whereas t032 and t022 are the more common spa types 
found within EMRSA-15, ST22 isolates (Aires-de-Sousa et al., 2008, Boakes et al., 
2011b, Otter and French, 2008), these spa types are however not commonly 
represented among the ST22 PVL-positive isolates circulating in the UK. A recent 
study by Boakes and colleagues involved the characterisation of 47 CC22 PVL-
MRSA isolates from the HPA collection (Boakes et al., 2011b). None of these isolates 
belonged to either t022 or t032 spa types. Rather the majority of them (34/47 72.3%) 
were spa type t005. Therefore, it is recommended that spa typing is regularly 
incorporated into the typing scheme of S. aureus, rather than being seen as an extra 
adjunct, in order to provide a balance to the information provided by PFGE and 
MLST. 
 
 Novel typing techniques 6.2
Despite the advantages associated with both MLST and spa typing, these sequence 
based typing systems in themselves are still not perfect. While their associated 
advantages of being less cumbersome, easy of interpretion and portability (especially 
when compared with PFGE), cannot be ignored, certain drawbacks still exist. With the 
need for amplification, sequencing and data interpretation of at least 8 loci per isolate, 
time and financial costs for these methods are significant. Given an increasing number 
of strains are now being routinely subjected to genotyping, costs continue to escalate. 
These limitations prompted the investigation of the alternative typing methods 
described in the present study. 
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As an emerging technique, high resolution melt (HRM) analysis has shown a great 
deal of potential with its remarkable degree of sensitivity and specificity (Erali et al., 
2008) and its potential for application as a rapid typing system. The high degree of 
specificity and sensitivity usually associated with HRM, was confirmed by detection 
of four variations in the lukSF-PV locus (Figure 4.2). Impressively, a great deal of 
information could be extrapolated from the data generated. In addition to confirming 
PVL isotypes as previously defined (O'Hara et al., 2008) mutations in the genes 
encoding both LukF and LukS subunits correlated with ST allowing strain genotyping 
(Takano et al., 2008b, Berglund et al., 2008b, Otter et al., 2010, Wolter et al., 2007). 
Based on HRM analysis of variations in the lukSF-PV locus therefore, this technique 
may be useful in an outbreak setting as a rapid, non-sequence based method for the 
typing of isolates as same or different if sufficiently discriminatory. 
 
However, attempts to improve discrimination by applying this technique to identifying 
variations in the spa gene (Figure 4.4) highlighted a number of issues (especially 
regarding data interpretation), which have not previously been reported in the 
literature. In the present study, the ultimate aim of using HRM to differentiate spa 
types was met resulting in improved discrimination for this technique. An analysis of 
the spa locus was however only possible following an awareness of the level of 
temperature variability across the plate (Figure 4.11) and the effect of temperature 
shift on data interpretation (Figure 4.4). Hence, in contrast to the HRM analysis of the 
lukSF-PV locus where types were automatically assigned, a high degree of user 
subjectivity would come into play in the interpretation of spa HRM data. 
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These added issues in data interpretation combined with its poor predictive ability 
(Table 4.12), might perhaps point to unsuitability of the spa locus as a candidate for 
HRM. HRM though, has been applied in genotyping based on size variation (Price et 
al., 2007). While this application is not as widespread as SNP detection and mutation 
scanning, it has successfully been applied (Stephens et al., 2006). Therefore, the 
failure to replicate this experiment, albeit on a different HRM platform, highlights a 
clear problem which could potentially undermine the advantages of HRM, the issue of 
portability. For a typing system to be successful, one important requirement is for 
portability so as to enable accurate comparison of data generated by such a technique 
from in any laboratory worldwide. 
 
In the case of HRM, the availability of several different commercial platforms and 
associated software (Herrmann et al., 2007), which differ in technology, dye 
employed and instrument capabilities, acts as a limiting factor. Hence, despite any 
associated successes in its use as a rapid typing tool, its widespread application 
presently would be plagued by issues of portability making the technique perhaps 
useful simply in regional studies. This might perhaps change with improved 
technologies but this is currently hard to envisage considering that the success of the 
technique has created a market for the manufacturers and a single supplier of HRM 
equipment might make the cost prohibitive. Conversely, as the technique becomes 
more commonplace, enough assays might be carried out on the various platforms 
making it possible to create a protocol designed to generate comparable results not 
withstanding equipment variation. 
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 Future Work 6.3
The present study was based on a small collection of PVL-MSSA isolates and 
provides information which suggests direct evolutionary links between specific UK 
PVL-MSSA and PVL-MRSA isolates. Further testing of more isolates is however 
required to determine if these findings are repeated on a larger scale. This would 
involve the characterisation of a wider collection of national and international PVL-
MSSA and PVL-MRSA strains to enable direct comparison. In addition to 
contributing to the limited current data on what appears to be the emerging PVL-
MSSA isolates, the data generated would form the basis for intervention strategies as 
previously mentioned. 
 
With the high level of potential demonstrated for the application of HRM as a rapid 
tool for typing of PVL-positive isolates, future work would also be geared towards 
improving this potential and harnessing it for maximum benefit. In order to do this, it 
will be necessary to incorporate a third locus into the assay to improve its 
discriminatory power. The candidate gene for this process would need to be one that is 
present in all strains of S. aureus, in a highly conserved form but with a few variations 
which correlate with S. aureus lineages. The hsdS restriction modification genes as 
described by Lindsay and colleagues (Waldron and Lindsay, 2006) looks like it might 
fit this profile. Hence the next step would be to explore the ability of HRM to detect 
variations in this gene in order to enable genotyping. 
 
One factor which could increase the usefulness of this HRM technique would be the 
use of a single mastermix to provide the same information gleaned from the three 
individual reactions. This is why the final step in the development of such a rapid test 
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would be to multiplex all three HRM reactions into one. Multiplexing in relation to 
HRM has been carried out (Garritano et al., 2009, Senapin et al., 2010, Curd et al., 
2011, Chroma et al., 2011), though it has not been commonly reported. In this case, as 
the annealing temperatures for the primers are already comparable and the expected 
melt temperatures variable, multiplexing would simply involve optimisation with 
respect to concentrations to generate individual different peaks which can then be 
analysed using the software. 
 
Finally, the ELISAs developed in the present study could provide a useful tool for the 
detection of PVL and HLA expression in research and diagnostic setting. Where 
previously Western blots had to be used to give a rough estimate of the level of these 
toxins produced by various isolates, an exact quantitative level can now be achieved. 
The first application of the ELISA developed in the present study would be to analyse 
how toxin levels for a large panel of isolates compare not just with the results obtained 
by Western blotting but also with mRNA transcript levels of the specific genes 
encoding the toxins. Various publications have cited these methods for assessing PVL 
expression but no single study has currently used all these techniques on a single set 
of isolates. 
 
It must be pertinent to note at this point, that there is an emerging field in science 
which has the potential to change the landscape of diagnosis, making all the 
techniques in use today either obsolete or second choice. With rapid advances in 
technology, concomitant cost reduction and increased speed of sequencing (Hall, 
2007, Koser et al., 2012a), whole genome sequencing (WGS) is increasingly 
becoming a force to be reckoned with. Following sequencing of the first bacterial 
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genome in 1995 (Fleischmann et al., 1995), over 1000 bacterial genomes have now 
been sequenced. Unlike most typing systems today which simply draw conclusions of 
evolutionary patterns and relatedness by the analysis of a single gene (as in spa 
typing), or at best a set of genes (as in MLST), WGS (as the name implies) provides a 
snapshot of the whole genome, eliminating the need to focus on a specific target and 
providing an immense amount of information. WGS could thereby find application in 
more accurate identification and characterisation of isolates, virulence and 
susceptibility studies as well as in novel drug target detection. This technique has 
currently been applied in several outbreak investigations (Eyre et al., 2012, Snitkin et 
al., 2012, Koser et al., 2012b). The development of next generation sequencing (NGS) 
systems (Niedringhaus et al., 2011, Quail et al., 2012), including benchtop facilities 
such as Illumina MiSeq which allows samples to be sequenced and data analysed 
within one day (Liu et al., 2012), looks set to usher in a new era in diagnostics. 
 
WGS has the ability to transform the face of diagnosis and contribute to improving 
patient care, but the major limitation of the large scale application technology would 
be the sheer amount of data it generates and associated complexities. While the 
information it provides is useful, superseding any current technologies, the question 
would have to asked at some point – is it necessary and does the benefit justify the 
cost? Answering this in the future, might lead to a balance between old and new 
technologies to provide healthcare professional with the ‗perfect‘ diagnostic system. 
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 Conclusions 6.4
In summary, the present study has generated useful comprehensive typing data for the 
neglected PVL-MSSA isolates which contributes to the sparse pool of worldwide 
information. At a local level, it clearly points at an evolutionary link between PVL-
MSSA and PVL-MRSA, particularly the ST22 strains, highlighting a need for more 
concerted efforts aimed at typing these strains and setting in motion intervention 
strategies. It also highlights the need for alternatives to the current typing systems 
given how cumbersome it is to generate complete typing information which could be 
used in evolutionary analysis for just a single isolate. 
 
In addition, despite the issues encountered with HRM at the spa locus, the present 
study demonstrates the potential the HRM technique shows as a rapid typing tool for 
genotyping of PVL-positive isolates. And while the potential for this could be 
improved by the addition of a third locus providing the same ease and clarity as the 
lukSF-PV locus, at present it could play quite a useful role as a preliminary analysis 
strategy for typing isolates as same or different. The need for a detailed comparison of 
the different HRM platforms was also clearly highlighted in the HRM analysis carried 
out in the present study. 
 
Finally, the present study has described a specific and sensitive ELISA protocol which 
not only detects the presence of the actual PVL toxin but also allows quantification of 
toxin concentrations. With the increase in PVL studies and a continuing need to 
unravel its role in pathogenicity, being able to quantify this toxin is an important part 
of PVL research which would form the basis for a variety of further studies. 
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Appendices  
 
Appendix 1: Media Composition 
 
Brain Heart Infusion broth 
 
Component per litre of water 
Brain Infusion Solids 12.5 g 
Beef Heart Infusion Solids 5.0 g 
Proteose peptone 10.0 g 
Glucose 2.0 g 
Sodium Chloride 5.0 g 
Di-sodium phosphate 2.5 g 
 
 
Luria Bertani Broth 
 
Component per litre of water 
Tryptone 10.0 g 
Yeast Extract 5.0 g 
Sodium Chloride 10.0 g 
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Tryptic Soy Broth 
 
Component per litre of water 
Pancreatic Digest of Casein 17.0 g 
Papaic Digest of Soybean 3.0 g 
Dextrose 2.5 g 
Sodium Chloride 5.0 g 
Dipotassium Phosphate 2.5 g 
 
 
CYGP broth 
 
Component per litre of water 
Casamino Acids 10.0 g 
Yeast Extract 10.0 g 
Glucose 5.0 g 
Sodium Chloride 5.9 g 
β-Glycerophosphate (1.5M) 40 ml 
 
 
 
  
Appendix 2: Buffer/Chemical Compositions 
 
SDS-PAGE buffer preparations 
 
SDS PAGE resolving gel buffer [RGB] (pH8.8) 
 
Component per 100 ml of water  
Tris 36.3 g 
1M HCl 48.0 ml 
 
SDS PAGE stacking gel buffer [SGB] (pH6.8) 
 
Component per litre of water  
Tris 6.0 g 
1M HCl 48.0 ml 
 
11.5% SDS PAGE resolving gel 
 
Component Volume  
30% (w/v) Acrylamide bis  3.6 ml 
RGB 1.25 ml 
10% (w/v) SDS  100 µl 
10% (w/v) Ammonium persulphate 150 µl 
ddH20 4.5 ml 
TEMED 7.5 µl 
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SDS PAGE stacking gel 
 
Component Volume  
30% (w/v) Acrylamide bis 750 µl 
SGB 1.5 ml 
10% (w/v) SDS 60 µl 
10% (w/v) Ammonium persulphate 150 µl 
ddH20 3.0 ml 
TEMED 6 µl 
 
 
SDS PAGE running buffer 
 
Component per litre of water 
Glycine 14.4 g 
Tris 3.03 g 
SDS 1 g 
 
 
SDS PAGE destain (Methanol/Acetic Acid) 
 
Component per litre of water 
Methanol 200 ml 
Glacial Acetic acid 75 ml 
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2× SDS PAGE sample buffer (pH 6.8) 
 
Component per 100ml of water 
Tris 1.5 g 
SDS 4 g 
Mercaptoethanol 10 ml 
Sucrose 20 g 
Bromophenol Blue 0.004 g 
 
50× TAE Buffer (pH 8.0) 
 
Component per litre of water  
Tris 242 g 
Glacial acetic acid 57.1 ml 
0.5M EDTA 100 ml 
 
 
 
  
Appendix 3: Identity of Blinded Isolates 
 
S/No Isolate ID 
1.  TS1 
2.  TS6 
3.  TS13 
4.  TS15 
5.  TS5 
6.  TS16 
7.  TS18 
8.  TS8 
9.  TS9 
10.  TS2 
11.  TS17 
12.  TS12 
13.  TS7 
14.  TS14 
15.  TS20 
16.  TS23 
17.  TS21 
18.  TS24 
19.  TS19 
20.  TS25 
21.  TS26 
22.  TS27 
23.  TS28 
24.  TS29 
25.  TS30 
26.  NRS123 
27.  NRS157 
28.  NRS162 
29.  NRS185 
30.  NRS158 
31.  NRS192 
32.  NRS194 
33.  NRS227 
34.  NRS229 
35.  NRS248 
36.  NRS255 
37.  RSS043 
38.  RSS063 
39.  RSS289 
40.  RSS290 
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Appendix 4: Demonstration of lack of haemolytic activity of HLA-H35L on blood 
agar plate 
 
 
 
 
The haemolytic activity of the recombinant HLA-H35L toxin was assessed on horse 
blood agar. A 20 µl volume of purified, dialysed protein (100 g/ml) was pipetted into 
wells cut in the agar plate. Purified S. aureus alpha toxin (Sigma-Aldrich, Dorset UK) 
(100 g/ml) was used as a positive control. The plate was incubated overnight at 37°C 
and examined for zones of haemolysis.  
  
HLA-H35L 
HLA 
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Appendix 5: Raw ELISA results 
 
S/No Isolate ID Concentration (µg/ml) 
  LukF HLA 
1.  TS1  0.27 0.12 
2.  TS2  0.39 0.10 
3.  TS5  0.03 0.32 
4.  TS6  0.60 1.50 
5.  TS7  0.01 0.07 
6.  TS8  0.07 0.10 
7.  TS9  0.15 1.53 
8.  TS12  0.01 0.06 
9.  TS13  0.04 0.64 
10.  TS14  1.11 0.05 
11.  TS15  0.03 0.46 
12.  TS16  0.08 0.10 
13.  TS17  4.34 4.48 
14.  TS18  1.37 0.32 
15.  TS19  0.97 2.067 
16.  TS20  1.32 0.15 
17.  TS21  0.07 0.19 
18.  TS23  1.27 4.62 
19.  TS24  7.91 5.06 
20.  TS25  0.08 0.16 
21.  TS26  0.15 0.03 
22.  TS27  0.11 0.30 
23.  TS28  0.10 0.21 
24.  TS29  ND  ND  
25.  TS30  ND  ND  
26.  NRS123  0.06 ND  
27.  NRS157  0.66 ND  
28.  NRS158  0.15 0.87 
29.  NRS162  0.06 ND  
30.  NRS185  1.58 ND  
31.  NRS192  0.04 0.23 
32.  NRS194  0.05 0.11 
33.  NRS227  0.61 8.52 
34.  NRS229  ND  0.24 
35.  NRS248  0.04 0.16 
36.  NRS256  0.06 0.78 
37.  RSS043  ND  6.70 
38.  RSS063  ND  0.70 
39.  RSS289  0.04 ND 
40.  RSS290  0.07 ND 
ND = Not Detected 
 
  
Appendix 6: Publication 
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